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Abstract
The urokinase-type plasminogen activator receptor (uPAR), is a multifunctional 
protein with an impressive range of distinct, but overlapping functions in the process of 
tissue remodelling and cell migration: 1) uPAR regulates extracellular proteolysis by 
promoting plasminogen activation; 2) uPAR regulates cell adhesion as an adhesion 
receptor for vitronectin and by its capacity to modulate integrin function; 3) uPAR 
regulates cell migration as a signal transduction molecule and by its intrinsic chemotactic 
activity. In this thesis I have analysed the consequences, and occurrence, of uPAR 
cleavage and shedding.
In chapter 3 I analyse the structural requirements for uPAR to promote cellular 
adhesion to vitronectin. I demonstrate that cell surface expression of intact uPAR is 
necessary and sufficient to promote binding of the myeloid cell line 32D to vitronectin. In 
this cell system the uPAR mediated cell binding does not lead to cell spreading and does 
not require integrin activation. In chapter 4 I demonstrate that the chemotactic activity of 
uPAR maps to the linker region which connects the first and second domain of uPAR. 
This chemotactic epitope (the SRSRY motif) is required and sufficient for the 
chemotactic activity of soluble uPAR fragments and appears to induce signalling similar 
to that induced by uPAR ligands such as uPA. In chapter 5 I show that uPAR and the 
uPAR fragments D l and D2D3 are indeed generated on the cell surface and released to 
the surroundings by several different cell types. In chapter 6 I describe and characterise 
the presence of soluble uPAR and uPAR fragments in vivo. I demonstrate that suPAR as 
well as the suPAR fragments D l and D2D3 are present in human urine. Using mice 
xenografted with human model tumours I demonstrate that the tumour tissue is a source 
of urinary suPAR antigen and that the suPAR fragment pattern in urine correlates with 
uPAR cleavage in the tumour tissue.
Chapter 1 : 
INTRODUCTION
Chapter 1: Introduction
Preface
The development and normal functioning of all cell types in the multicellular organism 
depends upon interactions with molecules present in their environment. The major types of 
molecules that regulate and determine cell growth and development include growth and 
differentiation factors, extracellular matrix proteins, and their respective cellular membrane 
receptors.
The extracellular matrix (ECM) is the intercellular mesh, which provides the mechanical 
strength, rigidity and elasticity of virtually all tissues. Initially, the ECM was mostly considered 
important for its mechanical properties, an inert structure through which nutrition and signalling 
molecules can diffuse. However it has become clear that the extracellular matrix per se plays 
many fundamental roles in cell function. One example of this is the nervous system in which cell 
interactions with the ECM play a fundamental role in cell migration, neuronal survival, axon 
guidance and synapse formation.
Rather than being static, the organism undergoes continuous remodelling throughout 
development and in the adult phase. Physiological processes that involve extensive tissue 
remodelling include wound healing, mammary gland involution and embryo implantation. The 
process of tumour invasion and metastasis in cancer provides an "excellent" example of the 
extensive tissue remodelling that may occur in pathological processes.
Tissue remodelling is almost synonymous with cell migration; a process in which the 
ECM plays the dual role of the substratum on which the cells move as well as the physical 
obstacle that the cells have to surpass. To degrade the physical obstacle, which the ECM poses in 
the direction of migration, cells use proteolytic enzymes capable of degrading the ECM 
components. The best studied proteolytic systems responsible for ECM degradation are the 
plasminogen activation system, which generates the potent serine protease plasmin, and the 
family of matrix metalloproteases (MMPs).
The subject of this thesis, the urokinase-type plasminogen activator receptor (uPAR), is a 
multifunctional protein with an impressive range of distinct, but overlapping functions in the 
process of tissue remodelling and cell migration: 1) uPAR regulates extracellular proteolysis by 
promoting plasminogen activation; 2) uPAR regulates cell adhesion as an adhesion receptor for 
vitronectin and by its capacity to modulate integrin function; 3) uPAR regulates cell migration as 
a signal transduction molecule and by its intrinsic chemotactic activity.
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Cell adhesion molecules
The interactions between cells and the ECM play a fundamental role in cell adhesion and 
migration. Cell-cell and cell-ECM contacts are mediated by cellular adhesion receptors, which 
may interact with proteins in the ECM or on the surface of other cells. Cell-cell contacts range
from the stable interactions between epithelial cells to the transient and highly regulated»
interactions between cells of the immune system and between leukocytes and the vascular 
endothelium. The most well characterised adhesion receptors are members of the cadherin, 
immunoglobulin, selectin and integrin super families.
Cadherins are a family of single-pass transmembrane glycoproteins that play a crucial role 
in Ca2+-dependent cell-cell interactions. The function of these molecules is to establish tight cell­
cell associations and to define the adhesive specificity of cells. The expression of the cadherins is 
both temporally and spatially regulated in a fashion that correlates with (re)organisation of 
tissues. Proteins from the cadherin family are responsible for the formation of gap junctions and 
thus for intercellular signalling, and for the formation of desmosomes which contribute to the 
tensile strength of epithelial tissues.
Cell adhesion receptors from the immunoglobulin (Ig) superfamily have one or more of 
the typical Ig domains in their extracellular portion. The receptors are either single-pass 
transmembrane proteins or linked to the cell surface by a glycosylphosphatidyl inositol (GPI) 
anchor. Adhesion receptors from the Ig superfamily play a multitude of functions in embryonic 
development and are also expressed by many cells in the adult organism. Many proteins from this 
superfamily play important functions in the cell-cell interactions of the immune system and 
between leukocytes and the vasculature. This family includes proteins such as ICAM-1, ICAM-2 
and VCAM.
Selectins are single-pass transmembfane proteins that are expressed by leukocytes, 
platelets and vascular endothelial cells. Through their extracellular lectin-like domains these 
receptors interact with carbohydrate structures present on other cells. The selectins mediate cell­
cell interactions between leukocytes and the vessel wall and participate in platelet aggregation. 
The selectins play important functions in processes such as neutrophil extravasation and 
lymphocyte homing.
The integrin family of adhesion receptors plays many important functions in cell-cell and 
cell-ECM interactions. Integrins are heterodimers composed of one a-subunit and one p-subunit. 
The existence of at least 15 different a-subunits and 8 different p-subunits gives rise to an 
immense number of possible combinations, however only a limited number (around 20) seem to 
exist. Integrins interact with a variety of ECM proteins including vitronectin, fibronectin, 
collagen, laminin and with a number of different cell surface proteins. Integrins are the major
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type of adhesion receptors mediating cell-ECM contacts but also have important functions in cell­
cell contacts and in signal transduction.
The subject of this thesis, the urokinase receptor (uPAR), is not a member of these protein 
families. However, uPAR is capable of mediating cell-ECM and cell-cell contactsi and can 
therefore also be considered an adhesion receptor, maybe the first of a yet to be defined family.
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Extracellular proteolysis
Processes involving tissue remodelling and cell migration require the degradation of ECM 
components. To accomplish this degradation cells express a variety of proteases with variable 
activity and substrate specificity. The activity of these proteases is localised and regulated by 
their interactions with ECM components and a variety of specific inhibitors and cell surface 
receptors. The two major proteolytic systems responsible for ECM degradation are the matrix 
metalloproteases (MMPs) and the plasminogen activator system.
Some of the proteases in these two systems appear to be highly specific while others have 
a broad range of substrates. Proteases from both systems are secreted as inactive zymogens, 
which require a proteolytic cleavage to gain full activity. The activating cleavage may be 
executed by a protease from the same system, as exemplified by the activation of pro-uPA by 
plasmin, or by the action of a protease from another system, as exemplified by the activation of 
proMMP-2 by plasmin. The redundancy within and between these two protease systems most 
likely reflects the importance of regulated extracellular proteolysis.
uPAR is intimately connected to the plasminogen activator system which will therefore be 
discussed in detail. However, to provide a more complete picture I will start with a very brief 
introduction to the MMP system.
Matrix metalloproteases (MMPs)
MMPs are a family of proteins capable of degrading ECM components under 
physiological conditions. The family currently consists of 16 members but more may exist. The 
proteins share a common catalytic domain, which binds the Zn2+ necessary for function, and a 
region responsible for the maintenance of zymogen latency. Various other domains present in the 
enzymes determine activity, substrate specificity, ECM association and inhibitor binding. Four of 
the MMPs are integral membrane proteins (membrane-type MMPs, MT-MMPs). The MT-MMPs 
have a domain structure which is similar to the other MMPs except for the addition of a 
transmembrane domain and a cytoplasmic tail. The MMPs have been classified based on their 
substrate preferences: the gelatinases, which degrade non-fibrillar and other types of denatured 
collagens; the collagenases, which degrade fibrillar collagen; and the stromelysins, which 
preferentially degrade glycoproteins and proteoglycans.
Four specific inhibitors of matrix metalloproteases (tissue inhibitor of metalloproteases, 
TIMPs) have been identified. The TIMPs inhibit MMP activity through the formation of 
complexes with the active MMPs. The TIMPs have in common their inhibitory effect on MMPs 
but have different expression patterns. TIMPs are found to have other functions and may even 
promote MMP activation under certain circumstances.
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MMP activation occurs by proteolytic cleavage of the propeptide which blocks the active 
site cleft and is a critical point in the regulation of these enzymes. The activation can be 
accomplished by other members of the MMP family or by enzymes from other protease systems 
as for instance by plasmin which is capable of activating several of the MMPs. Furthermore, MT- 
MMPs may be activated before they reach the cell surface by action of the protease furin.
In parallel to what will be described later for the plasminogen activator system, interesting 
mechanisms exists for the activation of MMPs on the cell surface. The activation of MMP-2 on 
the cell surface for example starts with the binding of MMP-2 to a preformed cell surface 
complex composed of MT1-MMP and TIMP-2. The formation of the trimeric MT1 -MMP/TIMP- 
2/pro-MMP-2 complex localises pro-MMP-2 to the cell surface where it is efficiently activated 
by flanking MT1-MMP free of TIMP-2. In accordance with this model the concentration of 
TIMP-2 plays a critical role in the cell surface activation of pro-MMP-2. TIMP-2 is required to 
create the binding sites for pro-MMP-2 on the cell surface, but too much TIMP-2 will block all 
the active MTl-MMPs and prevents the concomitant activation of bound pro-MMP-2 (for recent 
reviews on the interesting field of MMP activation, MT-MMPs and MMPs in angiogenesis see 
Murphy et al., 1999; Seiki, 1999; Stetler-Stevenson, 1999; Werb et al., 1999.)
The plasminogen activator system
Plasmin is capable of degrading virtually all proteins present in the ECM, either directly 
or through the activation of pro-MMPs. Plasminogen, the zymogen of plasmin, is present almost 
everywhere in the organism and can be activated by either of the two known plasminogen 
activators: urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator 
(tPA).
The uPA-type of plasminogen activation is very efficiently exerted on the cell surface in a 
process which require the concomitant binding of both pro-uPA and plasminogen to the cell 
surface. The binding of pro-uPA to the cell surface is critical for the acceleration of plasminogen 
activation and is mediated by a specific uPA-receptor (the subject of this thesis, uPAR). The 
activity of the enzymes from the plasminogen activator system is regulated by a number of 
plasmin and plasminogen activator inhibitors, which prevent the potentially disastrous 
consequences of uncontrolled ECM proteolysis. Plasminogen activation thus provides a highly 
versatile, directed, and regulated system for the degradation of the ECM.
The plasminogen activator system has for many years been considered the major 
proteolytic system responsible for ECM degradation in processes involving tissue remodelling 
and cell migration. However, the accumulation of information about other protease systems, and
Chapter 1 : Introduction
in particular about the MMPs, has demonstrated the existence of an extensive functional overlap 
and complementarity between these systems.
As the different players of the plasminogen system are intrinsically connected to the 
function of uPAR, I will in this section describe these molecules in some detail.
Plasminogen
Plasminogen is the zymogen for the serine protease plasmin. The major form of 
plasminogen is a single chain glycoprotein of 92 kDa with an aminoterminal glutamic acid 
residue and is known as Glu-plasminogen (Glu-Plg). Minor forms of plasminogen are generated 
by limited proteolysis of the aminoterminal sequence and are collectively known as Lys- 
plasminogen (Lys-Plg)(Lijnen and Collen, 1982). The different forms of plasminogen have 
different binding affinities for fibrin and different activation characteristics (Claeys and 
Vermylen, 1974; Lijnen and Collen, 1982). By its "kringle" domains plasminogen is able to bind 
many different ECM proteins including fibrin, fibronectin, thrombospondin, vitronectin and 
laminin (Preissner, 1990; Salonen et al., 1985; Salonen et al., 1984; Silverstein et al., 1990).
Plasminogen activation is catalysed by one of the two known plasminogen activators uPA 
and tPA and occurs by a specific proteolytic cleavage between aminoacids Arg 560 and Val 561. 
The cleavage generates the plasmin A and B chains, which remain linked by two disulphide 
bonds. The generated plasmin is a trypsin-like, broad specificity serine protease that cleaves most 
of the ECM proteins to which it binds including fibrin, fibronectin, thrombospondin and laminin 
(Dan0 et al., 1985; Pôllànen et al., 1991). Plasmin is rapidly inactivated by the serum inhibitors 
o^-antiplasmin and c^-macroglobulin, which are present abundantly in the organism.
Virtually all cells have high capacity, low-affinity (1 pM), cellular binding sites for 
plasminogen (reviewed by Pelez et al., 1990) and the concomitant binding of uPA to cell surfaces 
strongly enhances the generation of plasmin (Ellis et al., 1989; Stephens et al., 1989). Cell 
surface bound plasmin is resistant to inhibition by c^-antiplasmin and o^-macroglobulin (Hall et 
al., 1991) hereby enhancing and concentrating the plasmin activity to the pericellular space.
Mice with an inactivated plasminogen gene have been generated (Bugge et al., 1995). 
Plasminogen deficiency results in high mortality, wasting, spontaneous gastrointestinal 
ulceration, rectal prolapse, and severe thrombosis, but is however compatible with development 
and reproduction. A combined deficiency of fibrinogen and plasminogen rescues mice from most 
of the pleiotropic effects of plasminogen-deficiency (Bugge et al., 1996). In fact, mice deficient 
in both plasminogen and fibrinogen are phenotypically indistinguishable from fibrinogen- 
deficient mice, suggesting that the fundamental and maybe the only essential physiological role 
of plasminogen is fibrinolysis. However, plasminogen-deficient mice display impaired wound
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healing (R0mer et al., 1996a; R0mer et al., 1996b), arterial neointima formation (Carmeliet et al., 
1997d), and monocyte migration (Ploplis et al., 1998), demonstrating the important role of 
plasminogen in processes involving cell migration.
Plasminogen is capable of activating some pro-MMPs (Mignatti et al., 1986; Murphy et 
al., 1992; Werb et al., 1977) and may thereby promote the degradation of ECM proteins which 
plasmin fails to degrade directly. The role of plasmin in the activation of pro-MMPs has been 
addressed in vivo using Pig-deficient mice (Lijnen et al., 1998). In an experimental system of 
arterial injury plasminogen appears to be required for the activation of pro-MMP-9 but not for 
pro-MMP-2 activation. These latter data suggest that plasmin may be important for the activation 
of some pro-MMP, while others are more dependent upon other activation mechanisms such as 
the activation by (MT-)MMPs.
Plasmin may also have a function in the activation of precursor forms of cytokines and 
growth factors (reviewed by Rifkin et al., 1999) as exemplified by the activation of transforming 
growth factor p (TGFP)(Nunes et al., 1995).
The important role of plasminogen in cancer is substantiated by the finding that tumour 
growth and metastasis in Polyoma virus middle T (PymT) antigen-induced mammary cancer is 
reduced in plasminogen-deficient mice (Bugge et al., 1998). However, in the Lewis-Lung cancer 
model system plasminogen deficiency has no significant effect on metastasis, and only a mild 
effect on primary tumour growth and overall survival (Bugge et al., 1997). The latter observation 
is particularly intriguing as plasminogen is the precursor for the anti-angiogenic molecule 
angiostatin which has strong effects on metastasis of the Lewis-Lung tumour (O'Reilly et al.,
1994).
Plasminogen activators
Plasminogen activators (PA) are highly specific serine proteases capable of activating 
plasminogen to plasmin. In mammalians two different PAs have been identified, urinary-type and 
tissue-type plasminogen activator (uPA and tPA). Even though the two PAs catalyse the same 
reaction, uPA is thought to be more important in tissue remodelling and tPA in vascular 
fibrinolysis. As these enzymes catalyse the same reaction, a significant functional overlap 
between the tPA and uPA has been observed. This functional overlap is best illustrated by gene 
inactivation experiments in which the single inactivation of uPA or tPA causes only rather mild 
phenotypes, while the double deficiency causes extensive spontaneous fibrin deposition and 
consequent serious effects on growth, fertility and survival (Carmeliet et al., 1994). The 
consequences of uPA and tPA double deficiency, is similar to the consequences of plasminogen 
deficiency (Bugge et al., 1995).
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Urokinase-type plasminogen activator uPA
The zymogen form of human uPA (pro-uPA) is secreted as a single glycoprotein chain of 
52 kDa. The protein is composed of three distinct regions namely the growth factor domain, the 
kringle domain and the catalytic domain. The growth factor domain has significant homology 
with epidermal growth factor (EGF), while the kringle domain is homologous to those present in 
tPA and plasminogen.
Many different cell types secrete pro-uPA and elevated levels of production are in 
particular associated with transformed phenotypes of cells. In adherent cells uPA is almost 
exclusively localised at cell-cell contacts and at focal adhesion contacts with the ECM (Pôllànen 
et al., 1988; Pôllànen et al., 1990).
Both pro-uPA and uPA bind with high affinity (0.1-1 nM) to a glycosylphosphatidyl 
inositol (GPI) anchored glycoprotein, uPAR. The coincident binding of pro-uPA and 
plasminogen to the cell surface strongly enhances pro-uPA and plasminogen activation (Ellis et 
al., 1991; Stephens et al., 1989) by a mechanism which probably involves a constructive 
alignment of the two pro-enzymes (Ellis and Dan0, 1993). Low affinity interactions between uPA 
and ECM proteins such as thrombospondin, fibrin and vitronectin have also been described 
(Moser et al., 1995; Pannell and Gurewich, 1986; Silverstein et al., 1990).
Active uPA is generated by plasmin cleavage of pro-uPA between Lys 158 and lie 159, 
resulting in a molecule composed of two polypeptides held together by a single disulphide bond. 
Plasmin is also able to cleave pro-uPA at Lys 135 / Lys 136 generating two separate fragments: 
the aminoterminal fragment (ATF) composed of the EGF and kringle domains, and the 
carboxyterminal fragment containing the catalytic domain (often referred to as low molecular 
weight uPA (LMW-uPA)).
uPA deficient mice have been generated (Carmeliet et al., 1994). The mice have normal 
life-span and fertility, and the only histological phenotype is the occasional occurrence of fibrin 
deposits. Experiments with uPA-deficient mice and cells derived from these have identified a 
number of interesting abnormalities with respect to cell migration, immune response, growth 
factor activity and activation of MMPs.
uPA-deficiency causes an in-efficient pulmonary inflammatory response to C. 
neoformans (Gyetko et al., 1996) with concomitant elevated mortality, suggesting that uPA plays 
important functions in the immune system. Furthermore, T cells isolated from the uPA-deficient 
mice display impaired activation and proliferation in vitro (Gyetko et al., 1999).
uPA-deficient mice display impaired arterial neointima formation after injury, most likely 
caused by an impaired migration of smooth muscle cells (Carmeliet et al., 1997a). Analysis of 
atherosclerotic aortas in mice with a combined deficiency of apolipoprotein E and uPA indicates
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that deficiency of uPA protects against media destruction and aneurysm formation, probably by 
means of reduced plasmin-dependent activation of pro-MMPs (Carmeliet et al., 1997b).
Experiments using smooth muscle cells isolated from uPA-deficient mice show that uPA 
catalysed plasminogen activation, through the generation of active TGFP from latent TGFP, is 
required for the anti-apoptotic activity of TGFP on smooth muscle cells (Herbert and Carmeliet,
1997).
Tissue-type plasminogen activator ftPAl
tPA is a secreted single chain 70 kDa glycoprotein. The protein is composed of a 
aminoterminal finger domain, a growth factor domain, two kringle domains, and a 
carboxyterminal catalytic domain. tPA is secreted from vascular endothelial cells and measurable 
levels of tPA are found in the circulation (Holvoet et al., 1985). tPA is also secreted from many 
cultured tumour cells, including melanoma and neuroblastoma (Andreasen et al., 1984), Cellular 
binding sites exist on many cells including endothelial, neuronal and melanoma cell lines (Bizik 
et al., 1990; Hajjar et al., 1987), but the function of the cellular binding site for tPA has not been 
finally determined.
. Single chain tPA has, unlike pro-uPA, notable enzymatic activity (Boose et al., 1989). 
The enzymatic activity is enhanced by plasmin cleavage at Arg 275, which generates the two- 
chain form held together by a single disulphide bond. The catalytic activity of both forms of the 
enzyme is strongly enhanced by the interaction with fibrin (Hoylaerts et al., 1982), which also 
reduces the rate of inhibition by PAI-1 and PAI-2 (Leung et al., 1987). The fibrin requirement for 
optimal catalytic activity of tPA suggests that this enzyme may predominantly play a functional 
role in fibrinolysis.
tPA-deficient mice have been generated (Carmeliet et al., 1995). The mice are fertile and 
have a normal life-span. However, the mice display impaired lysis of blood clots supporting the 
view that tPA is involved in the maintenance of vascular fibrinolysis.
Interestingly, tPA appears to play a role in neuron function. Mice deficient for tPA are 
resistant to excitotoxin-mediated hippocampal neuronal degeneration (Tsirka et al., 1997) and 
long-term potentiation in different neuronal cells is also impaired (Huang et al., 1996). The role 
of tPA in the brain has recently been substantiated, as transgenic mice overexpressing tPA have 
enhanced hippocampal long-term potentiation and learning ability (Madani et al., 1999).
Plasminogen activator inhibitor type 1 fPAI-D
Plasminogen activator inhibitors (PAIs) belong to the family of serine protease inhibitors 
(serpins). The inhibitors form 1:1 complexes specifically with the active (two chain) forms of the
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plasminogen activators (Wun and Reich, 1987). The formed complexes are SDS-PAGE resistant 
suggesting a covalent binding between the two molecules.
PAI-1 is a 52 kDa glycoprotein (Andreasen et al., 1986; Nÿ et al., 1986; Pannekoek et al., 
1986) secreted by a wide range of cell types including vascular endothelium, platelets, 
hepatocytes, fibroblasts, and many different tumour cell lines. The protein is present in normal 
plasma at 10-30 ng/ml but elevated levels are observed in different physiological and 
pathological conditions. In solution, secreted active PAI-1 rapidly loses activity by a 
conformational change into a latent form (Levin, 1986). PAI-1 interacts with circulating and 
ECM forms of vitronectin and this binding stabilises PAI-1 in its active configuration (Declerck 
et al., 1988; Pôllànen et al., 1987; Salonen et al., 1989; Wiman et al., 1988).
PAI-1 is considered to be the principal regulator of fibrinolysis in the vasculature and 
recent findings demonstrate that it also plays important roles in processes as cell migration and 
adhesion. The latter aspects of PAI-1 will be described later in the introduction.
PAI-1-deficient mice are viable and fertile, and show no apparent macroscopic 
histological abnormalities (Carmeliet et al., 1993). A more detailed analysis of PAI-1-deficiency 
demonstrates impaired vascular wound healing and arterial neointima formation after injury, 
probably caused by reduced cell migration (Carmeliet et al., 1997c). Absence of host PAI-1 
prevents invasion and vascularisation of transplanted malignant kératinocytes (Bajou et al.,
1998), suggesting that PAI-1 may play a role in angiogenesis and tumour invasion. Also the 
resolution of experimentally induced thrombi is enhanced in PAI-1-deficient mice strengthening 
the view that PAI-1 is indeed an important determinant of thrombolysis for instance at sites of 
arterial injury (Farrehi et al., 1998).
Plasminogen activator inhibitor type 2 (PAI-2)
PAI-2 exists in a 47 kDa intracellular and in a glycosylated 60 kDa extracellular form 
(Wohlwend et al., 1987). PAI-2 is secreted from stimulated monocytes, cultured U937 cells and 
from placental trophoblastic epithelium (Àstedt et al., 1985; Colder and Stephens, 1983; Wun 
and Reich, 1987). Unlike PAI-1, PAI-2 does not spontaneously lose activity in solution and has 
no known binding proteins in the extracellular matrix.
PAI-2 is thought to predominantly be an inhibitor o f uPA, as its activity towards fibrin 
bound tPA is strongly reduced (Leung et al., 1987; Wun and Reich, 1987).
The understanding of the role of PAI-2 in extracellular matrix proteolysis is complicated 
by the fact that induction of PAI-2 expression in fibroblasts and melanoma cells leads to 
accumulation of an intracellular form, without notable secretion (Pytel et al., 1990).
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PAI-2 deficient mice have been generated (Dougherty et al., 1999) and are phenotypically 
normal.
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The Urokinase Receptor (uPAR)
uPAR was discovered in 1985 as a cellular high affinity binding site for uPA present on 
fibroblasts, monocytes and cultured U937 cells (Bajpai and Baker, 1985; Stoppelli et al., 1985; 
Vassalli et al., 1985). Utilising its affinity for uPA the receptor was purified, partially sequenced, 
and a human uPAR cDNA was cloned (Roldan et al., 1990). Since then, uPAR encoding cDNAs 
from mouse, rat, and bovine cells have been cloned and sequenced (Kràtzschmar et al., 1993; 
Kristensen et al., 1991; Rabbani et al., 1994; Reuning et al., 1993).
uPAR mediated cell binding of uPA is regulated at various levels. The steady state level 
of uPAR mRNA is regulated on the level of transcription and mRNA stability. Posttranslational 
glycosylation affects the affinity of the receptor for uPA and sorting of uPAR to secretory 
organelles provides means for a rapid up-regulation of the cell surface expression. Once uPAR is 
on the cell surface the capacity to bind uPA is also regulated by receptor shedding, a process in 
which uPAR is released from the cell surface, and by proteolytic cleavage of uPAR which 
prevents uPA binding.
uPAR gene structure and expression
The human uPAR gene is composed of seven exons and six introns. (Wang et al., 1995) 
and in man maps to chromosome 19 (B0rglum et al., 1992).
uPAR is present on many cells, including migrating kératinocytes, tumour-infiltrating 
fibroblasts, T lymphocytes and macrophages, many cancer cells, and most cultured cell lines 
(Pyke et al., 1991; R0mer et al., 1994a; R0mer et al., 1994b). In leukocytes uPAR is expressed by 
monocytes, neutrophils and activated T cells, but not B cells, resting T cells, and undifferentiated 
myeloid cells (Plesner et al., 1997; Ploug et al., 1992b; Vassalli et al., 1985). uPAR expression in 
T cells can be efficiently induced by co-clustering of the T cell receptor complex and integrins 
(Bianchi et al., 1996), or by infection with HIV (Nykjaer et al., 1994; Speth et al., 1998), 
identifying uPAR as a T cell activation antigen. uPAR is also a monocyte activation antigen 
(Dore-Duffy et al., 1992; Picone et al., 1989).
Basal transcription of the uPAR gene is driven by a TATA-less proximal promoter 
(Soravia et al., 1995). A number of cytokines, such as TNFa and TGF(J, and phorbol esters may 
regulate uPAR transcription (Lund et al., 1995; Lund et al., 1991; Niiya et al., 1998; Picone et al., 
1989; Wang et al., 1994). The expression level of uPAR is also regulated on the level of mRNA 
stability and the responsible regions within the uPAR mRNA as well as mRNA binding proteins 
have been identified (Lund et al., 1995; Lund et al., 1991; Niiya et al., 1998; Shetty and Idell, 
1998; Shetty et al., 1997; Wang et al., 1998).
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The protein structure of uPAR
The human uPAR cDNA encodes a 335 amino acid polypeptide. The nascent polypeptide 
chain is posttranslationally modified in several ways to generate the mature receptor. An 
aminoterminal signal peptide and a carboxyterminal GPI-anchor peptide are removed during the 
processing for glycosylphosphatidyl inositol (GPI) anchoring and cell-surface sorting. Finally, 
the protein is extensively glycosylated (Mpller et al., 1992; Ploug et al., 1991; Roldan et al., 
1990).
Glycosylation
The glycosylation of uPAR is highly heterogeneous and responsible for approximately 
half of uPAR's apparent molecular weight of 50-60 kDa (Behrendt et al., 1990; Roldan et al., 
1990). Based on the primary sequence, human uPAR contains five potential N-glycosylation sites 
(Roldan et al., 1990). However on recombinant human suPAR expressed in Chinese hamster 
ovary cells (CHO) only four ôf the five asparagine residues (Asn52, Asnl62, Asnl72, and, 
Asn200) are glycosylated. The glycosylation profile of uPAR has recently been determined 
(Ploug et al., 1998c).
The glycosylation profile of uPAR is dependent on cell-type and differentiation, and may 
play a role in the regulation of the affinity for uPA (Behrendt et al., 1990; M0ller et al., 1993; 
Picone et al., 1989; Ploug et al., 1998c).
GPI-anchoring
During the post-translational processing of the nascent uPAR polypeptide the -28 
carboxyterminal amino acids are removed and the GPI-moiety covalently attached to the novel 
carboxyterminus. The exact carboxyterminus, and thus the position of the GPI-anchor on mature 
uPAR, has not been determined yet but mutagenesis studies strongly suggest that Gly 283 is the 
GPI-anchorage site (M0ller et al., 1992).
The fact that uPAR is anchored to the outer leaflet of the plasma membrane is essential 
for the understanding of its biology. Lacking a membrane or intracellular protein segment, the 
highly regulated cell-surface distribution and signal transduction by uPAR must be mediated 
through the interaction of uPAR with other integral membrane proteins and/or specific lipids. 
GPI-anchoring of uPAR also renders the protein prone to release from the cell surface by 
phospholipases, generating soluble forms of uPAR (termed suPAR) which can indeed be found in 
vitro and in vivo, although the biological relevance of this still has to be clarified.
Much of the biochemical analysis of uPAR has been performed using recombinant 
soluble forms of uPAR, termed suPAR, generated by carboxyterminal truncation after amino acid
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274. Truncation of uPAR at this position generates a receptor which is correctly folded but 
secreted rather than GPI-anchored. suPAR apparently possesses the same binding properties as 
GPI-anchored uPAR purified from eukaryotic cells (R0nne et al., 1994).
Domain structure of mature uPAR
Mature uPAR is composed of three similar domains which will be termed D l, D2 and D3 
from now on (figure 1.1). Each of these domains consists of approximately 90 amino acids and 
they are characterised by a particular pattern of Cys residues (Behrendt et al., 1991; Ploug et al., 
1993). uPAR belongs to a superfamily of proteins comprising the mouse antigen Ly-6, the 
complement component CD59, the murine thymocyte / B cell antigen ThB, a human homologue 
of ThB (Ag E48), the rat bone protein RoBo-1, the herpes virus protein HVS-115, the snake 
serum protein PLI-1 (Nobuhisa et al., 1997), and the snake venom a-neurotoxins (Albrecht et al., 
1992; Brakenhoff et al., 1995; Gumley et al., 1992; Palfree, 1991).
The disulphide pairing pattern of uPAR D l has been determined (Ploug et al., 1993) and 
conforms to that of CD59 (Sugita et al., 1993). The structure of CD59 has been determined by 
NMR-studies and has been used to model the individual uPAR domains. The structure is 
composed of a disulphide cross-linked core from which three loops extend. The structure is 
dominated by p sheets and a short a-helical segment in the third loop (Fletcher et al., 1994; 
Kieffer et al., 1994; Ploug and Ellis, 1994).
Molecular uPAR interactions
uPAR is anchored to the outer leaflet of the plasma membrane by a GPI-anchor, has no 
intracellular domain or transmembrane spanning segment, is devoid of catalytic activity, and 
therefore must perform all its known functions through its interaction with other proteins. These 
interactions can be divided into two groups, depending whether they occur with other membrane 
molecules on the same cell (lateral interactions) or with molecules in solution, in the extracellular 
matrix, or on other cells (ligand interactions).
Lateral interactions between uPAR and other membrane proteins are crucial for the 
function of uPAR as a modulator of cell adhesion and migration, and for its chemokine activity. 
The existence of these uPAR interactions relies so far only on circumstantial evidence. The 
techniques employed include co-localisation by immunohistochemistry, fluorescence resonance 
energy transfer (RET) analysis, chemical cross-linking and co-immunoprecipitation. The 
structural basis for these direct molecular interactions is presently unknown.
The ligand interactions of uPAR include its classical interaction with uPA and vitronectin. 
The interaction of uPAR with these two molecules forms the molecular basis for many of the
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biological roles of uPAR in proteolysis and cell adhesion are they are very well documented in 
the literature.
The interaction between uPAR and uPA
uPAR was initially identified as the cellular binding site for uPA, and the structural basis 
for this interaction has now been studied for more than a decade. While the binding determinants 
within uPA have been mapped to a single epitope, the regions of uPAR critical for binding are 
multiple and may involve conformational changes of the receptor.
In uPA, the region necessary and sufficient for high-affinity binding to uPAR is located in 
the aminoterminal growth factor-like domain (GFD, Appella et al., 1987). The binding site is 
located within the omega-loop (amino acid residues 22-28, Hansen et al., 1994)), a region which 
is critical for binding (Magdolen et al., 1996; Ploug et al., 1995). Glycosylation of uPA does not 
seem to be important for binding because uPA expressed in E.co/z interacts with uPAR with 
similar affinity as the glycosylated protein.
Cleavage of uPAR by chymotrypsin in the linker region between D l and D2 generates the 
two uPAR fragments D l and D2D3 (Behrendt et al., 1991). This cleavage dramatically reduces 
(>2000 fold) the affinity for uPA, and specific uPA binding can only be demonstrated for the Dl 
fragment (Behrendt et al., 1991; Ploug et al., 1994). The fact that uPAR cleavage reduces the 
affinity dramatically suggests that determinants within D2 and/or D3 are also important for uPA 
binding. In fact, a soluble uPAR lacking D3 displays strongly impaired binding of uPA (Behrendt 
et al., 1996). Photoaffinity labelling experiments using synthetic peptides that mimic the binding 
characteristics of uPA (Goodson et al., 1994), have indeed demonstrated the existence of a 
composite binding site involving regions within both D l and D3 (Ploug, 1998a). In particular Tyr 
57 in loop 3 of Dl has been demonstrated to be localised at the interaction interface (Ploug et al.,
1995).
The glycosylation of Asn 52 in D l also appears to be required for high affinity, as an 
engineered uPAR lacking D l glycosylation displays moderately reduced binding affinity (M0ller 
et al., 1993). The kinetic explanation for this appear to be an increased dissociation rate (Ploug et 
al., 1998c).
The interaction between uPAR and vitronectin
The second well-characterised ligand for uPAR is vitronectin. Vitronectin is glycoprotein 
present at high concentrations in plasma and produced by the liver (Preissner, 1989). It is found 
in a single-chain form with an apparent molecular weight of 75 kDa, and in a two-chain form (65 
and 10 kDa) in which the two domains are held together by a single disulphide bond. Vitronectin
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is found in a monomeric form (the native form) and in a denatured multimeric form (the matrix 
form).
The interaction between uPAR and vitronectin appears to be even more complex than the 
interaction between uPAR and uPA, and is not yet well understood. Both soluble and cellular 
uPAR interact with vitronectin (Waltz and Chapman, 1994; Wei et al., 1994; Chapter 3) and the 
binding takes place with both the native and denatured form (H0yer-Hansen et al., 1997a; Kanse 
et al., 1996). uPAR binding has been mapped to the aminoterminal somatomedin B domain of 
vitronectin (Deng et al., 1996), a region which also contains the binding sites for PAI-1 and the 
vitronectin receptor. Another region in vitronectin, close to the carboxyterminus, has also been 
demonstrated to bind uPAR but less efficiently (Waltz et al., 1997).
Vitronectin binding requires multiple regions within uPAR, as both the D l and D2D3 
fragments fail to display appreciable affinity (H0yer-Hansen et al., 1997a; Chapter 3). Several 
antibodies against D l inhibit the interaction between uPAR and vitronectin suggesting a crucial 
role for this domain in the binding (H0yer-Hansen et al., 1997a; Kanse et al., 1996; Chapter 3). 
These data are in contrast to the initial observations which suggested that a fragment containing 
D2 and D3 was capable of interaction with vitronectin (Wei et al., 1994).
The binding to vitronectin is connected to the occupancy of uPAR by uPA (H0yer-Hansen 
et al., 1997a; Waltz and Chapman, 1994; Wei et al., 1994; Chapter 3). In most studies a notable 
increase in binding to vitronectin is observed, and in one case a strict requirement, upon binding 
of uPA. However, the affinity as assayed by real-time biomolecular analysis is not affected by 
uPA (H0yer-Hansen et al., 1997a). Taken together, most data are consistent with a model in 
which uPAR can exist in more than one conformation and that the vitronectin binding 
conformation is acquired upon uPA binding (Wei et al., 1994).
Other molecular uPAR interactions
Besides the (well-established) interactions with uPA and vitronectin, uPAR has been 
reported to directly interact with a couple of other proteins.
High molecular weight kininogen (HK) has been shown to interact with both cellular and 
soluble uPAR in a Zn2+ dependent mechanism through interactions with a region within D2 
and/or D3 (Colman et al., 1997), The interaction between uPAR and kininogen, however, still 
needs more study.
A direct interaction between soluble uPAR and purified immobilised Mac-1, in a reaction 
which requires the active ligand binding conformation of Mac-1, has been demonstrated (Wei et 
al., 1996). The modulatory role of uPAR on Mac-1 function, which will be discussed in detail 
below, gives some support to the existence of this interaction.
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Cleaved and soluble forms of uPAR
Cellular uPAR has been shown to undergo two major types of cleavage that profoundly 
alter the characteristics of the receptor.
The first type is a proteolytic cleavage in the linker region connecting D1 and D2 and 
results in the release of the D1 fragment from the rest of the receptor. The cleavage changes the 
biochemical properties of the receptor completely. I will refer to this phenomenon as uPAR 
cleavage.
The second type of uPAR cleavage has not been characterised at the molecular level, but 
is either a proteolytic cleavage of the polypeptide chain close to the GPI anchor or hydrolysis of 
the GPI-anchor by a phospholipase. This cleavage releases the entire receptor from the cell 
surface, with concomitant functional changes, but does not alter the ligand binding properties of 
the receptor notably. I will refer to this process as uPAR shedding.
uPAR cleavage
Mechanism
The clues for the domain structure of uPAR relies on the fact that uPAR can be 
fragmented into two parts using very low concentrations of chymotrypsin and that one of these, 
D l, is endowed with weak but specific uPA-binding activity (Behrendt et al., 1991). Together 
with the internal homology revealed by sequence analysis, these data suggested that uPAR is 
composed of three domains connected by two "linker regions" of approximately 20 amino acids. 
The linker region connecting D l and D2 contains a number of potential cleavage sites for trypsin- 
and chymotrypsin-like proteases and for leukocyte elastase as shown in figure 1.1 (Behrendt et 
al., 1991; Ploug and Ellis, 1994).
Trypsin and chymotrypsin are not likely candidates for the uPAR cleavage in vivo and it 
is shown that biologically more relevant proteases, such as plasmin and uPA itself, are capable of 
cleaving the receptor in this region (Hpyer-Hansen et al., 1992). The cleavage of uPAR by uPA 
in solution does not require binding of uPA to uPAR as the ligand binding domain of uPA can 
not inhibit the reaction, and because the cleavage is equally well performed by a binding- 
deficient form of uPA (LMW uPA).
The cleavage of uPAR by uPA is accelerated on the surface of U937 cells in a mechanism 
that requires the binding of uPA to uPAR (H0yer-Hansen et al., 1997b). The use of anti-catalytic 
uPA antibodies in cell culture lias indeed demonstrated that uPA activity is required for the 
cleavage of uPAR on cultured U937 cells. The reason for the cell surface acceleration is not 
clear, but it has been suggested uPA bound to uPAR does not cleave the receptor it is occupying,
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but rather nearby, receptors on the same cell. The latter implies that efficient receptor cleavage is 
expected to occur most efficiently in uPAR rich zones on the cell surface, and even in the 
presence of low concentrations of uPA.
The high affinity between uPAR and uPA makes uPA a good candidate for uPAR 
cleavage in vivo. However, whether other proteases are also involved still remains to be resolved.
The linker region connecting D2 and D3 does not contain similar cleavage sites and is 
indeed much less susceptible to cleavage. The D2-D3 linker region is also expected to be less 
flexible than the D1-D2 linker region as D l has one disulphide bond less than D2 and D3. 
Specific cleavage of uPAR between D2 and D3 can however be achieved in solution using pepsin 
(Behrendt et al., 1996).
Biochemical consequences
As described in the previous section, the cleavage of cellular uPAR in the region between 
D l and D2 profoundly alters the biochemical properties of the receptor. The released D l has a 
2000 fold reduced affinity for uPA as compared to the intact receptor and the D2D3 fragment has 
no measurable affinity at all (Ploug et-al., 1994). Also the interaction with vitronectin is lost as 
none of the generated fragments binds with measurable affinity (H0yer-Hansen et al., 1997a). In 
this respect the cleavage of uPAR can be seen as an inactivation mechanism. However, as the 
cleavage of uPAR exposes novel epitopes capable of interacting with so far unidentified 
membrane proteins (Fazioli et al., 1997; Resnati et al., 1996), the cleavage of uPAR may also be 
considered an activation event.
The occurrence of receptor cleavage
Cleaved uPAR (D2D3) has been found on the surface of many cells including endothelial 
cells, lymphocytes, U937 cells, and in several different cancer cell lines (Holst-Hansen et al., 
1999; Hpyer-Hansen et al., 1992; Ragno et al., 1998; Solberg et al., 1994; Chapter 6). Cleaved 
uPAR has also been identified in detergent extracts of transplanted human tumours grown in 
nude mice and in the mouse Lewis Lung tumour (Holst-Hansen et al., 1999; Solberg et al., 1994; 
Chapter 6). The cleavage of cellular uPAR releases D l to the surroundings and D l can indeed be 
found in the conditioned medium from cells with cleaved uPAR on the surface (Chapter 5).
One of the major obstacles in the analysis of cleaved uPAR is caused by the highly 
heterogeneous glycosylation of uPAR that often masks the difference between D2D3 and full- 
length uPAR in ordinary immunoblots. Only the careful use of domain-specific monoclonal 
antibodies and/or deglycosylated extracts allows this type of analysis to be performed in an 
unambiguous way (Chapter 5).
Chapter 1: Introduction
uPAR shedding
Soluble forms of uPAR (suPAR) are thought to lack the GPI-anchor, rendering the 
molecule more soluble in aqueous solutions. The absence of the GPI-anchor has been 
demonstrated for suPAR isolated from ascitic fluid of ovarian cancer patients (Pedersen et al., 
1993). However, I will in the following consider all uPAR molecules found in cell-free liquids 
such as conditioned medium, serum and urine, as suPAR, even though the absence of the GPI- 
anchor often has not been confirmed.
Mechanism
The mechanism of uPAR shedding has not been determined yet. Bacterial phosphatidyl- 
inositol specific lipase C (PIPL-C) is able to release uPAR from the surface o f cells, but no 
equivalent eukaryotic activity has been described (Ploug et al., 1991). A human cellular 
phosphatidylinositol specific phospholipase D (PIPL-D) is able to release GPI-anchored proteins 
from the cell surface (Metz et al., 1994), and this phospholipase has also recently been implicated 
in the release of uPAR (Wilhelm et al., 1999).
Another possibility is that uPAR shedding is caused by "imperfect" sorting, possibly in 
cases where uPAR expression is very high or rapidly upregulated.
Biochemical consequences
uPAR shedding does apparently not alter its affinity for uPA and vitronectin (Rpnne et al., 
1994; Wei et al., 1994).
Occurrence of suPAR and suPAR fragments
suPAR is present in the conditioned medium from endothelial cells, leukocytes, U937 and 
HT1080 cells (Chavàkis et al., 1998; Lau and Kim, 1994; Ploug et al., 1991; Chapter 5) and in 
biological fluids such as plasma, urine, spinal fluid, ascites, and ovarian cyst fluid (Pedersen et 
al., 1993; Sier et al., 1999; Stephens et al., 1997; Wahlberg et al., 1998).
Until recently, soluble forms of cleaved uPAR (D2D3) have only been described in 
ovarian cyst fluid (Wahlberg et al., 1998) while it had been suggested that D2D3, unlike full- 
length uPAR, was not released from the cell surface (Holst-Hansen et al., 1999). However, data 
presented in this thesis demonstrate the presence of a soluble D2D3 fragment in the conditioned 
medium from several different cell types as well as in human and mouse urine (Sier et al., 1999;
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Chapter 5; Chapter 6), suggesting that cleaved uPAR is indeed shed from the cell surface both in 
vitro and in vivo.
Serum and plasma from healthy individuals contain suPAR with a reported median value 
of 1.2-1.5 ng/ml (Sier et al., 1998; Stephens et al.,- 1997). Leukocytes and endothelial cells are 
likely sources for the circulating suPAR as these cells indeed shed uPAR (Chavakis et al., 1998; 
Chapter 5).
Enhanced levels of suPAR have been observed in plasma from patients with paroxysmal 
nocturnal hàemoglobinuria (PNH)(Ninomiya et al., 1997; Rpnne et al., 1995). PNH is a rare 
acquired defect in the membrane attachment of GPI-anchored proteins on bone marrow derived 
cells. The reduced GPI-anchoring in leukocytes from PNH patients results in the secretion of 
suPAR (Ploug et al., 1992; Ploug et al., 1992a), and it is therefore likely that the increase in 
circulating suPAR present in these patients is caused by suPAR release from leukocytes.
Elevated levels of suPAR in serum have also been described in ovarian, breast and colon 
cancer patients (Sier et al., 1998; Stephens et al., 1999; Stephens et al., 1997), and recently also in 
patients with leukaemia (Mustjoki et al., 1999). The excess serum suPAR in these patients has 
been suggested to derive from malignant tumour cells or surrounding stromal cells (Sier et al., 
1998; Stephens et al., 1997). Nude mice xenografted with human tumours have human suPAR in 
the blood demonstrating that the tumour releases suPAR the circulation (Holst-Hansen et al., 
1999; Chapter 6 ).
suPAR is also found in urine (Sier et al., 1999; Chapter 6 ). While all suPAR in the 
circulation is full-length)(Holst-Hansen et al., 1999; Chapter 6 ), urine also contains the D l and 
D2D3 fragments (Chapter 6 ). There is a strong correlation between the levels of suPAR antigen 
in serum and in urine and it is therefore likely that suPAR present in the urine derives from the 
circulation (Sier et al., 1999). Leukocytes and endothelial cells release suPAR fragments m vitro 
(Chapter 5) and similar fragments are present in urine (Chapter 6 ), suggesting the transient 
’ presence of these fragments in the circulation. Urine from ovarian cancer patients contains 
elevated levels of suPAR antigen and experiments with mice xenografted with human tumours 
demonstrate that the tumour derived suPAR indeed ends up in the urine (Chapter 6 ). The pattern 
of suPAR fragments in urine of xenografted mice correlates with uPAR cleavage on tumour cells. 
Mice xenografted with a tumour having high degree of cleaved uPAR in the tumour tissue have 
high levels of the D l fragment in the urine, while D l is not present in urine from mice 
xenografted with a tumour that expresses only intact uPAR. These data indicates that uPAR 
fragments in urine may reflect uPAR cleavage in distant parts of the organism.
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Functions of uPAR
The function of uPAR in plasminogen activation
Acceleration of plasminogen activation
In solution, the binding to purified suPAR does not strongly affect the proteolytic activity 
of uPA towards plasminogen, or the activation of pro-uPA by plasmin (Behrendt and Dan0 , 
1996; Ellis, 1996; Ellis et al., 1991). Whether uPAR binding affects the zymogenic nature of pro- 
uPA is still an open question (Behrendt and Dan0 , 1996; Behrendt and Dan0 , 1997; Higazi et al., 
1995; Higazi, 1997).
The reciprocal activation of pro-uPA and plasminogen is strongly accelerated by the 
presence of cells and both plasmin-catalysed conversion of pro-uPA to uPA and the uPA- 
catalysed conversion of plasminogen to plasmin are accelerated (Ellis et al., 1991; Ellis et al.,
1989). The cell surface acceleration of plasminogen activation requires both pro-uPA binding to 
uPAR and plasminogen binding to other cell surface elements (Rpnne et al., 1991). It is thus 
likely that the higher local concentration and the spatial organisation of the reagents caused by 
the binding to the cell surface is responsible for the acceleration of the reactions. Cell surface 
acceleration of plasmin formation can almost be abolished by molecules that block the interaction 
between pro-uPA and uPAR (Stephens et al., 1989).
Cell surface bound plasmin is protected against its abundant plasma inhibitors a2- 
antiplasmin and (x2 -macroglobulin, restricting the presence of active plasmin to the surface of 
cells under conditions where serum proteins are present (Ellis et al., 1991; Stephens et al., 1991). 
In contrast to plasmin, cell surface bound ÙPA is not protected from its specific inhibitors PAI-1 
and PAI-2, which inactivate both free and uPAR bound uPA with comparable efficiency 
(Cubellis et al., 1989; Ellis et al., 1990; Stephens et al., 1989).
The reduced capacity of peritoneal macrophages isolated from uPA-deficient mice to 
promote plasminogen activation in vitro confirms the important role of uPAR in plasminogen 
activation (Dewerchin et al., 1996).
Internalisation of uPA inhibitor complexes
Enzymatically inactive uPA/PAI complexes are internalised in a process which requires 
the binding to uPAR (Cubellis et al., 1990; Estreicher et al., 1990; Jensen et al., 1990) and 
involves cell surface proteins from the family of low-density lipoprotein receptor (Heegaard et 
al., 1995; Herz et al., 1992; Moestrup et al., 1993; Nykjaer et al., 1992). The process of
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internalisation leads to the degradation of both uPA and PAI-1 but uPAR is recycled to the cell 
surface (Nykjaer et al., 1997).
As the acceleration of plasminogen activation depends upon pro-uPA binding to uPAR, 
the clearance of inactive uPA/PAI complexes and recycling of uPAR, is a process that maintains 
the cells capacity to bind pro-uPA and therefore to promote plasminogen activation.
Localisation of uPA activity
Besides concentrating pro-uPA to the cell surface, uPAR is also capable of localising the 
protein to specific sites where plasminogen activation is required. uPAR is usually located to 
specific compartments of the cell surface such as cell-ECM contacts, cell-cell contacts and in 
particular to the leading edge of migrating cells (Conese and Blasi, 1995; Conforti et al., 1994; 
Estreicher et al., 1990; Rpmer et al., 1994a; Xue et al., 1997). The localisation of uPAR and of 
uPA activity is often overlapping or identical, supporting the idea that uPAR plays an important 
role in the regulation of localised pericellular proteolysis. The mechanism that governs the spatial 
localisation of uPAR on the cell surface has not been determined yet but may very well depend 
on the association of uPAR with uPA, integrins and the extracellular matrix protein vitronectin. 
In polarised MDCK cells uPAR is sorted to the apical surface (Limongi et al., 1995).
uPAR is also found in cellular structures known as caveolae (Stahl and Mueller, 1995) but 
the significance of this localisation is hot known.
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The function of uPAR in cell adhesion and migration
Adhesion is the process by which cells make contacts to extracellular matrix proteins 
(ECM) and other cells. The mechanism of cell adhesion is fundamental to many, if not all, 
morphogenic processes occurring throughout the entire life span of multicellular organisms. 
Adhesive interactions regulate the mechanical strength of cell contacts and thereby determine cell 
morphology and motility.
It is important to note that increased cell adhesion is not necessarily associated with 
increased cell migration. In fact, too strong adhesion may block cell migration as the process of 
cell migration requires repeated cycles of cell attachment and release.
Integrins are ubiquitous transmembrane receptors and represent the major family of 
adhesion receptors regulating dynamic cell-cell and cell-ECM contacts by providing the physical 
link between extracellular proteins and the intracellular cytoskeleton. Integrins are heterodimeric 
membrane proteins composed of an nc- and a p-suhunit. The difference between the various 
integrins is mostly determined by their binding selectivity and their affinity for binding sites on 
the extracellular adhesion ligands such as the versatile integrin-binding RGD-motif located in 
many extracellular matrix proteins. Integrin occupancy and clustering causes the short 
intracellular portion of the integrin molecules to connect with the cytoskeleton by the associating 
with a variety of intracellular proteins such as talin, vinculin, a-actinin, focal adhesion kinase 
(FAK) and many more. These intracellular proteins provide the regulated physical link between 
the integrins, actin filaments, and the rest of the cytoskeleton. Signal transduction by integrins 
plays an important role in the biology of these receptors and can be classified depending on the 
directionality of the signal flow. Signalling information originating from the ligand binding 
interactions between the integrins and the ECM proteins may be transduced across the plasma 
membrane into a variety of signal transduction pathways in a process termed "outside-in" 
signalling. In addition, intracellular regulators may modify the binding affinity of the integrins in 
a process termed "inside-out" signalling.
Over the last years evidence has accumulated for an important role of uPAR in cell 
adhesion in which it appears to play a dual role. First, uPAR may promote cellular adhesion to 
vitronectin by a direct high affinity interaction. Second, uPAR may modulate cellular adhesion to 
a number of different ECM proteins by lateral interactions with integrin receptors and regulation 
of their activity.
uPAR mediated cell adhesion to vitronectin
Stimulation of in suspension-growing HL60 and U937 cells with phorbol esters, or with a 
combination of vitamin D3 and transforming growth factor TGF|5, leads to differentiation into
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macrophage-like cells with an adherent phenotype. Antibodies against uPA block the adherence 
phenotype and the function of uPA in this adhesion can be traced to a requirement for uPAR 
occupancy (Nusrat and Chapman, 1991; Waltz and Chapman, 1994). The ECM protein 
responsible for the observed adhesion is vitronectin (Waltz and Chapman, 1994; Wei et al., 1994; 
Chapter 3) and it has been shown that both cellular and soluble forms of uPAR bind vitronectin in 
a reaction which is stimulated by uPA occupancy of uPAR and requires intact, three domain 
uPAR (Hpyer-Hansen et al., 1997a; Waltz and Chapman, 1994; Wei et al., 1994; Chapter 3).
Binding to vitronectin mediated by uPAR most likely depends on a direct interaction 
between cellular uPAR and vitronectin, because agents blocking the uPAR/vitronectin interaction 
also block cell adhesion (Chapter 3). Vitronectin adhesion mediated by uPAR has also been 
observed in smooth muscle and thyroid cells lines (Chang et al., 1998; Ragno et al., 1998), 
suggesting that it may be a general phenomenon and not only restricted to leukocytes.
Inhibitors of integrin binding function such as RGD-containing peptides and EDTA do 
not inhibit uPAR mediated adhesion to vitronectin, suggesting that the underlying mechanism 
does not require direct ligand interactions between integrin receptors and the extracellular matrix 
(Waltz and Chapman, 1994; Wei et al., 1994; Chapter 3). uPAR does not have any intracellular 
or transmembrane spanning segments and is therefore incapable of providing a direct 
protein/protein connection between the ECM and the cytoskeleton. However, it is possible that 
the GPI-anchor interacts with lipid anchors of intracellular membrane-associated proteins. It 
appears that uPAR mediated cell spreading on vitronectin requires integrin activation and 
function as evidenced by the observation that low temperatures or dominant negative integrin 
molecules (lacking the intracellular domain) inhibit uPAR mediated vitronectin adhesion of 
uPAR transfected HEK293 kidney cells (Wei et al., 1996).
uPAR as a regulator of integrin function
Besides mediating direct cellular adhesion to vitronectin uPAR also associates with and 
modulates the function of adhesion receptors from the integrin family. The connection between 
these properties and the vitronectin-binding features are not clear.
Interactions between uPAR and fil and p3 integrins
As demonstrated by resonance energy transfer (RET) and immunoprécipitation, uPAR is 
found associated with p, integrins on the surface of HT1080 fibrosarcoma cells and in particular 
at focal adhesions contacts (Xue et al., 1997). The association between uPAR and p, integrins in 
these cells does not depend on the substrate as it is observed on fibronectin, vitronectin and 
laminin. In contrast, the pattern of P3 and a-subunits which closely associated with uPAR does 
depend on the substrate. On fibronectin uPAR is associated with the oc3 subunit, on vitronectin
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with P3, a 5 and a v, and on laminin with and a 6. Importantly, uPAR is not closely associated 
with any of the integrins when the cells are plated on the non-specific poly-D-lysine substrate. 
Although these data do not provide any information regarding the functional role of uPAR in cell 
adhesion, they do suggest that the uPAR/integrin interactions are dynamic and that uPAR mostly 
forms close associations with ECM engaged integrins. In uPAR transfected HEK293 kidney 
cells, uPAR associates and modulates the function of P, integrins (Wei et al., 1996). Upon uPAR 
transfection these cells become adherent to vitronectin and lose the P, mediated adhesion to 
fibronectin. The adhesion to fibronectin can be restored by a synthetic uPAR-binding peptide 
blocking the interaction between uPAR and integrins.
The functional interaction between uPAR and P, integrins apparently also involves the 
membrane protein caveolin (Wei et al., 1996). Caveolin has been demonstrated to associate with 
a number of signalling molecules, including src-family kinases, G proteins, and notably uPAR 
(Li et al., 1996; Stahl and Mueller, 1995; Wary et al., 1998). Caveolin co-immunoprecipitates 
with Pi-integrins and uPAR in transfected HEK293 cells, and the majority of p, /uPAR 
complexes in these cells appears to contain caveolin (Wei et al., 1996). Evidence for a functional 
role for caveolin in uPAR and integrin mediated adhesion comes from recent experiments 
demonstrating that down regulation of caveolin expression (by antisense technology) inhibits 
both Pi and uPAR mediated cell adhesion of HEK293 cells (Wei et al., 1999). The inhibition is 
on the biochemical level characterised by the disruption of the association between Pi integrins, 
scr-kinases and uPAR. If thus appears that caveolin plays an important role for P, and uPAR 
mediated adhesion, maybe by providing the physical link between uPAR, integrins and the 
signalling machinery including src-kinases.
Interaction between uPAR and leukocyte integrins
The integrin subunit P2 is specifically expressed in leukocytes and plays a pivotal role in 
cellular adhesion and migration in connection with processes such as inflammation, extravasation 
and in the resolution of fibrin clots. The p2 integrin subunit associates with different a-subunits 
forming the a MP2 (Mac-1, CR3), o^P2 (leukocyte function-associated antigen, LFA-1), and a xp2 
(complement receptor 4, CR4). These integrins mediate the cell-cell binding of leukocytes to the 
vascular wall by interactions with cellular integrin ligands such as ICAM-1 and to vascular fibrin 
deposits. Other important ligands for these integrin receptors include fibrinogen that is bound and 
degraded through its interaction with Mac-1, and Factor X, which is bound by Mac-1 and may be 
activated and cause blood clotting. Most of these integrins are expressed at rather low levels in 
resting leukocytes but can be rapidly up-regulated, both in number and affinity, by stimulation 
with cytokines and chemokines.
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Histological analysis, co-capping and immunoprécipitation experiments have provided 
extensive documentation for the co-localisation of uPAR and p2 integrins in monocytes and 
neutrophils (Bohuslav et al., 1995; Petty et al., 1997; Simon et al., 1996; Xue et al., 1994).
On monocytes uPAR and Mac-1 form a functional complex with reciprocal stimulation of 
the two receptor functions (Simon et al., 1996). uPAR mediated cellular adhesion to vitronectin is 
stimulated by Mac-1 engagement with fibrinogen, while Mac-1 mediated degradation of 
fibrinogen is stimulated by uPAR mediated vitronectin adhesion. In accordance with these data, 
monoclonal antibodies against uPAR and antisense-mediated down regulation of uPAR 
expression partially inhibit Mac-1 mediated adhesion of monocytes to fibrinogen (Sitrin et al., 
1996).
In neutrophils, antibodies against uPAR block chemotactic migration (Gyetko et al., 
1994) and neutrophils isolated from PNH-patients deficient in cell surface uPAR (and other GPI- 
anchored proteins!) fail in chemotaxis and trans-endothelial migration (Pedersen et al., 1996). 
The association between uPAR and p2-integrins in neutrophils is a dynamic process, as uPAR is 
associated with Mac-1 on resting cells, and with CR4 at lamellipodia of migrating cells 
(Kindzelskii et al., 1997).
The important functional role of uPAR in leukocyte adhesion and migration is evidenced 
by recent experiments with uPAR-deficient mice. Leukocyte adhesion to endothelial cells and 
recruitment to an inflamed peritoneum is significantly impaired in uPAR-deficient mice as 
compared to wild-type control animals (May et al., 1998).
The role of uPA in these processes seems to be inhibitory. In monocytes uPAR 
engagement by uPA or ATF inhibits the Mac-1 mediated binding of fibrinogen and Factor X 
(Simon et al., 1996). Adhesion of leukocytes to vascular endothelium is inhibited by binding of 
inactivated uPA, suggesting that it is the ligand-free form of uPAR that stimulates p2 mediated 
adhesion (May et al., 1998).
The tight functional connection between p2-integrins and uPAR is further substantiated by 
the fact that similar signalling pathways regulate the expression of both receptor types as 
exemplified by transforming growth factor p (TGF-P), which strongly upregulates both integrins 
and uPAR (Lund et al., 1991). Co-engagement of P2-integrins and the T cell receptor in 
lymphocytes upregulate uPAR expression (Bianchi et al., 1996), illustrating the cross talk 
between these systems.
Mac-1 represents the only integrin for which a direct molecular interaction with uPAR has 
been demonstrated in vitro (Wei et al., 1996). Soluble uPAR binds to purified Mac-1 immobilised 
on plastic surfaces and the interaction requires the active conformation of the integrin. Freshly 
isolated monocytes and neutrophils do not express caveolin and the interaction between p2
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integrins and uPAR is therefore different from the stable uPAR/p/caveolin complexes observed 
in epithelial cells (Wei et al., 1996; Wei et al., 1999).
PAI-1 and cell adhesion
Another member of the plasminogen activator system, PAI-1, plays a pivotal role in cell 
adhesion and migration (Blasi, 1997). The structural basis for the regulatory function of PAI-1 on 
cell adhesion is its capacity to interact with both vitronectin and uPA. PAI-1 binds with high 
affinity to vitronectin in a reaction that stabilises PAI-1 in its active conformation (Knudsen and 
Nachman, 1988). Vitronectin bound PAI-1 can still bind and inactivate uPA, but the formed 
uPA/PAI-1 complex has only low affinity for vitronectin and is rapidly released.
The fact that PAI-1 inhibits uPAR mediated cell adhesion was first suggested to be caused 
by the capacity of PAI-1 to mediate the internalisation of uPAR/uPA/PAI-1 complexes (Waltz 
and Chapman, 1994). However, later it was demonstrated that the binding sites for PAI-1 and 
uPAR on vitronectin are overlapping and that the binding of these proteins is competitive and 
mutually exclusive (Deng et al., 1996; Seiffert and Loskutoff, 1991). Low levels of active PAI-1 
are capable of releasing U937 cells adherent to vitronectin and an excess of uPA can revert this 
process by the formation of uPA/PAI-1 complexes (Deng et al., 1996).
The binding site of PAI-1 in vitronectin is also very close and overlapping with the 
binding site utilised by the vitronectin receptor (o t^ , VNR) (Stefansson and Lawrence, 1996). 
PAI-1 binding blocks the interaction between o t ^  and vitronectin and causes a functional 
inhibition of mediated migration of smooth muscle cells, human amnion WISH cells, and 
human epidermoid carcinoma HEp-2 cells on vitronectin (Kjpller et al., 1997; Stefansson and 
Lawrence, 1996).
These data demonstrate the central role of PAI-1 in both uPAR and integrin-mediated cell 
adhesion on vitronectin. An excess of active PAI-1 over uPA inhibits cell adhesion mediated by 
0 ^ 3  and uPAR, whereas an excess of uPA will stimulate this process. Complexes between uPA 
and PAI-1 are internalised and degraded in a mechanism that involve uPAR and the LRP 
receptor, adding further complexity to these processes.
The biological function of soluble and cleaved forms of uPAR
uPAR plays a fundamental role in pericellular proteolysis by accelerating and localising 
the process of plasminogen activation. The basis for this function of uPAR is the anchoring of the 
protein to the cell membrane, and its capacity to bind pro-uPA. Cleavage of uPAR in the linker 
region between D l and D2 generates receptor fragments that fail to bind uPA and vitronectin and 
thus inactivates the receptor with respect to uPA and vitronectin binding. The shedding of uPAR
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and uPAR fragments is expected to destroy the receptor functions of uPAR but creates the 
possibility of novel "paracrine" effects on other cells.
The broad occurrence of uPAR cleavage and shedding suggests that these phenomena 
play a functional role in the biology of uPAR.
uPAR cleavage and plasminogen activation
The shedding of uPAR from the cell surface does not affect the affinity for pro-uPA, but 
is expected to impair plasminogen activation as the co-localisation between plasminogen and pro- 
uPA on the cell surface is lost. Soluble uPAR may still associate with the cell surface and the 
extracellular matrix through its interactions with integrins (Mizukami and Todd, 1998) and the 
extracellular matrix protein vitronectin (Chavakis et al., 1998). The efficiency of cell associated 
suPAR in promoting plasminogen activation has not been analysed but is most likely inferior to 
that of the GPI-anchored protein. First, not all the suPAR is retained at the cell surface, as 
significant levels of suPAR can be found in the circulation and in urine (Sier et al., 1999; Sier et 
al., 1998; Stephens et al., 1999; Stephens et al., 1997; Chapter 6 ). Second, suPAR associated 
uPA/PAI-1 complexes are not expected to be internalised efficiently, although they might still 
bind LRP.
It should be noted that recently it has been found that suPAR/pro-uPA complexes, may 
have fibrinolytic activity (Higazi et al., 1998). However the importance of this observation in vivo 
remain to be established.
Cleavage of uPAR in the linker region between D l and D2 dramatically reduces the 
receptors affinity for pro-uPA (Behrendt et al., 1991) and is therefore expected to result in a 
complete loss of the receptors function in acceleration of plasminogen activation. In fact, the 
cleavage of uPAR has been suggested to be a negative feedback mechanism occurring at sites of 
high proteolytic activity (H0 yer-Hansen et al., 1997b).
Taken together, it appears likely that the processes of uPAR shedding and cleavage 
predominantly have; a negative effect on plasminogen activation.
Consequences of uPAR cleavage and shedding in cell adhesion and migration
The function of uPAR in cell adhesion and migration is mediated through its interactions 
with uPA, vitronectin and integrins. Cleavage of uPAR destroys the high affinity interaction 
between uPAR and vitronectin (Hpyer-Hansen et al., 1997a; Chapter 3) and also uPAR mediated 
adhesion to vitronectin requires intact uPAR (Chapter 3).
Impaired adhesion of PIPL-C treated leukocytes to vascular endothelium is reconstituted 
by pre-incubation with suPAR, suggesting that the function of uPAR in P2 mediated cell adhesion
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does not require the GPI-anchor (May et al., 1998). The same stimulation was not observed using 
a suPAR lacking D l, demonstrating that intact uPAR is required for the modulation of integrin 
function. In another study the exogenous addition of suPAR was shown to have the same 
inhibitory function as GPI-anchored uPAR on the integrin mediated adhesion of HEH293 cells to 
fibronectin (Wei et al., 1996).
It thus seems clear that suPAR may affect integrin mediated adhesion even in the absence 
of the GPI-anchor. However, as uPAR shedding results in the release from the cell surface it is 
questionable whether sufficiently high concentrations of suPAR occur in vivo.
uPAR in cell chemotaxis and chemokinesis
uPA has been known for many years to have chemotactic and chemokinetic effects on the 
migration of a range of different cell types (Fibbi et al., 1988; Sato and Rifkin, 1988; Sato et al.,
1990) (Busso et al., 1994; Fazioli et al., 1997; Nguyen et al., 1998; Resnati et al., 1996). 
Although binding to uPAR seems to be required for all of the chemotactic effects of uPA, the 
phenomena can be divided into two groups depending on whether uPA activity is also required.
By proteolysis uPA can directly activate pro-HGF (Naldini et al., 1995) and indirectly, 
through the activation of plasminogen to plasmin, also basic FGF and TGFP (Sato and Rifkin, 
1988; Sato et al., 1990). The activated cytokines may in these cases be responsible for the 
observed effects on cell migration.
In most cases there is no apparent requirement for uPA activity, because proteolytically 
inactive uPA or an uPA fragment lacking the catalytic domain (the aminoterminal fragment, 
ATF) are able to induce cell migration equally well (Busso et al., 1994; Fibbi et al., 1988; 
Nguyen et al., 1998; Odekon et al., 1992; Resnati et al., 1996). The protease-independent effects 
of uPA on chemotaxis, at least in THP-1 cells and fibroblasts, is strictly dependent upon uPAR as 
they can be inhibited by anti-uPAR antibodies preventing the ligand interaction, and fails to occur 
on cells lacking uPAR (Resnati et al., 1996).
Taken together, these data suggest that the binding of uPA to uPAR in some cell types 
causes the transmission of signalling over the cell membrane leading to increased motility. 
Indeed, ligand engagement of uPAR causes the transient activation of a variety of signalling 
proteins including src-family members (Chiaradonna et al., 1999; Fazioli and Blasi, 1994; 
Resnati et al., 1996), ERK-1 and ERK-2, (Nguyen et al., 1998), FAK (Tang et al., 1998), JAK 
and STAT1 (Dumler et al., 1998), and fo s ju n  and myc (Rabbani et al., 1997).
Chymotrypsin-cleaved suPAR is a potent chemoattractant for several different cell lines 
(Fazioli et al., 1997; Resnati et al., 1996). The chemotactic response and kinetics of p56/59hck 
phosphorylation induced by proteolytically inactive uPA derivatives and that of cleaved suPAR
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are similar, suggesting that the same signalling pathway is activated by these molecules (Resnati 
et al., 1996). Inhibitors of tyrosine kinases and heterotrimeric G proteins block the chemotactic 
response and the induced phosphorylation of p56/59hck. The fact that the pertussis toxin inhibitor 
of heterotrimeric G proteins also blocks the phosphorylation of p56/59/,ct, suggests that the 
heterotrimeric G protein is upstream of the tyrosine kinase in the signalling pathway.
Experiments using recombinant soluble uPAR mutants and synthetic peptides has mapped 
the uPAR chemotactic epitope to the linker region connecting D l and D2 (Fazioli et al., 1997). 
This linker region is susceptible to cleavage by several different proteases including plasmin and 
uPA itself (H0 yer-Hansen et al., 1997b; H0 yer-Hansen et al., 1992; Ploug and Ellis, 1994). Both 
GPI-anchored and soluble forms of cleaved uPAR have indeed been observed on different cell 
types and in diverse biological fluids.
The fact that cleaved soluble uPAR and peptides containing the uPAR chemotactic 
epitope are strong chemokine-like molecules this strongly suggests the existence of one or more 
membrane "adapter" molecule(s) capable of transmitting the chemotactic signal oyer the 
membrane (Fazioli et'al., 1997; Resnati et al., 1996). However, this adapter protein still has to be 
identified.
The strong chemotactic properties of suPAR fragments generated in the laboratory taken 
together with the cellular release of similar fragments in vivot strongly suggests that these 
fragments may play a role in biological processes such as leukocyte recruitment to sites of 
inflammation.
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uPAR in cancer
Tumour invasion and metastasis are processes associated with extensive ECM proteolysis 
and the plasminogen activator system together with the MMPs appear to play a central role in 
these processes.
In human cancers the components of the plasminogen activator and MMP system are 
expressed both by tumour and stromal cells. The cellular expression of individual components is 
often similar between different cases of the same type of cancer, but may vary a lot between 
different types of tumours. The expression pattern of the components of the plasminogen 
activator and MMP system has been determined in several tumour types, but I will in the 
following just give a brief introduction to the expression patterns observed in colon cancer (for a 
recent review see Danp et al., 1999).
In colon cancer the cells responsible for uPA production are fibroblast-like stromal cells 
while uPAR is expressed by cancer cells located adjacent to the uPA producing fibroblasts (Pyke 
et al., 1991). The uPAR-expressing tumour cells might therefore bind the fibroblast-expressed 
uPA and thus localise plasminogen activation to the surface of the tumour cells. uPAR is not 
expressed by all the tumour cells but is restricted to the budding cancer cells located at the tip of 
the invading malignant epithelium (Pyke et al., 1991; Pyke et al., 1994; Pyke et al., 1995). PAI-1 
is expressed by stromal endothelial cells surrounding the tumour and PAI-1 may serve to protect 
the tumour against excessive uPA-mediated plasminogen activation (Pyke et al., 1994). Several 
members of the MMP family are also expressed in human colon cancer. Stromal fibroblasts 
express among others MMP-2 and MT1-MMP, while the only MMP expressed by the tumour 
cells appears to be MMP-7 (McDonnell et al., 1991; Okada et al., 1995; Pyke et al., 1993):
The high levels and the localisation of components of the plasminogen activator system in 
tumour tissues provides a "smoking gun" link between plasminogen activation and the malignant 
process of cancer invasion. The correlation's between plasminogen activation and tumour 
invasion lead to a major interest in the possible usefulness of uPAR as a target for anti-cancer 
therapy and as a prognostic marker.
uPAR as a target for anti-cancer therapy
Urokinase mediated plasminogen activation appears to play an important role in tumour 
invasion and metastasis, and inhibition of this system is therefore an attractive target for anti- 
cancer therapy. Inhibition of uPA mediated plasminogen activation can be obtained by a direct 
inhibition of uPA activity, or by blocking the interaction between uPA and uPAR. Inhibition of 
uPA activity poses the problem of specificity, because the activity of tPA, which plays important 
functions in the maintenance of fibrinolytic activity in the vasculature, should not be affected.
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Interest has therefore mostly been focused on inhibition of the uPA/uPAR interaction, as this 
should provide a specific inhibition of uPA-mediated cell surface plasminogen activation 
associated with tumour invasion and metastasis.
Agents inhibiting the interaction between uPAR and uPA (uPAR antagonists) range from 
catalytically inactive fragments of uPA, to synthetic peptides constructed on basis of the uPAR 
binding region of uPA or isolated by phage-display techniques, to low molecular weight 
compounds isolated from chemical libraries by systematic screening (Appella et al., 1987; 
Goodson et al., 1994). The efficacy of these compounds in inhibiting tumour invasion and 
metastasis has been analysed in mouse models using syngeneic mouse tumours or human 
tumours xenografted in nude mice.
Spontaneous lung metastasis of the murine Lewis-Lung tumour grown subcutaneously in 
syngeneic mice can be efficiently inhibited by a peptide derived from the binding region of 
murine uPA (aminoacid 17-34)(Kobayashi et al., 1994) and metastasis of human prostate 
carcinoma cell line PC3 grown in nude mice is inhibited by a catalytically inactive uPA-IgG 
fusion protein (Crowley et al., 1993). Inhibition of tumour growth by uPAR antagonists may also 
work through other mechanisms than on the invasion of tumour cells. In vivo, basic fibroblast 
growth factor-induced neo-vascularisation and B16 melanoma growth in syngeneic mice is 
substantially suppressed by uPAR-antagonists suggesting that these compounds may provide 
additional anti-cancer effects through inhibition of angiogenesis (Min et al., 1996). Tumour cells 
often express reduced levels of adhesion receptors and also often fail to deposit ECM around 
themselves. The fact that uPAR is up-regulated in many tumour cells suggests that the cells may 
use this alternative adhesion pathway as a response to the altered expression of normal cell 
adhesion proteins. Some (but not all) uPAR antagonists stimulate uPAR mediated cell adhesion 
to vitronectin (Waltz and Chapman, 1994; Chapter 3) and it is possible that their effects on 
tumour metastasis may depend also on their effects on cellular adhesion.
The redundancy within the proteolytic system suggests that efficient inhibition of tumour 
invasion and metastasis will require the simultaneous inhibition of both plasminogen activation 
and of the MMPs. MMP inhibitors are indeed promising anti-cancer drugs and, in contrast to the 
uPAR antagonists, clinical trials are already underway (reviewed by Brown, 1999).
uPAR as a prognostic marker in cancer patients
Prognosis in cancer patients typically involves evaluation of tumour size, degree of 
differentiation, the extent of invasion and the presence or absence of metastasis. However, even 
patients with similar prognosis based on these parameters may very well have dramatically 
different disease progression. Identifying patients with good and bad prognosis might provide the
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physicians with a tool to tailor the therapy. For example, if it was possible to identify patients 
with a good prognosis one might avoid unnecessary adjuvant therapy and the associated 
suffering.
Not surprisingly, members of the plasminogen activator system, including uPA, uPAR 
and PAI-1, have been found to have prognostic value in several different cancers (reviewed by 
Schmitt et al., 1997). High levels of these proteins in extracts from the primary tumour are 
associated with poor survival in different cancers including lung, colon, bladder, ovarian and 
breast cancer. The fact that high levels of PAI-1, which is a negative regulator of plasminogen 
activation, is strongly correlated with poor survival may be explained by its capacity to protect 
the tumour against the high levels of proteolytic activity present at points of invasion. Another 
possibility is that PAI-1 facilitates tumour dissemination by modulation of cell adhesion (Deng et 
al., 1996). High levels of uPAR antigen in tumour extracts are associated with poor prognosis in 
patients with squamous cell lung cancer (Pedersen et al., 1994), breast cancer (Gr0 ndahl-Hansen 
et al., 1995) and colon cancer (Ganesh et al., 1996).
Measuring tumour markers and prognostic factors in plasma and serum samples of cancer 
patients provides at least two advantages to the measurement in tumour lysates. First, the 
measurements do not require tumour biopsies and can be performed prior to the surgical removal 
of the tumour. Second, the measurements can be performed repeatedly and may be used in the 
follow-up analysis of patients. The serum level of soluble uPAR (suPAR) is elevated in plasma 
and serum from patients suffering from ovarian (Sier et al., 1998), non-small-cell lung and 
colorectal cancer (Stephens et al., 1997). Indeed, it has recently been demonstrated that the 
plasma suPAR level in colorectal cancer patients is a strong and independent prognostic marker 
(Stephens et al., 1999).
Recently, we have demonstrated that suPAR is also present in urine, and that the suPAR 
antigen levels in urine and serum are highly correlated (Sier et al., 1999). The level of suPAR 
antigen in urine is stable under relevant storage conditions and might therefore substitute for the 
measurement of suPAR in serum samples (Sier et al., 1999).
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Materials
Chemicals
General chemicals used in this study were obtained from Sigma or Boehringer Mannheim 
and were of the highest available quality.
Enzymes
Restriction enzymes, alkaline phosphatase, bacteriophage T4 ligase, Klenow fragment, 
Taq polymerase and PNGase F were purchased from Boehringer Mannheim, Italy.
Antibodies
Monoclonal mouse antibodies against human uPAR (mAh: R2, R3, R4 and R5) and uPA 
(mAb: c6 ) were obtained from the Finsen Laboratory, Denmark. Monoclonal mouse antibody 
directed against the FLAG™-epitope (mAb: M2) was purchased from Sigma, Italy. Polyclonal 
rabbit antibody against human uPAR used in ELISA and immunoblotting analysis of native 
human uPAR, was obtained from the Finsen Laboratory, Denmark. Rabbit polyclonal antibodies 
against the FLAG-epitope were purchased from Santa Cruz Biotechnology, California, USA. The 
polyclonal rabbit antibody against human uPAR used in the analysis of reduced and 
deglycosylated uPAR was previously prepared in our laboratory by immunisation of rabbits with 
recombinant soluble human uPAR. All polyclonal rabbit antibodies used in this study were 
purified by affinity chromatography on prolein-A Sepharose (Pharmacia Biotech, Sweden) 
according to manufactures instructions.
Radioactive isotopes
Radioactive isotopes were purchased from Amersham, Italy.
Cell culture reagents
Cell culture reagents (RPMI, DMEM, glutamine, penicillin, streptomycin, FCS, trypsin) 
were purchased from Gibco-BRL, Italy. Serum free growth supplement Nutridoma NS and 
recombinant murine IL-3 were obtained from Boehringer Mannheim, Italy. Tissue culture plastic 
ware was from Costar, Italy. ELISA plates.
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Peptides
Synthetic peptides had the following sequences (N-C): Peptide-1: AVTYSRSRYLEC; 
Peptide-2: YTARLWGGTLLT; Peptide-3: SRSRYLEC; Peptide-4 (scrambled version of peptide 
1): TLVEYYSRASCR.
Oligonucleotides
Oligonucleotides were purchased from PRIMM (Italy) or GENSET (France) and had the 
following sequences (3-5'):
FRA 18 : ATTATACTCGAGGAAGACGTGCAGGGACCCCGCGCA
FRA 19 : TATATTGATCATTTAGGTCCAGAGGAGAGTGCCTC
D2.5T: AATGCATTCGAGGCCCCAAGAGGCTGGGA
FRA 18 : ATTATACTCGAGGAAGACGTGC AGGGACCCCGCGC A
D1.3T: TTATCGATGGTAACGGCTTCGGGAATA
D2.3T: TTATCGATGGCCATTCTGCGGCAGATT
D3.3'T: TTATCGATGTGGGTGGTTACAGCCACT
D 3.5 'T : T C C A T G G G T G C T G TT C C C C T TG C A G C TG T A A C A C TG G C G G C C C -
CAAGAGGCTGGGA
K/FOcs: CGACGAGCATCTGTCGACTATAAGGATGACGACGACAAGTAA K/FOas:
CGTTACTTGTCGTCGTCATCCTTATAGTCGACAGATGCTCGT
NS 1 : CCGCGGAAGAACCCATGGGACTCCCAA;
46D: CAAGCTTACTTGTCGTCGTCATCC.
Other reagents
Human ATF was a generous gift of Dr. Jack Henkin (Abbott Laboratories, IL, USA). 
Recombinant Pertussis toxin and its inactive mutant (Pizza et al., 1989) were generous gifts of 
Dr. Maria Grazia Pizza (IRIS, Siena, Italy). Native human vitronectin was obtained from 
Molecular Innovations INC, Michigan, USA. Fibronectin was obtained from Boehringer 
Mannheim, Italy.
Cells
The 32D and WEHI-1 cell lines were obtained from Drs. Jacalyn H. Pierce. U937, THP-1 
and COS7 cells were obtained from the ATCC (Rockville, MD, U.S.A.). The uPAR"/" cells were 
derived from spontaneous immortalisation of embryo fibroblasts prepared from uPAR~/~ mice 
(Dewerchin et al., 1996) and kindly donated by Drs. Peter Carmeliet and Désiré Collen.
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Human urine samples
Urine from twenty-five patients (mean age 62, range 20-78) admitted for surgery of 
ovarian carcinoma was sampled at the Department of Gynaecology and Obstetrics, San Raffaele 
Hospital, Milan. The FIGO (International Federation of Gynaecology and Obstetrics) stages of 
the tumours comprised 14 women with stage LTI, and 11 with stage ffl/TV respectively. Urine 
from 20 age-matched healthy women (median age 56* range 36-78) was used as controls. All 
samples were snap frozen and kept at -80°C. Before analysis, the samples were quickly thawed at 
37°C and centrifuged at 10.000 g for 10 minutes. In specific cases urine was 20-fold concentrated 
using ultrafiltration with a Centricon YM-10 filtration membrane (Amicon), followed by 
overnight dialysis against PBS.
Human serum samples
Serum from twenty five patients (mean age 62, range 20-78) . admitted for surgery of 
ovarian carcinoma was sampled at the Department of Gynaecology and Obstetrics, San Raffaele 
Hospital, Milan. The serum samples were obtained from the same patients, and on the same day, 
as the urine samples described above.
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Recombinant DNA techniques
Bacterial strains
The E.coli strain HB101 was used for the propagation of all plasmids.
Maintenance and media
E.coli were grown at 37°C in L-broth or on L-broth agar plates as described elsewhere 
(Sambrook et al., 1989). For selection of transformants and for plasmid preparations the L-broth 
was supplemented with 2 0 0  pg/ml ampicillin.
Preparation of competent cells
500 ml of L-broth was inoculated with 5 ml of an over night culture of HB101 cells and 
allowed to grow to until OD436 = 0.6. Cells were cooled on ice for 60 minutes and pelleted by 
centrifugation (3000 rpm, 15 minutes, 4°C). The supernatant was removed by decanting and the 
cells resuspended in 200 ml ice cold 100 mM CaCl2 by vortexing. After 20 minutes incubation on 
ice, the cells were pelleted and resuspended in 45 ml ice cold 100 mM CaCl2. The cells were 
incubated at room temperature for 20 minutes, pelleted by centrifugation (at 4°C), resuspended in 
5 ml ice cold 100 mM CaCl2 and added 1.2 ml 50% glycerol (v/v). The competent cells were 
aliquoted (200 pi), snap-frozen in liquid nitrogen, and stored at -80°C.
Transformations
Aliquots of competent cells were thawed on ice and added the plasmid or ligation mixture 
(10 pi) to be transformed. The cells were incubated for 30 minutes on ice and heat-shocked for 90 
seconds at 42°C before plating on L-broth agar plates containing 200 pg/ml ampicillin.
Mini-preparations of plasmid DNA
Plasmid DNA was isolated by the alkaline lysis method: 1.5 ml overnight culture was 
pelleted by centrifugation and washed in 1 ml Tris-HCl, EDTA buffer (TE, 1 mM 
ethylenedinitro-tetraacetic acid disodium salt (EDTA), 10 mM Tris-HCl pH 8 ). After 
centrifugation the pellet was resuspended in 50 pi Sol A (50 mM glucose, 10 mM EDTA, 25 mM 
Tris-HCl pH 8). Cells were lysed by addition of 200 pi Sol B (0,2 M NaOH, 1% sodium dodecyl
Chapter 2: Materials & Methods
sulfate (SDS) and incubated 5 minutes on ice. Cell/SDS aggregate was precipitated by adding 
150 pi Sol C (3 M KAc pH 4.5) and incubated 5 minutes on ice. After centrifugation, 400 pi of 
the supernatant was extracted once with phenol mix (PhChlaa: phenol/chloroform/isoamylalcohol 
(25/24/1) with 1 mg/ml hydroxyquinoline, neutralized with Tris-HCl pH 8 and equilibrated with 
TE) and precipitated with 2,5 volume 96% ethanol. The DNA was pelleted by centrifugation, 
washed once with 70% ethanol, dried and resuspended in TE. Plasmid DNA obtained by this 
method was sufficiently pure to be used in cloning and for sequencing.
Maxi-preparations of plasmid DN A
Plasmid DNA used for transfection of mammalian cells were prepared by CsCl density 
equilibrium centrifugation as described elsewhere (Sambrook et al., 1989).
Agarose gel electrophoresis
Agarose gels of appropriate percentage were cast using multi purpose agarose 
(Boehringer Mannheim) dissolved in TAE buffer by boiling in a microwave oven. Before casting, 
ethidiumbromide (Sigma) was added to 1 pg/ml from. Agarose gels were allowed to solidify and 
were run under standard conditions using TAE as running buffer.
DNA sequencing
Sequencing was performed using a T7 sequencing kit (Pharmacia) according to the 
manufactures directions using ^S-ot-dATP. The extension products were separated by 
electrophoresis on denaturing 8 % acrylamide/urea gels.
General DNA techniques
Standard recombinant DNA techniques were employed (Sambrok et al., 1989). T-tailing 
of EcoRV digested pBluescript SK- vector was performed as described elsewhere (Holton and 
Graham, 1991).
Restriction enzyme digestions
Plasmids and PCR products were digested with restriction enzymes in the buffers 
supplied, and according to the manufactures instructions. Klenow filling of blunt ends and 
dephosphorylation using alkaline phosphatase were performed as described (Sambrok et al., 
1989).
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Purification of DNA fragments
Prior to ligation all DNA fragments were purified by gel electrophoresis on agarose gels 
of appropriate concentration. Desired DNA fragments were cut out from the gels on a 
transilluminator and the DNA isolated from the gel pieces using the QiaQuick gel extraction kit 
(Qiagen).
PCR
PCR reactions were performed using Taq polymerase and the buffer supplied by the 
manufacturer. All reactions were performed using 1 pM of each oligonucleotide and 0.2 mM 
deoxynucleotides in a total volume of 50 pi. PCR reactions were generally performed using the 
following cycle parameters: an initial dénaturation (3 min at 94°C) followed by cycles consisting 
of: dénaturation (1 min, 94°C), annealing (1 min, 55°C), extension (2 min, 72°C), and a single 
final extension step (10 min, 72°C). Preparative PCR reactions were performed using a high 
concentration of template (typically 5 pg plasmid) and a low number of amplification cycles 
(typically 12) to minimise the introduction of mutations. Prior to restriction digestions, the PCR 
products were purified using the QuiaQuick PCR purification kit (Qiagen).
To limit the tedious work of plasmid preparations, PCR was extensively used to identify 
colonies containing plasmids with the desired structure. In this case, a fraction of fresh colonies 
were picked with a pipette tip and transferred to PCR reactions containing oligonucletides 
generating PCR products informative with respect to the presence and orientation of the insert. 
Amplifications were performed as before but using 30 cycles.
Ligations
In a total volume of 20 pi were mixed: DNA fragments, water, 10-fold concentrated, 
ligation buffer, and 2 units of bacteriophage T4 ligase (Boehringer Mannheim, Italy). Ligation 
was allowed to proceed over night at room temperature. Control reactions, receiving no vector or 
no insert, were always performed and colonies were only screened if the number of colonies in 
transformations receiving both vector and insert was significantly higher than in controls.
Vector construction
Expression vectors encoding GPI-anchored uPAR
Vectors expressing the wild type receptor (uPAR) and a deletion mutant lacking the first 
92 amino acids corresponding to domain 1 (D2D3) were constructed by first amplifying the
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entire uPAR cDNA (Roldan et al., 1990) with the primers FRA 18 and FRA 19 and cloning the 
product in a EcoRV digested and T-tailed pBluescript SK- vector. The expression vector LTR- 
2/uPAR was generated by transferring a Xhol-Clal fragment, containing the entire uPAR-coding 
region, from the pBluescript sub-clone to the LTR-2 expression vector digested with same 
enzymes. The LTR-2/D2D3 expression vector was constructed by first replacing the Nml-Nsil 
fragment (containing the entire D l coding region) of the pBluescript uPAR sub-clone with a PCR 
product generated by amplification of the uPAR cDNA with the primers FRA 18 and D2.5T and 
digested with the same enzymes (thereby restoring the desired signal-peptide/D2D3 junction 
aminoacid -1/93). Finally, the modified uPAR cDNA was transferred to the LTR-2 vector as 
described for the wild type cDNA.
Expression vectors encoding soluble uPAR molecules.
Mutant cDNAs encoding soluble uPAR were generated by PCR with the 
following primers: D I1.92 : oligonucleotides FRA18 and D1.3 T; D12i_igi: oligonucleotides 
FRAIS and D2.3T; D 1231-274: oligonucleotides FRA18 and D3.3T. The PCR-products were 
digested with Bell and Clal, and cloned in pBluescript SK-(Stratagene) digested with BamHI and 
, Clal. To generate the constructs encoding 0293.191 and 02393.274  the D l region in the D 12 and 
D123 constructs was deleted by substituting the Nrul/Nsil fragment containing the D l coding 
region, with a fragment generated by amplifying the uPAR cDNA with the primers FRA 18 and 
D2.5T and digested with the same enzymes. To generate D3192-274, the D12 region in D123 was 
deleted by substituting the Nrul/Ncol fragment containing the D12 coding region, with a 
fragment generated from uPAR cDNA with the primers FRA 18 and D3.5T and digesting with 
the same enzymes. All mutant receptors were tagged at the carboxyterminus with the peptide 
sequence HRRASVDYKDDDDK, which includes a protein kinase substrate and the FLAG™ 
epitope, by inserting in the carboxyterminal Clal site a linker made by annealing the two 
oligonucleotides K/FOcs and K/FOas. All the recombinant coding regions were amplified with 
the primers NS1 and 46D, digested with Ncol and transferred to the eukaryotic expression vector 
pBNSEN (Pallisgaard et al., 1994) digested with Ncol and Klenow-treated EcoRI.
Protein techniques
Cell and tissue lysates
Tumour tissue and cell detergent lysates were prepared by Dounce homogenisation (only 
tissue) in PBS (10 ml / gram of tissue) containing 1% Triton X-100 and protease inhibitors 
(Complete™, Boehringer, Mannheim) for 1 hour on ice. Lysates were centrifuged at 14.000 x g
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for 20 min at 4°C and the supernatants were stored at -80°C until analysis. Total protein was 
determined by the Dc protein assay (Bio-Rad) with bovine serum albumin as a standard.
Tyrosine Kinase Assay.
Kinase assay was performed as previously described (Resnati et al., 1996). THP-1 
cells were metabolically labelled with 35S-7r<27z$Label, acid washed (Stoppelli et al., 1986) and 
either mock-treated or treated with 1 pM peptide 1 (AVTYSRSRYLEC) for the indicated time at 
37°C. Radiolabeled cell lysates were immunoprecipitated with a polyclonal anti-p56/p59&c& 
antibody (Resnati et al., 1996) and part analysed by SDS-PAGE to control the amount of protein. 
The rest was used for in vitro kinase assay (5-10 pCi of y-32P-ATP, ~3000 Ci/mmol, Amersham, 
5 jig rabbit muscle enolase substrate, 5 minutes, room temperature) and resolved by SDS-PAGE.
Biotinylation of antibodies
Antibodies (concentration 0.5-1 mg/ml) were dialysed against 0.05 M NaHC03 pH 8.5 
prior to biotinylation. The antibody solution was added the biotinylation reagent (EZ-Link™ 
Sulfo-NHS-LC-Biotin, Pierce Chemicals) dissolved in water (10 mg/ml) immediately before use. 
The biotinylation was performed at room temperature for two hours using a molar ratio of 
biotinylation reagent to antibody of 100:1. The biotinylation was stopped by addition of 
concentrated NH4C1 to a final concentration of 0.01 M and the biotinylation regent removed by 
extensive dialysis against PBS. The biotinylated antibodies were diluted 1:1 with 100% glycerol 
and stored at -20eC.
Immunoprécipitations
In 1 ml of RIP A/PBS (1:1 mixture of PBS and 2-fold concentrated RIPA buffer (0.2 M 
TrisHCl pH 7.5, 0.3 M NaCl, 2% Triton X-100, 2% sodium deoxycholate, 0.2% SDS)) 2 pg of 
biotinylated antibody and 10 pi of a 50% suspension of streptavidin beads (Boehringer 
Mannheim) were mixed and incubated at 4°C for one hour under gentle agitation. The beads were 
pelleted by centrifugation (15 seconds at full speed in a micro centrifuge) and the supernatant 
aspirated. The beads were washed once with 1 ml of RIP A/PBS to remove unbound antibodies. 
The volume of the samples to be analysed were adjusted to 0.5 ml using PBS and then added 0.5 
ml 2-fold concentrated RIPA buffer containing protease inhibitors (Complete™, Boehringer 
Mannheim). The mixture was transferred to a tube containing the pellet of beads with pre-bound 
antibodies and binding was allowed to occur for 16 hours at 4°C under gentle agitation. At the 
end of the incubation, the beads were washed 3 times for 30 minutes with 1 ml aliquots of 
RIP A/PBS to remove unspecific proteins. For western blotting, the bound proteins were eluted in
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15 pi non-reducing sample buffer (0.125 M TrisHCl pH 6 .8 , 20% glycerol (v/v), 4% (w/v) SDS, 
20% (w/v) glycerol, 0.02% (w/v) bromphenol blue) by incubation at 95°C for 3 minutes and 12 
pi of the eluate used in 10% SDS-PAGE.
Deglvcosvlation of uPAR
Immunoprecipitates prepared as described above were deglycosylated in a modified 
previously described procedure (Behrendt et al., 1990). The washed beads were added 10 pi of 
PBS containing 0.5% SDS and 1.6 mM DTT and the samples were incubated at 98°C for 3 
minutes to denature the proteins under mildly reducing conditions. The samples were added 20 pi 
of 1.5-fold concentrated deglycosylation buffer (PBS containing 1% Triton X-100 and 15 mM 
EDTA), 1 unit of peptide-N-glycosidase F (PNGase-F) and incubated at 37°C for two hours. 
Control samples were treated in the same manner but did not receive PNGase-F. Prior to SDS- 
PAGE the samples were added 30 pi of 2-fold concentrated reducing sample buffer (0.125 M 
TrisHCl pH 6 .8 , 0.1 M DTT, 20% (v/v) glycerol, 4% SDS (w/v), 20% (w/v) glycerol, 0.02% 
(w/v) bromphenol blue) and the samples were incubated for 5 minutes at 95°C. For Western 
blotting 15 pi of the samples were analysed on 10% SDS-PAGE gels.
SDS-PAGE
SDS-GELS (0.75 mm thick) were cast and run in a Hoefer Mighty Small SE250 gel 
apparatus at 20 mA/gel (constant current) until the bromphenol blue front was about to exit the 
gel. Separation gels (10% acrylamide, 10 ml of solution) were prepared using the following 
ingredients: 3.33 ml 30% acrylamide monomer solution (acrylamide:bis-acrylamide, 29:1), 2.5 
ml 1.5 M Tris.HCl pH 8 .8 , 0.1 ml 10% SDS, 4.0 ml H20 , 50 pi of 10% (w/v) ammonium 
persulfate (APS) and 5 pi of N,N,N,N,-tetramethylethylerie diamine (TEMED). Separation gels 
were overlaid with water saturated isobutanol until polymerised. Stacking gels were prepared 
using the following ingredients (5 ml of solution): 0.67 ml 30% (w/v) acrylamide monomer 
solution (29:1), 1.25 ml 0.5 M Tris.HCl pH 6 .8 , 0.05 ml 10% (w/v) SDS, 3 ml H20 , 25 pi 10% 
(w/v) APS and 2 pi TEMED. The running buffer used for electrophoresis had the following 
composition: 0.025 M Tris, 0.192 M glycine and 0.1% SDS, pH 8.3.
Protein blotting
Semi-dry blotting, using a Sigma apparatus, was used to transfer proteins from SDS- 
PAGE gels to PVDF membranes. The following sandwich was made (bottom to top): Steel 
anode; three layers of Whatman 3MM filterpaper soaked with transfer buffer (39 mM Glycine, 48 
mM Tris, 10% methanol (v/v)); PVDF membrane (Immobilon P, Millipore) activated by soaking
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in methanol (20 seconds), equilibrated with water gel (5 minutes), and transfer buffer (5 minutes), 
gel, three layers of filter paper soaked with transfer buffer, and finally the platinum coated 
cathode. Transfer was allowed to proceed for 90 minutes at 0.8 mA/cm^ constant current. The 
transfer of pre-stained protein molecular weight markers was used to confirm efficient transfer.
Western hybridisation
After transfer the membrane was briefly washed with TBS-T (150 mM NaCl, 50 mM 
TrisHCL pH 7.5, 0.2 % Tween-20) and blocked over night at 4°C in blocking solution (5% non­
fat dry milk (Carnation, USA) in TBS-T). Membranes were probed for uPAR antigen by 
incubation for 1 hour at room temperature in blocking reagent containing 1 pg/ml of a rabbit 
polyclonal anti-uPAR antibody. The antibody solution was recycled for several blots and a 
dramatic improvement of the signal/noise ratio was observed after the first use. Membranes were 
washed 5 times ( 2 x 1  minute and 3 x 15 minutes) in TBS-T and probed for bound antibody by 
incubation with a horseradish conjugated goat anti-rabbit antibody (Amersham) diluted 1:10.000 
in blocking buffer for 1 hour at room temperature. The secondary antibody solution was made 
fresh every time. The blots were washed as before and developed using a chemoluminescent 
substrate according to the manufactures instructions (SuperSignal Ultra™*, Pierce Chemicals). 
Briefly, the humid membranes (protein side facing upwards) were overlaid with the 
chemoluminescent substrate solution for 5 minutes at room temperature. The membranes Were 
placed between two sheets of transparency film and exposed in ordinary x-ray cassettes (without 
amplifying screens) using Amersham multi-purpose films, Exposure times varied according to 
signal strength.
Enzyme-linked immunosorbent assay (ELISAS
Three different ELISA were applied in this study. The first two (from now on termed the 
"uPAR" and the "R2" ELISA) were developed at the Finsen Laboratory in Denmark and 
measures human uPAR antigen. Although very similar, these two ELISA have different 
selectivity and specificity. The third ELISA (the FLAG ELISA) was developed by me and was 
used to quantify recombinant FLAG-tagged proteins.
The uPAR ELISA (Stephens et al., 1997) uses a polyclonal rabbit anti-uPAR antibody to 
catch, a mixture of three different monoclonal anti-uPAR antibodies (mAb R2, R3 and R5) to 
detect, and an alkaline phosphatase conjugated rabbit anti-mouse antibody to report. The ELISA 
measures all known forms of uPAR including all known uPAR fragments and complexes. The 
ELISA is designed to measure uPAR antigen in biological samples of human origin. The R2 
ELISA (Holst-Hansen et al., 1999; Stephens et al., 1999) uses a mouse monoclonal anti-uPAR
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antibody (mAb R2) to catch, a polyclonal rabbit anti-uPAR to detect, and an alkaline phosphatase 
conjugated anti-rabbit IgG monoclonal mouse antibody to report. The R2 ELISA is an "inverted" 
variant of the uPAR ELISA and was developed to measure human uPAR in serum samples from 
mice xenografted with human tumours. This ELISA does not detect free D1 but is otherwise 
similar to the general uPAR ELISA,
I developed the FLAG ELISA to measure the concentration of recombinant proteins 
expressed in cell culture. The assay uses a mouse monoclonal anti-FLAG antibody (mAb M2) to 
catch, a rabbit polyclonal anti-FLAG to detect, and a horseradish peroxidase coupled polyclonal 
donkey anti-rabbit antibody to report.
96 well ELISA plates were coated O N. at 4°C with 0.1 ml antibody diluted in 0.1 M 
sodium carbonate buffer (pH 9.7) in the following concentrations; uPAR ELISA: 0.5 pg/ml anti- 
uPAR rabbit IgG; R2 ELISA: 0.5 pg/ml mAb R2; FLAG ELISA: 2 pg/ml mAb M2. The wells 
were washed six times with wash solution (PBS containing 0.1% Tween-20, PBS-T) and 
unspecific binding sites saturated by incubation with 0.2 ml blocking solution (PBS containing 
2% BSA) for one hour at room temperature. Wells were washed six times with wash solution. 
Samples to be analysed were diluted in dilution buffer (PBS containing 1% BSA) and added to 
the wells in duplicates. The plates were incubated for 1 hour at room temperature and washed six 
times with PBS-T. The plates were probed with secondary antibodies diluted to the following 
concentrations; uPAR ELISA: 0.375 pg/ml of a mix of mAb R2, mAb R3, and mAb R5 (mixed 
in the weight ratio 1:4:1); R2 ELISA: 0.5 pg/ml anti-uPAR rabbit IgG; FLAG ELISA: 2 pg/ml 
anti-FLAG rabbit IgG. Binding was allowed to proceed for 1 hour at room temperature and 
followed by six washes using PBS-T Bound secondary antibodies were detected using enzyme- 
conjugated antibodies diluted in blocking buffer as follows; uPAR ELISA: alkaline phosphatase 
conjugated rabbit-anti-mouse IgG 1:1000 (DAKO); R2 ELISA: alkaline phosphatase conjugated 
mouse-anti-rabbit IgG 1:2000 (SIGMA); FLAG ELISA: horseradish conjugated donkey-anti- 
rabbit IgG 1:10000 (Amersham). After incubation for 1 hour at room temperature the plates were 
washed six times with PBS-T and 3 times with water. Colorimetric enzyme substrates (alkaline 
phosphatase conjugates: 1.7 mg/ml p-nitrophenyl phosphate (pNPP, Sigma) in 100 mM NaCl, 
100 mM TrisHCl pH 9.5, 5 mM MgCl2; horseradish peroxidase conjugates: ready-to-use ABTS 
substrate solution (Boehringer Mannheim). The absorbance at 405 nm (pNPP substrate) and 436 
nm (APTS substrate) was measured after 1 hour incubation at room temperature using an ELISA 
reader.
Concentrations of antigen in the individual samples were calculated by comparison with a 
standard curve obtained by a two fold dilution series of purified soluble human uPAR (1.0, 0.5, 
0.25, 0.12, 0.06, 0.03, 0.015 ng/ml). Inter-assay variations were, if necessary, corrected by the 
value obtained for a reference sample included on all plates.
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Purification of recombinant soluble uPAR molecules.
Recombinant proteins were purified from COS7 conditioned medium by passage over an 
anti-FLAG™ affinity column (M2 Affinity gel, Sigma). After washing of the column with PBS, 
the recombinant proteins were eluted using 0.1 M glycine pH 3.0. The fractions were 
immediately neutralised using 1/10 volume of 1 M TrisHCL pH 8.0 and analysed by SDS-PAGE 
and ELISA. Fractions containing the recombinant protein were pooled and dialysed against PBS. 
Recombinant proteins were stored at -80°C until use.
Purification of chymotryptic fragments of soluble uPAR
Purified soluble uPAR (D 1231.274) was dialysed against 0.1 M (NH4) 2CO3 and digested 
with chymotrypsin (Boehringer Mannheim) in the molar ratio 1:2000 (chy motry sin : suP AR) for 
16 hours at 37°C. Complete digestion was confirmed by SDS-PAGE and the mixture was added 
PMSF to 1 mM to stop the digestion. The domain 1 fragment (Dli.g?) was separated from the 
domain 2+3 fragment (D2388-274) by chromatography on a small FLAG™ affinity column. The 
D li -87 was recovered in the flow-through and the FLAG tagged D23g8-274 fragment eluted from 
the column with 0.1 M glycine pH 3.0. Both flow-through and eluate were dialysed against PBS 
and the concentration of the purified fragments estimated by SDS-PAGE and commassie 
staining.
Purification and iodination of recombinant suPAR
Recombinant soluble uPAR was purified by affinity chromatography from conditioned 
medium of Chinese hamster ovary cells transfected with a soluble (non membrane-anchored)
125mutant uPAR cDNA (Masucci et al., 1991). The purified suPAR was labeled with I using the 
lodogen procedure (Pierce Chemicals), resulting in a specific activity of 80 x 106 cpm/pg. For the 
analysis of suPAR degradation in urine, aliquots were supplemented with 125I-suPAR to a 
concentration of 2 ng/ml and incubated for 24 hours at 37°C. Non-reducing sample buffer was 
added, and the samples were boiled and separated by 12% SDS-PAGE. Dried gels were analysed 
by autoradiography at -80°C using two amplifying screens. The chymotrypsin used in suPAR 
cleavage experiments was from Boehringer (Mannheim), whereas the uPA was a kind gift from 
Dr J. Henkin, Abbott Laboratories, Chicago).
In vitro binding assays
ELISA plates (Nunc Maxisorb) were coated with vitronectin (0.1 ml, 5 pg/ml, unless 
otherwise indicated) in PBS for two hours at 37°C or over night at 4°C. The remaining protein 
binding sites were blocked using 1% blocking reagent (Boehringer Mannheim) in TBS for one
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hour at room temperature. All further incubations were performed with gentle agitation at room 
temperature in 0.1 ml TBS containing 1% blocking reagent (Boehringer Mannheim) and followed 
by extensive washing with TBS containing 0.1% Tween-20. First, wells were incubated with the 
FLAG™-tagged soluble uPAR molecules diluted to the indicated concentrations for 1 hour at 
room temperature. In some cases the recombinant suPAR was co-incubated with pro-uPA, ATF 
and/or antibodies. After washing, wells were probed for the FLAG-epitope by incubation with 
0.2 pg/ml rabbit anti-FLAG antibody (Santa Cruz) for one hour. After washing, wells were 
probed for bound antibody by incubation with a horseradish conjugated goat anti-rabbit antibody 
(Amersham) diluted 1:1000. After another round of washing, bound horseradish conjugate was 
quantified by colorimetric development using the chromogenic substrate ABTS (Boehringer 
Mannheim). The absorption at 436 nm was recorded in an ELISA plate reader and the signal 
obtained from wells that were coated with blocking reagent subtracted.
Creatinine measurement
Urinary creatinine was measured with à modification of the Jaffé-method according to the 
manufacturers instructions (Boehringer Mannheim), using a BM/Hitachi 747 analyser.
Cell culture techniques
General cell culture
All cell culture media used were supplemented with glutamine (5 mM), penicillin (100 
U/ml), streptomycin (100 pg/ml). WEHI-1 cells were cultured in complete RPMI medium 
containing 15% FCS. U937 cells were cultured in complete RPMI medium supplemented with 
5% FCS and the cells split by dilution. 32D cells were cultured in complete RPMI medium 
supplemented with 10% FCS and 10% conditioned medium from the cell line WEHI-1 as a 
source of IL-3. Stable pools and clones of transfected 32D cells were maintained under weak 
selective pressure in medium containing 0.2 mg / ml G418.
Preparation of conditioned WEHI medium
Cultures of proliferating WEHI-1 cells were split 1:100 in fresh medium and allowed to 
grow until the medium turned acidic (5-6 days). Cells were pelleted by centrifugation and the 
conditioned medium sterile filtered (0.2 pm) and stored at 4°C until use.
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Isolation and purification of blood leukocytes
Whole blood was fractionated by Ficoll-Hypaque gradient centrifugation (Seromed- 
Biochem KG). Monocytes were isolated from the peripheral blood mono-nuclear cells (PBMC) 
by gradient centrifugation on 46% Percoll (Pharamacia & Upjohn). Polymorph nucleated cells 
(predominantly neutrophils) were collected from the pellet of the initial Ficoll-Hypaque 
fractionation and further purified by gradient centrifugation on 62% Percoll.
Transfections
Transfection of CQS7 cells
Semi-confluent COS7 cells were harvested in PBS containing 1 mM EDTA, 
washed 3 times with RPMI medium. The cell suspension (0.8 ml, l-2xl07 cells/ml in RPMI) was 
electroporated in 0.4 cm, Bio-Rad cuvettes containing plasmid DNA (30 p,g, 1 mg/ml in water) at 
960 pF, 240 V (GenePulser, Bio-Rad). After recovery overnight in complete DMEM medium 
containing 10% FCS, cells were washed with PBS and supplemented with 50 ml of serum-free 
medium (DMEM containing 1% Nutridoma NS, Boehringer Mannheim). Every 4-5 days, 
conditioned medium was collected and fresh medium added. The conditioned medium was stored 
frozen at -2 0 °C until purification of the recombinant proteins.
Transfection of 32D cells
Growing 32D cells (0.5 x 106 / ml) were harvested and washed twice in RPMI medium. 
Cells were resuspended in RPMI (50 x 106 / ml) and 0.2 ml aliquots were added to 
electroporation cuvettes (0.4 cm, Bio-Rad) already containing 20 pg of the desired expression 
vector and 2 pg of pRSVneo (1 pg/ml in water). Cells were electroporated using a single 280 V, 
960 pF pulse in an electroporation apparatus (Bio-Rad, Gene Puiser H) and transferred to 
complete medium for recovery. After 48 hours cells were transferred to complete medium 
containing 0.8 mg/ml G418 for selection of stable transfectants. Single clones of transfectants 
were obtained by limited dilution of G418 resistant pools into 96 well tissue culture plates.
Chemotaxis Assays.
Chemotaxis analyses were performed in modified Boyden chambers, using 
polyvinylpyrrolidone-free polycarbonate filters (13 mm diameter, 5 pm pore size) coated with 
type I collagen (100 pg/ml in PBS pH 7.4). After an acid wash (Stoppelli et al., 1986), 2x105 
THP-1 cells in serum-free medium were added in the upper chamber. Attractants were diluted in
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serum-free medium at the indicated concentrations and added in the lower chamber. The assays 
were incubated at 37°C in 5% C 0 2 in air for 90 minutes. The upper surface of filters was scraped 
free of cells, the filters fixed in methanol, stained with crystal violet and cells counted. All 
experiments were performed in triplicate; data are reported as the number of cells counted for 
high power field (ten fields for each condition) and expressed as percentage of the control values. 
Data points represent the mean of three independent experiments (± SEM). When cells of the 
fibroblast-type were employed for the assay, the time required for migration was longer and the 
Boyden chambers were usually incubated overnight.
Pertussis toxin sensitivity was carried out by pre-incubating cells with 100 ng/ml 
wild-type or mutated (Pizza et al., 1989) pertussis toxin in RPMI for 4 hours at 37°C. After 
treatment, cells were exstensively washed, resuspended in RPMI and assayed in chemotaxis, as 
described above, or in kinase assays (see below).
Adhesion assays
Coating of 96 well tissue culture dishes were performed by incubation with 5 pg/ml 
vitronectin or 10 mg/ml fibronectin in PBS for 2 hours at 37°C or over night at 4°C. Remaining 
binding sites were saturated by incubation of the wells with 2 % bovine serum albumin in PBS 
for 1 hour at 37°C. Immediately before the adhesion assay, cells were washed twice in RPMI 
containing 0.1% BSA and resuspended in the same medium at 2 x 106/ml. Cells (0.05 ml) were 
added to wells already containing 50 pi RPMI with 0.1 % BSA and the agonists / antagonists to 
be tested. The plates were centrifuged at 1000 rpm for one minute to sediment the cells and 
incubated in a humidified incubator at 37eC for 1 hour. At the end of the incubation the wells 
were washed with 37°C warm RPMI as follows: to the medium already present in the wells was 
added 2  x 100  pi medium, at normal pipetting speed, using a multi-well pipettor, row by row, and 
from two opposite sites of the wells. The medium (containing the suspended non-adherent cells) 
was then immediately aspirated from one side of the well and 100 pi of fresh medium added. The 
procedure of washing was repeated, if necessary, until BSA coated wells contained only few 
remaining cells. Adherent cells were fixed for 10 minutes with 37eC warm PBS containing 3 % 
(w/v) formaldehyde and the cells stained for 5 minutes with 0.05 ml crystal violet solution (0.5 % 
(w/v) in 20 % (v/v) methanol). After washing of the plate by immersion in tap-water, the cells 
were lysed in 1% SDS in water and the absorption at 540 nm was measured in an ELISA plate 
reader. To obtain a measure for specific adhesion the readings were subtracted the value obtained 
in BSA coated wells, unless otherwise indicated. All experiments were performed at least twice 
and the shown values are the mean +/- SD of triplicate or quadruplicate determinations from a 
representative experiment.
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FACS analysis
32D cells to be analysed (1 x 106) were pelleted by centrifugation and resuspended in 0.1 
ml ice-cold wash buffer (PBS containing 5% FCS) containing 10 mg/ml of the R2 monoclonal 
antibody and incubated on ice for 30 minutes. The cells were washed twice with 3 ml ice cold 
wash buffer and resuspended in 0.1 nil wash buffer containing a FITC conjugated goat anti- 
mouse antibody (DAKO) diluted 1:50 in wash buffer and incubated for 20 minutes on ice. After 
another round of washing, the cells were resuspended in 0.5 ml PBS and analysed in a Becton 
Dickinson flow cytometer according to manufactures instructions. Relative values for the mean 
fluorescence were calculated using the Lysis II software package. Non-transfected cells were 
used as controls for specificity.
Animal experiments
The HOC8 xenografts were established and maintained as ascites in NCr nu/nu mice 
(Taconic, Germantown, NY) as described previously (Massazza et al., 1989; Pedersen et al.,
1993). Urine, serum and tumour cells were obtained four weeks after the interperitoneal injection 
of a tumour suspension (1 0  million cells) from nude mice all bearing ascites and metastatic 
tumours in the peritoneal cavity (Pedersen et al., 1993). Urine collected from 5 mice, kept in a 
metabolic cage for 24 hours, was centrifuged and stored frozen at -80°C until analysis. Blood was 
obtained by intracardiac puncture from anaesthetised mice. As control, blood and urine were 
collected from five non tumour bearing nude mice and processed in the same way.
The MDA-MB-435-BAG (MDA435) cells (Brünner et al., 1992) were cultured in 
EagleMEM containing glutamax (Life Technologies) and 5% foetal bovine serum. Semi- 
confluent cell cultures were harvested by scraping and the concentration was adjusted to 10 x 106 
cells/ml. Six to eight weeks old male META-Bom-nu/nu mice (Bomholdtgaard, Denmark) were 
injected subcutaneously and bi-laterally with 0.1 ml MDA435 cell suspension. After 50 days, 
urine, plasma, and tumor tissue, were collected from two tumour-bearing mice as described for 
the HOC8 xenografted animals.
Procedures involving animals and their care were conducted in conformity with the 
institutional guidelines that are in compliance with national (D.L. n.116, G.U., suppl. 40, 18 
Febbraio 1992, Ciruulare No. 8 , G.U., Luglio 1994) and international laws and policies (EEC 
Council Directive 86/609, OJ L358,l, Dec. 12, 1987; Guide for the Care and Use of Làboratory 
Animals, U.S. National Research Council, 1996).
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Statistics
To evaluate differences between group median values, the data were analysed with the 
Mann-Whitney rank-test. P values below or equal to 0.05 were considered significant.
Chapter 3:
RESULTS & DISCUSSION (I)
Molecular analysis of uPAR mediated vitronectin adhesion.
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Summary
In this chapter I analyse uPAR mediated cellular binding to vitronectin using the murine 
erythroid progenitor cell line 32D. I show that expression of uPAR in the 32D promotes cellular 
binding to vitronectin, but fails to support cell spreading. The strength of binding is correlated to 
the expression level of uPAR and is strongly stimulated by the presence of the uPAR ligand pro- 
uPA. Using a recombinant truncated variant of uPAR lacking domain 1, and by antibody 
inhibition experiments, I demonstrate that domain 1 plays a crucial role in uPAR mediated 
cellular binding. The failure of the mutant uPAR lacking domain 1 to promote cellular binding is 
paralleled by strong reduction in the affinity for vitronectin in vitro.
Introduction
The presence of a cellular proteolytic variants of uPAR composed of domain 2 and 3 
(D2D3), and thus lacking the major uPA binding domain 1 (Dl), was first identified in U937 
cells (Hpyer-Hansen et al., 1992) and has since then been observed in other cell lines and tumour 
detergent extracts (Ragno et al., 1998; Solberg et al., 1994; Chapter 5; Chapter 6 ). The formation 
of the D2D3 uPAR variant may involve the proteolytic cleavage by uPA, which is capable of 
cleaving uPAR in the linker region between domain 1 and 2 both in vitro and at physiological 
concentrations in vivo (H0 yer-Hansen et al., 1997b; H0 yer-Hansen et al., 1992). The cleavage of 
uPAR in this region results in profound changes in the biological properties of uPAR: First, 
uPAR looses the capacity to bind uPA with a concomitant loss of potential to enhance uPA 
mediated cell surface plasmin generation (Ellis et al., 1989; H0yer-Hansen et al., 1997b). Since 
the cleavage is expected to occur most efficiently under conditions of high uPA activity it might 
function as a negative feedback mechanism (H0yer-Hansen et al., 1997b). Second, the cleavage 
in the hinge region unmasks bioactive epitopes of uPAR that have the potential to induce cellular 
chemotaxis and activation of kinases from the src-family (Fazioli et al., 1997; Resnati et al., 
1996).
Cellular binding to vitronectin, mediated by uPAR, was first shown in the human 
histiocytic lymphoma cell line U937. This cell line becomes strongly adhesive to vitronectin 
when stimulated with a combination of vitamin D3 and transforming growth factor (31 or phorbol 
esters in the presence of uPAR ligands (Nusrat and Chapman, 1991; Waltz and Chapman, 1994). 
This has later been extended to other cell lines and it has been shown that both cellular and 
soluble uPAR interact directly with certain forms of vitronectin (H0 yer-Hansen et al., 1997a; 
Waltz and Chapman, 1994; Wei et al., 1994). The region of uPAR responsible for the interaction 
with vitronectin was initially assigned to D2D3 (Wei et al., 1994) but recent data obtained using 
real-time biomolecular interaction analysis have demonstrated that also D l is required for the
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interaction in vitro (H0yer-Hansen et al., 1997a). At present, very few data on the effect of 
cleavage on the potential of uPAR to mediate cellular binding to vitronectin have been presented 
(Ragno et al., 1998).
Besides mediating cellular binding to vitronectin uPAR also modulates the function of 
adhesion receptors from the integrin family (Simon et al., 1996; Sitrin et al., 1996; Wei et al., 
1996; Yebra et al., 1996) and data for a direct interaction between uPAR and purified Mac-1 have 
been presented (Wei et al., 1996).
In this chapter I analyse the consequence of uPAR cleavage on the affinity for vitronectin 
and on the capacity to mediate cell binding to vitronectin. Using cellular and soluble uPAR 
mutant receptors I report that D l plays a crucial role for the capacity of uPAR to mediate cellular 
binding to vitronectin as well as for the high affinity interaction with vitronectin in vitro. The 
system employed, 32D erythroid progenitor cells, is suitable for this analysis as these cells 
display low intrinsic binding to the extracellular matrix proteins vitronectin. Thus the uPAR- 
mediated binding is not confused with possible integrin mediated binding.
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Results
Adhesive properties of 32D cells
To analyse the structural requirements of uPAR as an adhesion receptor I wanted to use a 
cell system that fulfils two criteria. First, the cell line should be easy to transfect in order to 
introduce the desired recombinant uPAR receptors to test for their properties as adhesion 
receptors. Second, the cell line should have low basal binding to vitronectin in order to 
discriminate between binding caused by the transfected molecules and binding mediated by 
endogenously expressed adhesion receptors.
To evaluate the murine myeloid 32D cell line as a model system for uPAR mediated 
adhesion I compared the adhesive properties of these cells with those of the well characterised 
human myeloid U937 cells (figure 3.1, panel A). While U937 cells displayed significant binding 
to both fibronectin and vitronectin, 32D cells completely failed to adhere to vitronectin and only 
displayed moderate binding to fibronectin. Stimulation with cytokines or phorbol-esters have 
been shown to enhance the cellular binding of U937 cells to vitronectin as a result of enhanced 
expression of uPAR and of its ligand uPA (Waltz and Chapman, 1994). To analyse the effect of 
phorbol-esters stimulation on the cellular binding of 32D cells I stimulated cultures of 32D and 
U937 with PMA for 18 hour prior to the adhesion assay (figure 3.1, panel B). As expected, PMA 
treatment strongly stimulates the binding of U937 cells to vitronectin as previously described 
(Waltz and Chapman, 1994). However, the PMA treatment fails to modulate the binding of the 
32D cells to any of these substrates. The 32D cells express a range of integrin receptors including 
fibronectin and vitronectin receptors (Bazzoni et al., 1996; Zhang et al., 1996) and it has been 
shown that the failure of PMA to induce the activation of these receptors can be reverted by the 
expression of protein kinase C-Ô (Mischak et al., 1993). The activation state of integrin receptors 
and the binding to fibronectin of 32D cells has been reported to be regulated by the IL-3 
stimulation state of the cells (Bazzoni et al., 1996). My experimental protocol uses cells grown in 
medium where the IL-3 is supplied in the form of conditioned medium from the WEHI cell line 
and the level of IL-3 stimulation is therefore ill defined. To analyse the effect of IL-3 stimulation 
on binding to fibronectin and vitronectin I performed experiments where the 32D cells had been 
IL-3 starved for 8 hours prior to the adhesion assay (figure 3.2). Under these conditions the 
presence of IL-3 stimulate the cellular binding of 32D cells to fibronectin approximately 2-fold, 
but fails to modulate the binding to vitronectin.
From these experiments I conclude that the 32D cells represent a suitable model system 
for the analysis of uPAR-mediated cellular binding to vitronectin as these cells fails to display 
any notable binding to vitronectin under all the conditions analysed.
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uPAR expression promotes 32D cell binding to vitronectin
To analyse uPAR-mediated cell binding I transfected 32D cells with an expression vector 
in which I had engineered the fiill-length human uPAR cDNA (Roldan et al., 1990). By selection 
of the transfected cells with G418 I obtained a pool of resistant cells representing a population of 
clones expressing variable amounts of uPAR on the cell surface as determined by FACS analysis 
using the anti-uPAR monoclonal antibody R2 (results not shown). I observed that during normal 
passage, the pool of uPAR transfected cells are notably more adherent to the tissue culture plates 
than the mock transfected cells (results not shown). To investigate whether this increased binding 
of the uPAR transfected cells is mediated by the vitronectin present in the culture medium, I 
performed adhesion assays with the stable pools of transfected 32D cells under serum free 
conditions, to purified vitronectin immobilised in 96 well tissue culture plates (figure 3.3). 
Indeed, the pool of uPAR transfected cells binds stronger to vitronectin than the mock-transfected 
cells over a range of coating concentrations, demonstrating that expression of uPAR in 32D cells 
causes specific cellular binding to vitronectin.
Binding is proportional to the expression level of uPAR
Only a small fraction of the 32D cells (less than 10%, not shown) in the pool of uPAR 
transfected cells remain bound after washing, even at the highest vitronectin coating 
concentration, and I speculated that this is a result of heterogeneous uPAR expression in the pool 
of transfected cells. To analyse the relationship between the expression level of uPAR and the 
strength of binding to vitronectin I cloned the pool of transfected cells by end-point dilution. I 
analysed the cell surface expression of uPAR in 50 clones by FACS analysis using the anti-uPAR 
monoclonal antibody R2 (figure 3.4, panel B and not shown) and selected a number of clones 
representing a range of expression levels for analysis of their binding to vitronectin (figure 3.4, 
panel A). I found that there is a good correlation between the expression level of uPAR and the 
strength of binding to vitronectin as higher expression levels of uPAR are associated with 
stronger binding to vitronectin. In the highest expressing clones (clones 22 and 1) more that 90% 
of the cells remain bound after washing of the plates (not shown), while the lowest expressing 
clones (clone 21 and 24) display binding comparable to the pool of transfected cells. Some clones 
(clones 14 and 17) do not express detectable levels of cell surface uPAR and are included in the 
analysis as negative controls.
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Binding is stimulated by uPAR ligands
uPAR mediated binding of U937 cells to vitronectin is stimulated by uPA (Waltz and 
Chapman, 1994) and I therefore wanted to analyse the effect of uPA on the binding of the uPAR 
transfected 32D cells. To do this I performed adhesion assays in the presence of saturating levels 
of pro-uPA (figure 3.4, panel A). Clones expressing high levels of uPAR (clone 22 and 1) bind 
strongly to vitronectin in the absence of ligand and the addition of pro-uPÀ does not stimulate 
this binding further. The binding of clones expressing low and intermediate levels of uPAR are 
stimulated by pro-uPA and the stimulation is inversely correlated with the expression level of 
uPAR. Clones expressing low levels of uPAR (clone 24A and 21) are strongly stimulated and 
clones expressing intermediate to high levels of uPAR (clone 22.7, 8 , and 2) are only weakly 
stimulated. The presence of pro-uPA during the adhesion assays has no significant effect on the 
binding of mock transfected cells (not shown) or control clones expressing undetectable levels of 
uPAR (clone 14 and 17) demonstrating that the stimulatory effect of uPAR ligands is indeed 
mediated by uPAR.
The dose-dependency of the stimulation by pro-uPA analysed in two clones (c21 and 
c24A) which are strongly stimulated by pro-uPA, is shown in figure 3.5. For both clones the 
stimulation is half-maximal at 0.1-0.3 nM pro-uPA which is consistent with the Kd for the 
interaction between uPAR and pro-uPA (0.1-1 nM). Also two-chain uPA and the amino-terminal 
fragment (ATF) of uPA, which contains the entire uPAR binding site, stimulates the binding with 
equal efficiency demonstrating that it is the ligand binding capacity, rather than the catalytic 
activity of uPA, responsible for the stimulation of binding (results not shown).
A uPAR mutant lacking domain 1 fails to promote binding
The occurrence of uPAR cleavage in tumour cell lines and xenografted tumour tissue 
prompted me to investigate whether cleaved uPAR supports cellular binding to vitronectin. To 
analyse this I constructed a mutant uPAR cDNA encoding a deletion variant of uPAR where the 
region encoding domain 1 (amino acid 1-92) was deleted creating a receptor composed of domain 
2 and 3 (termed D2D3). This recombinant receptor is equivalent to cellular cleaved uPAR 
observed in cell culture as it lacks domain 1. I cloned this mutant uPAR cDNA into the 
expression vector and generated clones of 3 2D cells expressing the mutant receptor as described 
for full-length uPAR. I identified several clones expressing the truncated receptor at levels 
comparable to what I observe with full-length uPAR (figure 3.4, panel B). However, even though 
the D2D3 receptor is efficiently expressed the cells fail to adhere to vitronectin (figure 3.4, panel 
A). The failure to adhere to vitronectin is independent of the addition of pro-uPA.
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Antibodies against domain 1 inhibit binding
To further analyse which region of uPAR is involved in cellular binding to vitronectin, I 
tested four monoclonal antibodies against uPAR for their ability to inhibit the binding of uPAR 
transfected 32D cells (figure 3.6). I used the 32D/uPAR clone 1 cells, as these adhere strongly to 
vitronectin in the absence of pro-uPA, and I performed the adhesion assay in the absence of pro- 
uPA to avoid the potential interference between antibody and pro-uPA binding to uPAR. 
Adhesion assays were performed in the presence of 50 pg/ml of monoclonal antibodies 
recognising different epitopes on uPAR or an irrelevant control antibody. Two antibodies 
recognising epitopes within domain 3 of uPAR (mAb R2 and R4) and the control antibody (M2) 
do not affect the binding to vitronectin. The two antibodies recognising epitopes within domain 1 
of uPAR (mAb R3 and R5) strongly inhibit the binding. In line with the data from the mutant 
D2D3 receptor, these results suggest a fundamental role of domain 1 in uPAR mediated cell 
binding.
uPAR mediated binding to vitronectin is independent of integrin activation
uPAR mediated vitronectin adhesion of transfected HEK293 cells depends upon integrin 
activation as it is inhibited at low temperatures and by the introduction of dominant negative 
integrin molecules (Wei et al., 1996). To analyse the requirement for integrin function and 
activation in the 32D cell system, I performed adhesion assays in which I regulated the integrin 
activation state using IL-3 and temperature (figure 3.7). The binding to vitronectin is not 
significantly affected by IL-3 stimulation and is not reduced at 4°C, suggesting that uPAR 
mediated cell binding to vitronectin does not require integrin activation or metabolic energy in 
the 32D cell system. The binding to fibronectin, which is mediated by integrin receptors, is 
enhanced by IL-3 stimulation at 37°C, and almost completely inhibited at 4°C demonstrating the 
requirement for metabolic energy. The inhibitors of integrin function EDTA, and ROD 
containing peptides also fail to inhibit the binding uPAR-expressing cells to vitronectin (not 
shown).
In support of the lack of integrin involvement in the observed binding, I also fail to 
observe cellular spreading of the uPAR transfected cells on vitronectin (figure 3.8) as the 
morphology of the uPAR transfected cells bound to vitronectin or to BSA is indistinguishable.
The data suggest that uPAR mediated binding of the transfected 32D cells to vitronectin 
occurs independently of integrin function and activation. The observed binding may therefore 
simply reflect an affinity between the cells and the tissue culture plastic mediated by the 
interaction between uPAR (on the cell surface) and vitronectin (on the plastic). To investigate this 
possibility I performed adhesion assays to plates that I had coated with monoclonal antibodies
Chapter 3: RESULTS & DISCUSSION (I)
against uPAR (figure 3.9). In fact, uPAR transfected 32D cells bind strongly to wells coated with 
antibodies against both domain 1 (mAb R3) and domain 3 (mAb R2). The 32D cells transfected 
with the mutant D2D3 receptor, which fail to adhere to vitronectin, adhere to the uPAR antibody 
recognising an epitope within domain 3 (mAb R2). The results suggest that any high affinity 
interaction between a cell surface molecule (in this case uPAR) and an immobilised protein (in 
this case vitronectin or anti-uPAR antibodies) can mediate cellular binding of the 32D cells.
Domain 1 and uPAR ligand are required for the high affinity binding of 
soluble uPAR to vitronectin
Taken together the data suggest that the inabillity of D2D3 receptors to mediate cellular 
binding is caused by a reduced or abolished ability to interact with vitronectin. I therefore 
proceeded to analyse if the D2D3 receptor also has a reduced affinity for vitronectin in vitro. To 
do this I performed in vitro binding assays to immobilised vitronectin using a soluble form of 
full-length uPAR and the mutant D2D3 receptor. The GPI-anchoring sequence in these 
recombinant receptors has been replaced with a short peptide sequence (the FLAG epitope) 
recognised by specific antibodies and thus represent soluble forms of the cellular receptors used 
in the 32D cells. The construction, expression and purification of these soluble receptors are 
described in detail in chapter 4. The in vitro binding assay used in this analysis is in principle 
similar to the adhesion assay as the molecules are allowed to bind to immobilised vitronectin. 
After washing, bound protein is quantified by virtue of the FLAG-tag in an ELISA-like assay 
(see material & methods).
I incubated vitronectin-coated wells with increasing concentrations of the recombinant 
proteins in the presence or absence of pro-uPA and detected bound proteins using an antibody 
directed against the FLAG-epitope located at the carboxy-terminus of the recombinant receptors 
(figure 3.10). In the presence of pro-uPA, I detect specific binding of the full-length receptor 
down to approximately 1 nM, while I fail to observe any significant binding in the absence of 
pro-uPA, even at 100-fold higher concentrations. The soluble D2D3 receptor mutant fails to bind 
notably to vitronectin over the entire concentration range analysed and does so both in the 
presence or absence of pro-uPA.
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Discussion
Firm cellular attachment to the extracellular matrix is a complex process, which involve 
numerous molecular interactions between extracellular proteins, cell surface receptors, and the 
intracellular cytoskeleton. The process is initiated with the cellular binding to the extracellular 
matrix, mediated by the interaction between cellular receptors and extracellular matrix proteins, 
and is followed by a complex process of signalling, receptor activation, and cytoskeleton 
reorganisation, eventually leading to cell spreading and firm attachment.
The expression of uPAR in 32D cells promotes cellular binding to vitronectin but not 
promote firm adhesion and cell spreading on the substrate. This is in contrast to the epithelial 
HEK293 cell line in which expression of uPAR leads to firm cell adhesion and spreading on 
vitronectin (Wei et al., 1994). The apparent discrepancy between these observations may be 
found in differences between the two cell lines. HEK293 grow firmly adherent and therefore 
clearly possesses the necessary cell program and machinery to promote firm cell adhesion and 
spreading. The 32D cells are highly undifferentiated, grow in suspension, and are only expected 
to undergo firm adhesion and cell spreading upon differentiation. It is therefore likely that these 
cells do not posses the required cell program and/or machinery to support cell spreading. 
Expression of uPAR in 32D cells evidently promotes the initial cellular binding to vitronectin, 
but fails to initiate the process of cell spreading. It is possible that in the 32D cells uPAR fails to 
associate to integrin molecules or that the uPAR/integrin complexes fail to connect to the 
cytoskeleton. The strength of binding of cells to vitronectin is comparable to that of anti-uPAR 
antibodies suggesting that the only requirement for binding is a sufficiently high number of 
interactions between the cell and the substrate to resist the hydro-dynamic pressure applied 
during washing of the plates.
The structural requirement for a high affinity interaction between vitronectin and uPAR 
has been addressed in a couple of studies (H0yer-Hansen et al., 1997a; Wei et al., 1994). Wei and 
co-workers have suggested that a region within the D2D3 part of uPAR is responsible for the 
interaction. This conclusion is based on experiments with a D2D3 fragment purified from 
chymotrypsin-cleaved suPAR and inhibition by the R4 antibody (recognising an epitope within 
domain 3). H0 yer-Hansen and co-workers have, based on real-time biomolecular analysis, 
concluded that intact uPAR is required for the high affinity interaction between uPAR and 
vitronectin. My data are in accordance with the latter, as I do not observe any significant binding 
of D2D3 to immobilised vitronectin. A likely explanation for the discrepancy between the 
observations could be the presence of low levels of contaminating fiill-length soluble uPAR in 
the D2D3 preparations used by Wei and co-workers. In my experimental set-up this potential
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problem has been eliminated using recombinant uPAR fragments expressed in cells that do not 
produce any full-length suPAR.
I observe a strict requirement for the pro-uPA to obtain significant binding of suPAR to 
immobilised vitronectin in vitro. This observation is in contrast to data published by others who 
observe no difference (H0yer-Hansen et al., 1997a) or a moderate to high stimulation (Wei et al., 
1994) by uPAR ligands. The reason for this discrepancy probably lies in the different assays, as 
well as in the different soluble uPAR molecules or vitronectin preparations used in the 
experiments. The binding of suPAR to vitronectin is not a simple first order binding reaction and 
probably involves conformational changes of both uPAR and vitronectin (H0yer-Hansen et al., 
1997a). This is in accordance with the model proposed by Wei and co-workers who suggest that 
uPAR, with respect to vitronectin binding, is in an equilibrium between a high and a low affinity 
conformation which is pushed towards the high affinity state upon ligand binding. Modifications 
such as radio labelling, biotinylation or the engineered addition of epitopes may potentially affect 
the equilibrium between the different conformations present in the recombinant soluble uPAR 
preparations used by different laboratories.
In contrast to my data in vitro, I did not observe a strict requirement for ligand binding in 
the process of cellular binding to vitronectin in vivo. This apparent difference may have a number 
of explanations. First, the local concentration of membrane bound uPAR at the interface between 
the cell and the substratum might be high enough to allow a sufficient number of low affinity 
interactions between uPAR and vitronectin to obtain the required resistance to the hydrodynamic 
stress applied in the adhesion assay. Second, the high affinity conformation of uPAR could be 
stabilised by the GPI-anchor, which is not present on soluble uPAR, or by the interaction with 
other membrane proteins. Third, the presence of the FLAG-epitope on our soluble uPAR might 
stabilise the low affinity conformation of the soluble receptor. However, these explanations only 
apply to cells that express high levels of uPAR. Low-uPAR cells requires ligand to bind to 
vitronectin.
uPAR antagonist are molecules that inhibit the uPA/uPAR interaction through binding to 
uPAR. These molecules include non-catalytic derivatives of uPA (ATF, GFD and derivatives), 
antibodies as R3 and R5, and different low molecular weight compounds. uPAR antagonists are 
therapeutically interesting as they have been shown to inhibit tumour growth and metastasis in 
certain model systems. The anti-cancer effect of these molecules has been assigned to the 
capacity to block the binding of uPA to uPAR with its concomitant reduction in plasminogen 
activation potential of the cells. However, it is likely that the effect of these compounds might, at 
least partially, be caused by their pro- or anti adhesive properties. A great deal of work is done in 
the pharmaceutical industry to develop non-toxic low molecular weight uPAR antagonists and
Chapter 3:  RESULTS & DISCUSSION (I)_______________________________
the 32D/uPAR cell system is perfect to test the pro- or anti adhesive properties of these 
compounds.
Contributions:
All the experimental work presented in this chapter was planned and performed by me.
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The chemotactic epitope in uPAR
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Summary
Through the expression and testing of several uPAR variants, I have located and 
functionally characterised a potent chemotactic uPAR epitope that mimics the effects of the 
uPA/uPAR interaction. The chemotactic activity lies in the region linking domains 1 and 2, 
which is highly sensitive to proteolytic cleavage. Synthetic peptides carrying this epitope promote 
chemotaxis and activate p56/p59*** tyrosine kinase. Both the chemotaxis and kinase activation are 
pertussis-toxin sensitive and thus involve a protein in the pathway.
Introduction
The role of urokinase (uPA) and uPAR in cell migration and invasion is well 
substantiated. It was previously shown that uPA-induced chemotaxis requires interaction with 
and modification of uPAR, which is the true chemoattracting molecule acting through an 
unidentified cell surface component which mediates this cell surface chemokine activity (Resnati 
et al., 1996). Cell recruitment is an essential component in inflammation, neo-angiogenesis and 
cancer invasiveness. Urokinase-type plasminogen activator (uPA), its receptor (uPAR) and 
inhibitor (PAI-1) are directly involved in these mechanisms (Blasi, 1997). An important proof of 
this statement is the profound impairment of inflammatory cell recruitment in uPA"/" mice which 
do not properly respond but succumb to infection by Cryptococcus neoformans, due to deficient 
T-lymphocytes and monocytes-macrophages recruitment (Gyetko et al., 1996). Moreover, uPA- 
deficient mice fail to support the growth and development of experimental melanomas, while 
inhibition of the uPA/uPAR interaction in vivo blocks angiogenesis, growth and spreading of 
syngeneic tumours (Min et al.,. 1996; Shapiro et al., Î996). A chemotactic activity of uPA has 
long been recognised in vitro on different cell types in culture (Busso et al., 1994; Fibbi et al., 
1988; Gudewicz and Gilboa, 1987; Gyetko et al., 1994; Resnati et al., 1996). The chemotactic 
activity of uPA strictly depends on binding to its receptor uPAR: First, it does not occur in 
murine cells lacking uPAR; second, it does not occur in cells containing uPAR but not 
recognising human uPA; third, it can be restored by transfection of the uPAR cDNA; fourth, it is 
inhibited by antibodies that prevent the uPA/uPAR interaction (Resnati et al., 1996). Occupancy 
of uPAR transduces a signal that results in the movement of cells; indeed, a rapid and transient 
activation of intracellular serine and tyrosine kinases (PTK) has been observed in different cells 
(Busso et al., 1994; Resnati et al., 1996). That tyrosine kinase activation is required for the
chemotactic activity of uPA is shown by the ability of 3T3 fibroblasts from wild-type but not
/
from Src mice to respond to uPAR-mediated chemoattraction (our unpublished data), or by the 
block of ligand-induced chemotaxis by tyrosine kinase inhibitors in THP-1 cells (Resnati et al.,
1996).
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uPAR is a GPI anchored protein made up of three cysteine-rich CD59-like domains 
connected by short linker regions (Ploug and Ellis, 1994), expressed by a variety of cells 
including neutrophils, T-lymphocytes, monocytes-macrophages and fibroblasts. In addition, most 
cancer cells express uPAR, often at rather high levels (Blasi, 1988). In T-lymphocytes and 
monocytes, uPAR is an activation antigen and its expression appears to he relevant to the 
function of these cells at least in culture (Bianchi et al., 1996; Nykjaer et al., 1994; Picone et al., 
1989).
The membrane attachment of uPAR via a GPI-anchor (Ploug et al., 1991) i.e. the lack of 
an intra-cytoplasmic region capable of connecting with the cytoplasmic signal transducers, 
suggests that transmembrane adapter(s) must mediate the activation of intracellular transducers. 
Indeed, uPAR"^ ™ cells can respond to a chemotactic stimulus induced by exogenous, soluble 
uPAR (suPAR), indicating that the binding of uPA to uPAR transforms the latter into a ligand for 
another cell surface component. However, this activity of suPAR is apparent only after 
chymotrypsin cleavage at Tyr87 (Resnati et al., 1996), a modification causing a major 
conformational change, similar to uPA binding (Ploug and Ellis, 1994; Ploug et al., 1993). The 
chemotactic properties of uPA and chymotrypsin-cleaved suPAR are identical, i.e. they both 
induce p56/p59Ac* tyrosine kinase activation with the same time-course (Resnati et al., 1996) 
indicating that the same mechanism operates in both cases.
The above data show therefore that uPAR is a cell-surface chemokine-like molecule, the 
activity of which is regulated by the binding of its ligand uPA which in an as yet undefined way 
uncovers the chemotactic epitope. In this chapter I demonstrate that the uPAR chemotactic 
epitope is located in the sequence linking domains 1 and 2 , a region highly sensitive to cleavage 
by uPA and other proteases ( Hpyer-Hansen et al., 1992; Hpyer-Hansen et al., 1997b). Indeed, 
also a synthetic uPAR chemotactic epitope activates p56/p59/ic* and both chemotaxis and 
activation of p56/p59Ac* are pertussis-toxin sensitive, implying a connection between G-proteins 
and intracellular protein tyrosine kinases.
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Results
Identification and mapping of the uPAR chemotactic epitope.
To identify the chemotactically active region in uPAR, I constructed recombinant uPAR 
cDNA's encoding different parts of uPAR (figure 4.1). The recombinant receptors were expressed 
. by transient transfection of COS7 cells as this allowed me to obtain sufficient purified protein 
(0.05-0.5 mg depending on the construct) within one month of transfection. The recombinant 
receptors were purified from the conditioned medium by affinity chromatography utilising the 
flag epitope engineered onto the carboxyterminus of all the recombinant receptors.
We had previously shown that chymotryptic cleaved suPAR induced a very efficient 
chemotactic activity at picomolar concentrations (Resnati et al., 1996), but as the chymotrypsin 
digestion generates a mixture of the two fragments Dli.g? and D2D3g8-274> it was not possible to 
determine which of the fragments possessed the chemotactic activity.
To determine which of the two fragments possessed the chemotactic activity, I first 
purified the FLAG-tagged, full-size three domains suPAR, digested it with chymotrypsin and 
separated the resulting fragments D l i -87 and D2388-274 by antibody affinity chromatography. 
The Dl i_87 fragment was recovered in the flow through and the D2388-274 fragment eluted from 
the column by lowering the pH (not shown). The two fragments were individually tested in 
chemotaxis assays on human THP-1 cells. THP-1 cells were chosen, even though they are poor 
responders to chemotactic signals, because their basal level of tyrosine phosphorylation is low 
(Resnati et al., 1996) making the subsequent biochemical analysis easier. The carboxyterminal 
fragment, D2388-274, but not the aminoterminal D li-87, elicited a dose-dependent chemotactic 
response, demonstrating that the chemotactic region in uPAR is located within the D2388-274 
fragment (figure 4.2). To further map the chemotactic region I expressed and purified Flag™ 
tagged recombinant fragments of uPAR encoding different parts of uPAR (figure 4.1). Of these, 
only D ll -92 induced a dose-dependent chemotactic effect, while D2393.274, 0293,191 and D3i92- 
274 failed to induce chemotaxis through the entire concentration range analysed (figure 4.2). 
These findings show that only fragments containing the sequence 88 to 92 of uPAR, SRSRY, had 
a chemotactic effect. Since the presence of this motif correlates with enhanced migration of THP- 
1 cells it may represent the chemotactically-active epitope. Interestingly, the 88-92 sequence 
appears to be active both when present at the amino-, as in D2388-274, as well as at the carboxy­
terminus, as in D li.92.
To determine whether the identified SRSRY motif was responsible for the observed 
chemotactic effect, we tested synthetic uPAR peptides for their chemotactic activity on THP-1 
cells. Peptide 1 (AVTYSRSRYLEC) which corresponds to the amino acid sequence 84-95 of
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human uPAR (Roldan et al., 1990) and its shorter version, peptide 3 (SRSRYLEC, residues 88- 
95), both contain the SRSRY motif, exhibited chemotactic activity with a maximal response at 
concentrations as low as 0.1 pM (figure 4.3, panels A and C). On the other hand, peptide 4 
(TLVEYYSRASCR), a scrambled version of peptide 1, and peptide 2 (YTARLWGGTLLT), 
which covers residues 301-313, and thus is absent from processed mature uPAR (Ploug et al., 
1991), had no effect on cell migration over the entire concentration range analysed (figure 4.3, 
panels B and D). These results support the conclusion that peptides containing the sequence 
SRSRY of human uPAR have a potent chemotactic activity. It is important to note that this 
region is efficiently cleaved by uPAR-bound uPA at chemotactically active concentrations 
(H0yer-Hansen et al., 1997b).
Since THP-1 cells are not very sensitive to chemotactic stimuli, we also tested peptide 1 
on other cells. Peptide 1 was found to be active also on several other cells, including murine 
uPAR"/" fibroblasts, 3T3 and LB6 cells, and rat aortic smooth muscle cells (data not shown). On 
some of these cells the effect is much more pronounced (about four-fold over basal migration), 
but has the same concentration-dependence as in THP-1 cells.
The chemotactic effect of suPAR fragments and synthetic peptides was not a general 
effect on migration but was dependent on the establishment of a concentration gradient. Also, 
these agents did not display a chemokinetic effect on THP-1 cells, as addition in the upper well 
(containing the cells) had no effect on migration (data not shown).
Activation of p5 6 /p5 9 ^* by chemotactic UPAR peptides.
Treatment of THP-1 cells with the uPA fragment ATE at chemotactic concentrations 
induces the activation of p 5 6 /p 5 9 ^  tyrosine kinase. Treatment with exogenous chymotrypsin- 
cleaved suPAR, that substitutes for uPA in inducing chemotaxis', also activates p56/p59Ac* 
(Resnati et al., 1996). We therefore tested the effect of chemotactic concentrations of peptide 1 
on the activity of p56/p59/ic* kinase. Treatment of THP-1 cells at 37°C with 1 pM peptide 1, 
induced increased autophosphorylation as well as phosphorylation of the exogenous substrate 
enolase (not shown). The effect was apparent after 2 minutes, reached a maximum after 10 
minutes and returned to the basal level after 30 minutes and thus has a time-course very similar to 
that of ATE or chymotrypsin-cleaved suPAR (Resnati et al., 1996)(data not shown). No effect 
was observed when 1 pM of the corresponding scrambled peptide (peptide 4) was used in the 
assay (data not shown). Thus, the effect of peptide 1, containing the SRSRY sequence of uPAR, 
resembles that of uPA and chymotrypsin-cleaved suPAR not only in stimulating chemotaxis but
Chapter 4: RESULTS & DISCUSSION (II)
also in the activation of the same tyrosine kinase. This supports the view that the SRSRY motif 
present in peptide 1 is indeed the chemotactic epitope of uPAR.
Involvement of heterotrimeric G-proteins.
The activity of many chemokines is mediated through specific receptors and involves 
GTP-binding proteins (G-proteins) for the signal transduction. Pertussis toxin (PTX) inhibits the 
activity of some chemokines through the oq subset of G-proteins; the inhibitory effect of PTX is 
therefore an indicator of the involvement of heterotrimeric Gi/0 proteins in the involved 
signalling pathway (Baggiolini et al., 1995; Neer, 1995). To test the involvement of G proteins in 
uPAR-induced chemotaxis we tested the effect of PTX using as a control its active site mutant 
(Pizza et al., 1989). A pre-incubation with PTX-inhibited the chymotrypsin-cleaved suPAR and 
peptide-1 induced chemotaxis of THP-1 cells, while the inactive PTX mutant had no effect 
(figure 4.4). An identical result was obtained with peptide-1 induced chemotaxis of rat smooth 
muscle cells and on THP-1 chemotaxis induced by the amino terminal fragment of uPA (ATE, 
(Stoppelli et al., 1985)) (not shown). This result indicates that the uPAR epitope exerts its 
chemotactic activity through a G-protein-coupled cell surface protein.
Since both uPA and the chemotactic uPAR peptides activate the p56/p59Ac* kinase we 
also tested whether the action of the PTX toxin could inhibit the p56/p59Ac* activation. 
Activation of p56/p59^c^ by peptide-1 was inhibited by wild-type PTX, but not mutant PTX (not 
shown), supporting the G-protein dependence of uPAR chemotaxis and suggestive that the 
activation of tyrosine kinases occurs downstream of the heterotrimeric Gj/o protein.
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Discussion
GPI-anchored proteins are potent signalling molecules. However, the lack of a trans- 
membrane domain requires that they interact with another trans-membrane “adaptor”, i.e. with 
the real signalling molecule. This has been shown to be true for several GPI-proteins, including, 
among others, CD 14 (Ulevitch and Tobias, 1994). In the case of uPAR, the adapter (Resnati et 
al., 1996) is not yet known; however by identifying the chemotactic epitope of uPAR, we in fact 
suggest the nature of the actual ligand for such an adapter. We have shown that peptide-1 can 
reproduce, with the same time-course, the chemotactic effect of uPA and chymotrypsin-cleaved 
suPAR, causing cell migration and rapid and transient activation of p56/p59Af* in THP1 and 
other cells, through a PTX-sensitive signalling system. The concentration of peptide-1 required to 
elicit the signalling effects (about 0.1 pM) is far lower than the concentration of uPA or ATE 
required to generate the same biological response (0.5 to 5 nM, (Resnati et al., 1996)), but it is in 
the same order of magnitude of the effect obtained with chymotrypsin-cleaved suPAR. This 
represents a strong functional amplification, which follows or bypasses the uPA/uPAR 
interaction step. The shape of the dose-response curve for the various peptides closely resembles 
that for the chymotrypsin-cleaved suPAR (Resnati et al., 1996), and appears to be typical of the 
chemotactic response.
Our data show that the chemotactic effect of peptide-1 is not species-specific, as murine 
and rat cells also respond as well. This differs from the binding of uPA to uPAR which is species- 
specific (Appella et al., 1987; Estreicher et al., 1989).
The chemotactic epitope is located within the linker region connecting domains 1 and 2 
(figure 4.5). This is the only region that is in fact susceptible to proteases (Behrendt et al., 1991). 
The question arising from the identification of the chemotactic epitope is whether exposure of 
this epitope physiologically occurs through proteolytic cleavage. While we cannot exclude that a 
ligand-induced conformational change of uPAR is sufficient to transduce migratory signals, we 
must notice that a relevant proteolytic event does indeed occur in vivo: First, uPAR fragments 
missing domain D1 have been demonstrated in different cell lines and human cancer tissues 
(H0yer-Hansen et al., 1992; Solberg et al., 1994). Second, in purified suPAR, the linker region 
between domains 1 and 2 (figure 4.5) is susceptible to cleavage by uPA and other proteases, like 
chymotrypsin and neutrophil elastase (H0yer-Hansen et al., 1992; Ploug and Ellis, 1994). Third, 
at chemotactically active concentrations, endogenous or exogenous receptor-bound uPA cleaves 
50% of surface uPAR at residue 83 or 89 (H0yer-Hansen et al., 1997b). The former of these 
cleavage sites generates a chemotactically active uPAR fragment, starting with an N-terminal 
AVTYSRSRY sequence, identical to that of peptide-1. Fourth, the binding of uPA to uPAR
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activates cell surface plasminogen to plasmin which, too, might cleave uPAR in the same region 
(H0yer-Hansen et al., 1992; Ploug and Ellis, 1994).
While these data suggest that proteolysis activates the chemotactic activity of uPAR, in 
cultured cells the uPA protease domain is not necessarily required, since chemotaxis can be 
stimulated by uPA derivatives lacking protease activity (i.e. ATE or pro-uPA) (Fibbi et al., 1988; 
Resnati et al., 1996). It is known that ligand binding induces a conformational change (Ploug et 
al., 1994). Possibly, this may allow cleavage of uPAR by a different protease substituting for 
uPA. Since the sequence SRSRY is active both when amino- and carboxy-terminally positioned, 
. different types of proteases may be involved. Again, we cannot exclude that a conformational 
change be sufficient to expose the SRSRY epitope, and that the observed proteolytic event be 
unrelated.
It is also interesting to notice that uPA has two potential cleavage sites in the sequence of 
uPAR linking domain D l to domain D2. The second site, at position 89/90 might destroy the 
chemotactic activity, as it would cleave within the conserved region.
Whatever the mechanism, our data show that the uPA/uPAR system functions as a cell- 
surface regulated chemokine. The exposed chemotactic epitope must interact with a cell surface 
(adaptor) protein, which can signal through an heterotrimeric G protein. The nature of the adapter 
is still unknown: among already known proteins, possible candidates are chemokine receptors, 
integrins and caveolin. Chemokine receptors, as members of the seven trans-membrane-spanning 
protein family, interact with heterotrimeric G proteins (Baggiolini et al., 1995). Integrins and 
caveolin, on the other hand, have been shown to co-immunoprecipitate with uPAR (Bohuslav et 
al., 1995; Kindzelskii et al., 1996; Wei et al., 1996).
Our data show that uPAR-mediated chemotaxis requires a connection between 
intracellular tyrosine kinases of the Src family and heterotrimeric G proteins. In fact, peptide-1 
induces an early and transient activation of the p56-59Ac*, which is specifically prevented by 
PTX. It appears therefore that activation of p 5 6 -5 9 ^  occurs downstream from the heterotrimeric 
G protein. The tyrosine kinase activation appears to be essential for the chemotactic activity of 
uPAR since it can be inhibited by inhibitors of tyrosine kinases (Resnati et al., 1996) and since 
peptide-1 effect can be observed in murine wild-type, but not src'/_, fibroblasts (B. Degryse, F. 
Fazioli and F. Blasi, unpublished).
Mice lacking the uPA gene are strongly immunodeficient and succumb to bacterial 
infections (Gyetko et al., 1996). The mechanism outlined in this chapter is likely to contribute to 
the role of uPA in cell recruitment. The inability to induce a conformational change and/or to 
proteolytically cleave uPAR may explain the immunodeficiency of uP A '/' mice. If this 
hypothesis is correct, the uPAR'/_ mice will have to be immunodeficient as well. In man, uPAR is
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an activation antigen in T-lymphocytes and monocytes, and is required for T cell migration, at 
least in vitro (Bianchi et al., 1996; Chavakis et al., 1998; Nykjaer et al., 1994; Wei et al., 1999).
Finally, the results described in this chapter may have a practical application, as it is 
conceivable that agents acting on uPAR chemotaxis, for example blocking the function of the 
chemotactic epitope, may be employed to modify inflammatory reactions or cancer invasiveness. 
These agents would be acting downstream of the primary uPA/uPAR interaction step, and might 
have properties different from those of uPAR antagonists, expanding the application of agents 
inhibiting these functions.
Contributions
The experimental work presented in this chapter has been published (Fazioli et al., 1997). My 
contribution was the construction, expression and purification of recombinant receptors and 
receptor fragments. Massimo Resnati from our laboratory performed all the cell migration assays 
as well as the biochemical analysis of phosphorylation induced by peptides and recombinant 
receptors.
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Cellular uPAR cleavage and shedding
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Summary
In this chapter I present data on the expression, molecular structure, and shedding of 
uPAR and uPAR fragments in monocytic U937 cells, human leukocytes, human umbilical vein 
endothelial cells (HUVEC), and transfected 32D Cells. I have performed this analysis using a 
combination of ELISA and immunoprecipitation/western blotting techniques which provides 
accurate and sensitive quantification of the amount of uPAR antigen as well as indications on the 
molecular structure of the receptor and receptor fragments, even in dilute biological samples such 
as conditioned medium.
I find that: 1) Stimulation with phorbol esters up-regulates uPAR expression and 
promotes uPAR cleavage and shedding. 2) uPAR cleavage is associated with release of the D l 
fragment to the culture medium. 3) The pattern of soluble full-length uPAR and D2D3 fragment 
in conditioned medium corresponds to the cleavage state of uPAR on the cell surface.
While non-stimulated U937 cells predominantly express intact uPAR, monocytes, 
neutrophils and HUVEC also express high levels of cleaved receptor. Stimulation of neutrophils 
with the chemotactic peptide fMLP, and wounding of HUVEC monolayers, increases the 
shedding of uPAR antigen.
Introduction
Cellular uPAR can be released from the plasma membrane generating a soluble form of 
uPAR (suPAR). It has not been determined whether this receptor 'shedding' occurs following 
proteolytic cleavage close to the carboxy-terminus, or by the action of phospholipases that might 
cleave the GPI-anchor. The pro-uPA binding properties of suPAR are similar to that of the GPI- 
anchored protein (R0nne et al., 1994), but the release from the cell surface strongly alters other 
biological functions of the receptor. suPAR may partially maintain its capacity to promote 
pericellular proteolysis as it can concentrate uPA on the cell surface and in the extracellular 
matrix via its interaction with vitronectin (Chavakis et al., 1998). suPAR is not expected to 
promote cellular adhesion to vitronectin as the linkage to the cell surface is lost but may still be 
able to modulate adhesion by its interactions with integrin molecules (Wei et al., 1996; Wei.et al.,
1994).
Soluble uPAR (suPAR) has been identified in cell culture supernatants and in diverse 
biological fluids such as tumour ascites, cystic fluids, serum, plasma and recently also in urine 
(Chavakis et al., 1998; Holst-Hansen et al., 1999; Lau and Kim, 1994; Ninomiya et al., 1997; 
Pedersen et al., 1993; Ploug et al., 1992a; Ploug et al., 1991; R0nne et al., 1995; Sier et al., 1999; 
Sier et al., 1998; Stephens et al., 1999; Stephens et al., 1997; Wahlberg et al., 1998; Chapter 6).
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Plasma, serum and urine from healthy individuals contain detectable levels of suPAR 
suggesting that uPAR shedding indeed occurs in healthy individuals. Leukocytes, vascular 
endothelial and smooth muscle cells are good candidates for the source of circulating suPAR as 
they are intimately associated with the circulatory system and are known to express uPAR. 
Indeed, it has been shown that cultured human monocytes, endothelial and smooth muscle cells 
shed full-length uPAR (Chavakis et al., 1998). While healthy individuals have rather constant 
levels of suPAR in serum and urine, increased levels have been observed in patients with 
different types of cancer (Sier et al., 1999; Sier et al., 1998; Stephens et al., 1999; Stephens et al.,
1997) and in patients suffering from the rare paroxysmal nocturnal hemoglobinuria syndrome 
(PNH)(Ninomiya et al., 1997; R0nne et al., 1995). The PNH syndrome is at the molecular level 
characterised by a biochemical defect in biosynthesis of GPI-anchors, and the increased serum 
levels of suPAR in these patients has been explained by uPAR release from neutrophils (Ploug et 
al., 1992b; R0nne et al., 1995). Excess serum suPAR in cancer patients has been suggested to 
derive from the cancer cells and/or tumour-infiltrating cells as these cells express and release 
high levels of uPAR (Stephens et al., 1997). Recent experiments using xenografted mice carrying 
human tumours have indeed demonstrated that the tumour tissue indeed releases uPAR and 
uPAR fragments to the circulation and urine (Holst-Hansen et al., 1999; Chapter 6).
Cleavage in the linker region between domain 1 and 2 greatly reduces the capacity of 
uPAR to bind uPA and therefore blocks the receptors function in promoting plasminogen 
activation (Behrendt et al., 1991; Ploug et al., 1994). Cleavage of uPAR in this region also 
prevents the high affinity interaction with vitronectin (H0yer-Hansen et al., 1997a) and blocks 
uPAR mediated cell adhesion to vitronectin (Chapter 3). In this context, uPAR cleavage can be 
considered a loss of function. However, suPAR fragments generated in the laboratory, have 
strong chemokine-like activity in vitro (Fazioli et al., 1997), and in this respect the uPAR 
cleavage can be considered a gain of function event, generating molecules with biological 
activities not present in intact uPAR.
Cleaved forms of uPAR, lacking D l, are indeed present on the surface of several different 
cultured human cell lines and in detergent tumour extracts (Holst-Hansen et al., 1999; H0yer- 
Hansen et al., 1992; Ragno et al., 1998; Solberg et al., 1994; Chapter 6). The natural ligand for 
uPAR, uPA, is able to cleave its receptor and it has been demonstrated that uPA is responsible for 
the uPAR cleavage on U937 cells. The cleavage of cellular uPAR by uPA is an efficient process 
that occurs at physiological concentrations of uPA, while the reaction in solution requires high 
concentrations of uPA (H0yer-Hansen et al., 1997b; H0yer-Hansen et al., 1992). The cleavage of 
uPAR by uPA has been suggested to serve as a negative feedback mechanism occurring at sites 
of high uPA activity and high concentrations of uPAR such as at the leading edge of migrating 
cells and at areas of tumour invasion (H0yer-Hansen et al., 1997b).
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Cellular shedding of uPAR fragment has so far not been described, and selective shedding 
of full-length uPAR has in fact been suggested (Holst-Hansen et al., 1999). Soluble D2D3 
fragments have only been identified in fluid from benign and malignant cysts (Wahlberg et al.,
1998). The D l fragments of uPAR, which is supposedly released from the cell surface upon 
uPAR cleavage, has also failed to be identified in cell culture supernatants or in any biological 
fluid.
To understand the biological role of soluble and cleaved uPAR molecules it is of great 
importance to understand how, where and when they are generated. I have developed a sensitive 
immunoprecipitation/blotting technique with which I have performed a qualitative analysis of the 
presence of uPAR and uPAR fragments in dilute biological samples such as conditioned medium 
and urine. In this chapter I describe the expression, cleavage and shedding of uPAR from a 
number of different cell lines with special focus on leukocytes and endothelial cells.
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Results
U937 cells shed soluble uPAR antigen into the growth medium
To investigate cellular shedding of uPAR I analysed cell lysates and conditioned medium 
from human myeloid U937 cells cultured for variable periods of time in the presence or absence 
of the inducer PMA (figure 5.1). While the amount of cellular uPAR in untreated cells was 
relatively constant during the experiment, PMA induced a strong and persistent increase. The 
PMA induced increase in cellular uPAR antigen was strongest after 24 hours but remained high 
for at least 72 hours. Throughout the experiment suPAR antigen accumulated in the conditioned 
medium indicating a continuous shedding of uPAR from the cells to the medium. The amount of 
uPAR antigen released from non-treated cells during the first 24 hours of culture (0.4 ng / 106 
cells /  24 hours) corresponded approximately to a complete turnover of cellular uPAR in 24 
hours. The release rate was much higher in PMA stimulated cells (6.1 ng / 106 cells / 24 hours) 
corresponding to a turnover rate of cellular uPAR of approximately 3.5 hours.
Conditioned medium from U937 cells contain full-length suPAR, D2D3 and Dl 
fragments.
To determine the molecular structure of the uPAR antigen present in lysates and in 
conditioned medium I performed immunoprécipitation experiments using monoclonal antibodies 
to uPAR followed by western blotting with a polyclonal anti-uPAR antibody (figure 5.2). In non­
stimulated cells a prominent band with a molecular weight around 50-55 kDa representing full- 
length uPAR could be observed both in cell-lysates and in conditioned media. Stimulation with 
PMA resulted in a strong increase in the intensity of this band and the appearance of two shorter 
polypeptides. The intense band with a molecular weight around 35-40 kDa.suggests a cleaved 
receptor composed of domain 2 and 3 (D2D3), and could be observed in both cell lysates and in 
conditioned media. Long exposure of the blots revealed the presence of a fast migrating band in 
conditioned medium from PMA stimulated cell with molecular weight around 15 kDa 
representing the domain 1 fragment (Dl). Despite long exposures, the D l band was never 
observed in cell lysates in accordance with the model that D l is released from the cell surface 
upon receptor cleavage (not shown).
To unequivocally identify the different polypeptides present in lysates and conditioned 
media I immunoprecipitated conditioned medium from PMA-stimulated U937 cells with a panel 
of different monoclonal antibodies (figure 5.3). Antibodies recognising domain 3 (mAb R2 and 
R4) precipitated the two larger fragments in accordance with the identity of these bands being 
full-length suPAR and D2D3. An antibody against D l (mAb R3) precipitated full-length uPAR
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and the small -15 kDa fragment but not the D2D3 band, confirming the identity of these peptides 
to be full-length uPAR and the D l fragment. Full-length uPAR could furthermore be precipitated 
with a monoclonal antibody against uPA (mAb c6) demonstrating that the receptor in the 
conditioned medium, at least partially, is associated with uPA. A control antibody (mAb M2) did 
not precipitate any of these peptides. The highly heterogeneous glycosylation of uPAR causes a 
"smeary" appearance of uPAR and uPAR fragments in western blotting preventing a good 
separation of full-length uPAR and the D2D3 fragment. To eliminate this problem I performed 
western blotting on immunoprecipitates that had been reduced, denatured, and deglycosylated. 
Indeed, the migration pattern of uPAR, D2D3 and D l after deglycosylation was in complete 
accordance with the molecular weights based on the cDNA derived amino acid sequence of 
uPAR and a cleavage in the region between domain 1 and 2. Also, the separation of full-length 
uPAR and D2D3 was under these conditions excellent allowing an accurate identification of the 
different uPAR fragments.
Cleaved uPAR is efficiently shed from cells
The uPAR cleavage event generating the D2D3 fragment present in conditioned medium 
could occur while uPAR is still anchored to the cell membrane or derive from shed uPAR being 
cleaved in the medium. To determine whether the D2D3 fragment was generated on the cell 
surface or in the medium an experiment was set up using U937 cells PMA-stimulated for 72 hour 
to generate a high level of cleaved uPAR on the cell surface. The cells were acid washed to 
remove any uPAR bound uPA and plated in fresh medium prior to the experiment and after a 
one-hour incubation cells and medium were collected and analysed by immunoprécipitation. This 
experimental protocol should prevent further uPAR cleavage as uPA is removed from the cells 
and the medium. In fact, I observed a good correlation between the ratio of uPAR to D2D3 in the 
medium and on the cells suggesting that uPAR and D2D3 are shed at comparable speeds (not 
shown). Further evidence for shedding of cleaved uPAR comes from 32D cells transfected with a 
recombinant D2D3 uPAR receptor (Chapter 3) that indeed also shed the protein to the growth 
medium (figure 5.8).
Cleavage and shedding of uPAR in leukocytes.
To characterise the molecular forms of uPAR expressed on, and shed from, leukocytes I 
cultured freshly isolated monocytes and neutrophils for 48 hours in vitro and analysed cell lysates 
and conditioned medium for the presence of uPAR fragments by immunoprécipitation (figure 
N 5.4A). Cell lysates and conditioned medium from monocytes contained uPAR polypeptides, 
which could be readily identified as full-length uPAR and the D2D3 fragment. The level of these
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peptides was higher in cells that had been treated with PMA but the ratio of full-length uPAR to 
D2D3 fragment was not altered significantly. Long exposures of the blots also revealed the 
presence of the D l fragment in conditioned medium from PMA stimulated cells monocytes. The 
D l fragment was never observed in cell lysates. Cell lysates and conditioned medium from 
neutrophils contained a uPAR peptide with a migration intermediate between fiill-length uPAR 
and D2D3 fragment and therefore not readily identifiable. To obtain a better separation and 
identification of the uPAR peptides the analysis was repeated using deglycosylated material 
(figure 5.4B). Surprisingly, the pattern of uPAR peptides in lysates and conditioned medium from 
neutrophils was characterised by a prominent D2D3 fragment, and only a minor amount of full- 
length uPAR.
Neutrophils have been shown to up-regulate the cell surface expression of uPAR by the 
mobilisation of intracellular uPAR stores upon stimulation with fMLP. The reaction is fast (a few 
minutes) and occurs by the fusion between intracellular granules and the plasma membrane 
(Plesner et al., 1994). To determine if the process was accompanied by a release of soluble 
uPAR, I performed ELISA on the medium from neutrophils that had been stimulated with fMLP 
for 30 minutes (figure 5.5). Indeed, I observed that the medium from neutrophils stimulated with 
fMLP contained twice as much suPAR antigen as from non-stimulated cells.
Cleavage and shedding of uPAR in HUVEC cells.
HUVEC cells have been shown to express and shed full-length suPAR but no information 
are available regarding the presence and shedding of uPAR fragments. To address this point I 
cultured confluent monolayers of HUVEC cells for 72 hours in the presence and absence of 
PMA. Conditioned medium was collected after 24, 48 and 72 hours and cell lysates prepared at 
the end of the experiment. All the samples were immunoprecipitated and analysed by western 
blotting (figure 5.6).
Cell lysates from both treated and untreated cells contained uPAR peptides corresponding 
to intact uPAR and the D2D3 fragment. Soluble full-length uPAR could be observed after 24 
hours in the medium from PMA stimulated cells and after 72 hours in untreated cells. The uPAR 
peptides in the medium accumulated during culture and the appearance of the D2D3 fragment 
appeared later as it could first be detected after 48 hours in treated cells. The ratio of uPAR to 
D2D3 in conditioned medium and cell lysates was comparable after 72 hours of culture. As I did 
not prepare cell lysates at the 24 and 48 time points, it is possible that the cellular D2D3 fragment 
accumulated during culture as did the soluble form in the medium. As observed both in U937 
cells and monocytes, the D l fragment could be identified in the conditioned medium from PMA 
stimulated cells after 72 hours.
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PMA stimulation is not very physiological and to determine if the shedding of uPAR 
could be up-regulated under more relevant conditions I analysed the conditioned medium from 
HUVEC monolayers that had been 'wounded' using a rubber policeman (figure 5.7). The 
conditioned medium from wounded monolayers contained slightly more uPAR antigen than 
control plates, suggesting that wounding results in up-regulation of expression and/or shedding of 
uPAR. These data should however be taken with care as the experiment was performed only 
once, as the difference is small, and as several factors such as cell proliferation, cell death etc. 
may contribute to the increased uPAR release.
Urokinase independent cleavage of uPAR
Cleavage of uPAR on U937 cells is likely to occur through the direct cleavage of uPAR 
by its ligand uPA (H0yer-Hansen et al., 1997b), but whether other biologically relevant proteases 
can do the same in other cell lines is still not known. To address this point I analysed the cleavage 
of uPAR.in a cell system in which uPA-mediated uPAR cleavage is unlikely. I used the murine 
32D cells transfected with human uPAR (Chapter 3) as these cells do not express uPA (not 
shown) and as the species barrier between uPA and uPAR binding would prevent the binding of 
any low levels of murine uPA possibly expressed by these cells (Appella et al., 1987; Estreicher 
et al., 1989).
Indeed, I observed the presence of an uPAR fragment compatible with D2D3 in both cell 
lysates and conditioned medium from the uPAR transfected cells suggesting the existence of an 
uPA independent mechanism of uPAR cleavage (figure 5.8).
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Discussion
Serum, plasma and urine from healthy individuals contain measurable levels of suPAR 
and suPAR fragments suggesting that a constant release and cleavage of uPAR occurs in the 
healthy organism; however the cellular source of suPAR has not been determined. In accordance 
with other reports (Chavakis et al., 1998) I find that leukocytes and vascular endothelial cells 
shed full-length suPAR, and I therefore propose that these cells may, at least partially, is the 
source of circulating suPAR.
Elevated levels of serum suPAR have been observed in individuals suffering from PNH 
and in serum and urine from cancer patients. In these patients a deficiency in GPI-anchoring 
(PNH) or uPAR release from tumour cells (cancer) may explain the increased levels of 
circulating suPAR. I find a good correlation between the amount of released suPAR antigen and 
the expression level of uPAR on the cell surface. Any physiological or pathological condition 
involving the up-regulation of uPAR expression may therefore contribute to the serum suPAR 
levels. Malignant conditions such as cancer, HIV infection, chronic progressive multiple 
sclerosis, but also inflammation are associated with up-regulation of uPAR expression in 
leukocytes (Dore-Duffy et al., 1992; Nykjaer et al., 1994; Speth et al., 1998) and vascular 
endothelial cells (Graham et al., 1998; Washington et al., 1994). I therefore suggest that these 
pathologies may also be associated with increased serum/urine levels of suPAR antigen.
The close connection between uPAR and uPA with respect to spatial expression and 
affinity makes uPA a good candidate for the enzyme responsible for uPAR cleavage and it has 
indeed been suggested that uPAR cleavage preferentially occurs at sites of high uPA activity 
(Hpyer-Hansen et al., 1997b). However, my data suggest that other enzymes may also be 
involved in uPAR cleavage. First, uPAR cleavage occurs in transfected cells where uPA is absent 
and very unlikely to be relevant. Second, a high fraction of cleaved uPAR is present on 
monocytes and neutrophils, which have been isolated from a tissue (blood), characterised by the 
presence of protease inhibitors in general. The cleavage of uPAR in neutrophils may involve 
proteases such as neutrophil elastase which is indeed capable of cleaving suPAR in vitro (Ploug 
et al., 1991).
Rather than being only a reflection of tissular uPAR expression, circulating suPAR and 
suPAR fragments may actually have important functions in health and disease. Soluble full- 
length suPAR, can associate with circulating pro-uPA and the generated complex may have a 
function in the lysis of plasma clots (Higazi et al., 1998). Fragments of suPAR (generated in the 
laboratory) are endowed with strong chemokine-like activities in vitro, but the function of these 
fragments in vivo remains speculative (Fazioli et al., 1997; Resnati et al., 1996). I find that 
leukocytes and vascular endothelial cells shed cleaved forms of uPAR. However, only full length
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suPAR can be detected in plasma/serum (Holst-Hansen et al., 1999; Chapter 6). The shedding of 
uPAR fragments from leukocytes and vascular endothelial cells taken together with the presence 
of these fragments in urine (Sier et al., 1999; Chapter 6), suggests that these fragments are cleared 
to the urine at a rate preventing detection in the circulation. However, the transient presence of 
these fragments in the circulation is very likely. The expression of the uPAR chemotactic peptide 
on the surface of vascular endothelial cells may have a function in biological processes such as 
leukocyte extravasation and/or recruitment to points of endothelial damage. The release of 
chemotactically active suPAR fragments from activated neutrophils may be involved in the 
recruitment of monocytes and lymphocytes to sites of inflammation.
Contributions;
Simone Orlando from our laboratory performed the separation and purification of 
leukocytes. Cornells P.M. Sier (Called "Kees") did the ELISA determinations. All other 
experimental work was performed by me.
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Soluble and cleaved uPAR in urine
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Summary
A soluble form of the receptor (suPAR) is present in blood of healthy people and suPAR 
levels are increased in plasma/serum of cancer patients. Fragments Of uPAR, cleaved between 
domain 1 and domain 2, are found on the surface of carcinoma cell lines and experimental 
tumours. Cleaved forms of suPAR, generated in the laboratory, are potent inducers of chemotaxis 
of cultured cells, but their occurrence and possible function in vivo is presently unknown.
In this chapter I demonstrate the presence of full-size as well as cleaved forms of 
suPAR in urine of healthy volunteers and ovarian cancer patients: 1) The level of urinary suPAR 
antigen is significantly higher in cancer patient. 2) Immunoprécipitation / immunoblotting 
experiments show that in human serum suPAR was mostly full-length, whereas in urine a 
fragment corresponding to domain 2+3 (D2D3) was the most abundant form. 3) Urine also 
contained a fragment corresponding to domain 1 of suPAR (Dl), a fragment that has never been 
observed in vivo or in vitro before. 4) Urine from mice xenografted with human ovarian tumor 
cells also contained high levels of human suPAR antigen, and high levels of D l were found in 
mice carrying a human xenografted tumor displaying cleaved uPAR on the cell surface, but not in 
the urine from mice carrying a human xenografted tumor displaying only fiill-length uPAR.
Although all 3 forms of suPAR were also found in urine from healthy individuals, the 
distribution pattern of suPAR fragments was clearly different in ovarian cancer patients, with 
varying D1/D2D3 ratios in different patients. Control experiments demonstrated that the pattern 
of urinary suPAR fragments did not change after extensive incubation at 37°C. Moreover, 
incubation of iodinated recombinant suPAR in urine did not lead to significant fragmentation, 
indicating that cleavage of suPAR does not primarily take place in the urine. The data suggest 
that the enhanced presence of suPAR fragments in urine might reflect a cancer specific process, 
and that their assay might be exploited in clinical investigations of certain types of cancer.
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Introduction
The interaction between urokinase-type plasminogen activator (uPA) and its receptor 
(uPAR), plays a key role in physiological and pathological processes like cell migration, tissue 
remodeling and cancer invasion and metastasis (Andreasen et al., 1997; Blasi, 1997). Both uPA 
. and uPAR are made up of discrete domains endowed with specific functions. uPA has a protease 
domain, and an aminoterminal fragment that specifically binds the receptor. In addition to 
activating plasminogen, uPA is able to induce uPAR-dependent adhesion, proliferation and 
chemotaxis (Rabbani et al., 1992; Resnati et al., 1996; Waltz and Chapman, 1994).
uPAR is composed of three homologous domains (figure 6.2A) and is linked to 
the cell surface at the carboxy terminus by a glycosyl-phosphatidylinositol (GPI) anchor (Ploug et 
al., 1991). The aminoterminal domain of uPAR (D l) contains the main uPA-binding site 
(Behrendt et al., 1991), whereas the next two domains of uPAR (D2D3) bind the extracellular 
matrix protein vitronectin (Wei et al., 1994). However, full-size uPAR is required for the high 
affinity of both interactions (H0yer-Hansen et al., 1997a; Ploug et al., 1998b). Like uPA, uPAR is 
accessible to proteolytic cleavage, especially in the D l to D2D3 linker region which is cleaved by 
trypsin, plasmin, chymotrypsin and uPA itself (H0yer-Hansen et al., 1992; Ploug et al., 1994). 
Chymotrypsin-cleaved or recombinant soluble uPAR (suPAR) fragments have strong and 
specific anti-adhesive and chemotactic activities on cells that do not posses endogenous uPAR 
(Fazioli et al., 1997; Resnati et al., 1996; Wei et al., 1996).
The importance of proteolytic fragmentation of uPA and uPAR in vivo has not yet 
been addressed. ATF, the amino terminal fragment of uPA, is found in conditioned media of 
cancer cells (Rabbani et al., 1992). A variant of uPAR lacking D l has been identified on several 
tumour cell lines, in experimental tumours and similar fragments are found in the fluid from 
human ovarian cysts (Hpyer-Hansen et al., 1992; Ragno et al., 1998; Solberg et al., 1994; 
Wahlberg et al., 1998). However, released soluble D l has never been identified in any cell 
culture medium or biological fluid.
In the present paper, we show that the urinary levels of suPAR are enhanced in ovarian 
cancer patients, in accordance to what has been previously shown for serum (Sier et al., 1998). 
Moreover, urine from healthy women and ovarian cancer patients contains, in addition to full-size 
suPAR, also two suPAR fragments, representing D2D3 and DL The distribution pattern of 
suPAR fragments in urine from ovarian cancer patients is clearly different from that of healthy 
controls. Control experiments show that suPAR fragmentation does not depend on urine storage 
conditions, in fact it does not occur in the urine. Experiments in xenografted mice show a 
correlation between the presence of cleaved uPAR on tumour membranes and the appearance of
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D l in urine, indicating that fragmentation most likely occurs on the cell surface in the tumour 
tissue.
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Results
Urinary suPAR is increased in ovarian cancer patients
The suPAR/creatinine ratios in urine from 25 ovarian carcinoma patients and 20 
healthy controls are presented in figure 6.1. The ratio of suPAR and creatinine was used because 
it eliminate differences due to dilution and sampling time (Sier et al., 1999). The median level of 
urinary suPAR/creatinine was significantly enhanced in carcinoma patients compared with age- 
matched healthy women (P=0.004; Mann-Whitney U-test). A cut-off value of 5.5 (the median 
value determined in the 20 healthy women plus twice the standard deviation) distinguished 11 
cancer patients with low and 14 patients with high urinary suPAR values, resulting in a 
sensitivity of 56% and a specificity of 95%. In particular, high FIGO stage carcinomas (Hie, 
closed circles in figure 6.1) showed elevated values, but also some samples of patients with stage 
1/11 carcinomas were enhanced.
Urine contains full-length suPAR as well as suPAR fragments D2D3 and Dl
To determine the nature of suPAR antigen in urine I performed 
immunoprécipitation analysis on concentrated urine obtained from an ovarian carcinoma patient. 
I immunoprecipitated the sample with monoclonal antibodies recognising epitopes on domain 1 
(mAb R3) or domain 3 (mAb R2), and analysed the precipitated material by western blotting 
using a polyclonal anti-uP AR antibody (figure 6.2B). Three different polypeptides were 
identified; a ~55 kDa band immunoprecipitated by both mAb R2 and mAb R3, representing the 
full size receptor; a ~35 kDa band immunoprecipitated only by mAb R2 and hence corresponding 
to suPAR fragment D2D3; and finally, a ^17 kDa band identified only by mAb R3 and therefore 
compatible with fragment D l. Another set of monoclonal antibodies having similar recognition 
specificity (mAb R4 and mAb R5, respectively) displayed an identical pattern, confirming the 
identity of these fragments (data not shown). Serum from ovarian cancer patients and healthy 
controls contained only full-length suPAR, as no material with a molecular weight below ~50 
kDa could be identified (figure 6.3C and not shown).
The mAb R3 precipitated less full-length suPAR than mAb R2. This might be due to the 
different efficiency of the two antibodies; however, it might also indicate that urinary suPAR is 
partially associated with other molecule(s) able to inhibit the binding of mAb R3 (but not mAb 
R2) to the receptor. Indeed, mAb R3 has been shown to compete with the natural ligand of 
uPAR, pro-uPA (List et al., 1999; Rpnne et al., 1991).
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suPAR fragmentation is different in ovarian cancer patients
Figure 6.3 shows an immunoprecipitation/immunoblotting experiment carried out on 
urine from 7 healthy women (figure 6.3A) and 7 ovarian carcinoma patients (figure 6.3B). The 
pattern of distribution of suPAR fragments in control urine's was very consistent. The major 
urinary form of suPAR appeared to be the D2D3 fragment that was twice or more as abundant as 
full-size suPAR. In these non-concentrated urine's the D l fragment could be clearly detected in 
three samples (Cl, C4 and Cl). The suPAR fragment pattern in ovarian cancer patients, however, 
was clearly different (figure 6.3B). Some patients showed distribution patterns similar to normal 
urines (PI, P3, P5, and P6), whereas others had relatively high amounts of D l (P2, P4, and P7). 
Urine from patient P7 contained high amounts of all forms, but D l was most abundant (5 times 
more than D2D3, estimated from a short time exposure of the blot, data not shown). In contrast to 
urine, no fragments of suPAR were identified in serum from the same ovarian carcinoma patients 
(figure 6.3C). Even immunoprécipitation of five times more serum did not reveal any cleaved 
suPAR fragments (not shown).
suPAR and suPAR fragments are stable in urine.
The difference between the pattern of uPAR fragments in urine (full length, D2D3 
and D l) and in serum (only full length) prompted me to investigate whether the urinary suPAR 
fragments were actually generated in the urine by proteolytic degradation of full-length suPAR. 
First, I analysed whether the pattern of suPAR fragments in freshly sampled urine was stable 
when stored for 24 hours at different temperatures (-20°C, 4°C, 20°C and 37°C) or when 
subjected to repeated freeze/thaw cycles in the presence and absence of protease inhibitors. The 
pattern of suPAR fragments on immunoblots was found to be largely unaffected by the storage 
temperature and by the presence or absence of protease inhibitors (not shown). These findings 
indicate that the suPAR fragmentation pattern was stable in urine independently of storage
125conditions. To further examine suPAR stability in urine, we added full-length I-labelled 
recombinant suPAR at physiological concentration (2 ng/ml) to urine from seven different 
ovarian cancer patients. The samples were incubated for 24 hours at 37°C and then analysed by 
SDS-PAGE. Some degradation of full-size suPAR to the D2D3 and D l fragments was observed 
in the urine from one patient (approximately 20%), but not in any of the other samples (not 
shown). The absence of significant cleavage in those samples was not a consequence of a
125resistance of the used I-labelled suPAR to cleavage, because chymotrypsin and uPA could 
efficiently cleave this particular suPAR when incubated in buffered saline under the same 
conditions. Both proteases had no or very little effect when incubated in urine (data not shown). 
These experiments suggest that suPAR fragmentation most likely does not occur in urine.
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Urinary suPAR antigen is partially derived from distant tumour tissue
The increased urinary suPAR levels in cancer patients might derive from 
malignant cells or tumour infiltrating stromal cells. It is difficult to demonstrate this possibility in 
humans since it is impossible to discriminate tumour-derived suPAR from non-tumour derived 
suPAR. We therefore looked for the presence of human suPAR antigen in urine from nude mice 
xenografted with human carcinomas. The ELISA used for human urine could not be used in this 
analysis because of the interference with murine antibodies present in mouse urine. We therefore 
used a recently developed ELISA (Holst-Hansen et al., 1999) which is highly specific for human 
uPAR and suitable for analysis of murine samples (see materials and methods). We analysed 
urine samples obtained from mice xenografted with the ovarian carcinoma HOC8 (Giavazzi et 
al., 1998) and the metastatic breast carcinoma MDA435 (Cailleau et al., 1974). Indeed, we found 
that pooled urine from HOC8 or MDA435 xenografted mice contained soluble human uPAR 
(shuPAR) antigen (figure 6.4), whereas no shuPAR was detected in urine from non-xenografted 
mice. The rather low level of shuPAR antigen in the pooled urine from HOC8 xenografted mice 
(0.23 ng/ml) was confirmed in a second experiment (not shown) with urine samples from 
individual xenografted mice (n=5) and control mice (n=6) and the difference was highly 
significant (P=0.009, Mann-Whitney U-test). This result strongly suggests that the enhanced 
urinary suPAR levels from cancer patients at least partially could derive from tumour cells.
Urinary SUPAR fragments might reflect the cleavage-state of uPAR on tumour 
tissue in xenografted mice.
Urinary fragmented suPAR may reflect the presence of cleaved uPAR on tumour cells. To 
examine this possibility we compared uPAR in tumour lysates, blood samples, and urine from the 
HOC8 and MDA435 xenografts by immunoabsorption/immunoblotting (figure 6.5).
While the HOC8 tumour lysate only contained full-length uPAR, the MDA435 tumour 
lysate also contained cleaved receptor (D2D3). Both tumours release the full-length receptor 
since it was detected in the circulation. In both tumours circulating suPAR apparently undergoes 
proteolytic cleavage during translocation from blood to urine since a prominent D2D3 fragment, 
but no full-length suPAR, was identified in urine from the animals. However, in addition to the 
D2D3 fragment, a very abundant D l fragment was observed in urine from mice bearing the 
MDA435, but not the HOC8 tumour. From shorter exposures the intensity of the D l band present 
in urine from MDA435 xenografts was estimated to be approximately ten fold more intense than 
the D2D3 fragment (not shown). In HOC8 xenografts, the D2D3 fragment in urine was less 
abundant than in MDA435. No D l fragment was detected, even after very long exposures (not 
shown). The difference between the urinary Dl levels of both tumour models correlates with the
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presence of cleaved uPAR on the tumour cells and indicates that urinary D l could be a reflection 
of suPAR cleavage on tumour cells.
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Discussion
Components of the plasminogen activation system are found in enhanced amounts in 
various types of tumours (Andreasen et al., 1997). High tissue and serum levels of uPA, uPAR, 
and inhibitor PAI-1 are associated with bad prognosis in human cancers (Casslèn et al., 1994; 
Chambers et al., 1998; Kuhn et al., 1994; Mustjoki et al., 1999; Nielsen et al., 1998; Pedersen et 
al., 1994; Schmitt et al., 1997; Sier et al., 1998; Verspaget et al., 1995). Since we previously 
showed that urinary and serum suPAR levels are strongly correlated (Sier et al., 1999), we 
hypothesised that enhanced urinary suPAR levels might also be associated with malignancy. The 
present study shows that approximately 50-60 % of the patients with ovarian carcinoma display 
an increased urinary concentrations of suPAR, comparable to what was found previously in 
serum and tissue from ovarian carcinoma patients (Casslèn et al., 1991; Schmalfeldt et al., 1995; 
Sier et al., 1998; Young et al., 1994).
The source of suPAR in serum or urine from healthy individuals has not been 
identified yet. Enhanced levels of circulating suPAR might reflect an increase in tissue uPAR, as 
for instance found in many tumour types. Indeed, plasma levels of human suPAR correlate with 
tumour burden in nude mice carrying ovarian and breast cancer xenografts (our unpublished data 
and (Holst-Hansen et al., 1999)).
We never observed any fragmented suPAR in serum/plasma of healthy volunteers, nor in 
patients with various types of cancer, nor in serum from mice xenografted with human tumours. 
In the last case, urinary suPAR must derive from tumour cells as these represents the only human 
component in the xenografts. Assuming that in cancer patients the enhanced serum suPAR 
derives from the surface of tumour and/or stromal cells, the absence of fragments implies that 
either suPAR is not fragmented in the tissue (which is at least not the case in some mouse 
xenografts) or that the fragments does not enter the circulation. More likely, however, since 
uPAR uPAR fragments are indeed released from the tissue, their half-life in the circulation 
maybe too short to generate a detectable steady-state level.
After entering the bloodstream, suPAR may bind circulating molecules that could 
potentially modify its clearance. Two likely serum ligands for suPAR are pro-uPA and 
vitronectin. Association of suPAR with these molecules would bring the molecular weight of the 
complex well above the limit for simple diffusion into the urinary compartment. The uPAR 
fragments are unable to associate with physiological concentrations of uPA and vitronectin 
(Hpyer-Hansen et al., 1997a; Ploug et al., 1994) or with any other presently known serum 
protein, and their half-life is therefore not expected to be modulated by these interactions.
In addition to tissue cleavage, one cannot forget that both uPA and uPAR are present in 
the human kidney. In particular uPA is found ubiquitously and abundantly in all segments of the
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tubular epithelium, where it is thought to be essential for the prevention of fibrin clot formation in 
kidney and urine (Wagner et al., 1996). Therefore, uPA, or other proteases present in the kidney 
like kallikrein or meprin A (Chen et al., 1995; Walker et al., 1998), might be responsible for the 
cleavage of full-size suPAR and hence for the presence of suPAR fragments in the urine. Our 
immunoblot data in urine from healthy volunteers clearly show that in fact most of the suPAR is 
present as D2D3 fragment. The striking difference with cancer patient's urine is, that while in 
healthy volunteers the ratio between full-size suPAR and D2D3 is rather stable, this is not the 
case in urine from cancer patients. Therefore, changes in the urinary suPAR fragment pattern 
might reflect the cleavage of uPAR in distant parts of the organism. Mice xenografted with 
human tumours release full-size receptor in the blood, and present suPAR fragments in the urine. 
The urinary level of the D l fragment correlates with the extent of surface uPAR cleavage in the 
xenografted tumour tissue. This result argues for a similar phenomenon in human cancer patients.
Compared to the very regular pattern of suPAR fragments in urine from healthy 
volunteers, some patients showed relatively high urinary D l levels. It will therefore be relevant 
to evaluate the clinical usefulness of this observation. So far, the only easily obtainable human 
body fluid in which suPAR fragment analysis is possible is urine.
Recently, a number of cleaved extracellular matrix and cell surface proteins have been 
discovered, and the presence of some of these fragments has been associated with cancer 
(O'Reilly et al., 1994; Taraboletti et al., 1997). Some of these fragmented proteins have biological 
or pharmacological activity, like angiostatin. Also cleaved forms of suPAR have biological 
activity, at least in vitro. First, suPAR cleavage results in fragments possessing a very strong 
chemotactic activity, provided they contain at the carboxy-terminus (D l) or at the amino- 
terminus (D2D3) the specific chemotactic epitope of uPAR that lies in the linker region between 
D l and D2D3 (Fazioli et al., 1997). Second, D2D3 can affect the interaction of uPAR with 
integrins, thus modifying cell adhesion (Wei et al., 1996). Third, in addition to gaining 
chemotactic functions, suPAR fragments lose the properties of the full-size molecule, i.e. the 
binding to uPA and vitronectin.
In conclusion, the enhanced presence of cleaved fragments of suPAR in urine of cancer 
patients might provide clinically relevant information about the actual tumour and should 
therefore be studied in larger groups of patients with various types of cancer. The presence of 
suPAR fragments in human urine suggests that suPAR release and fragmentation may be 
biologically relevant processes. In particular, the adherence/chemotactic activities (Fazioli et al., 
1997; Wei et al., 1996) of these fragments may influence cell migration and hence the increase in 
fragments may be related to the degree of aggressiveness and invasiveness of a tumour. This 
hypothesis still needs to be proven.
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Chapter 7: 
FINAL DISCUSSION
Chapter 7: Final discussion
Final discussion
In this thesis I have sought to define the occurrence and biological significance of uPAR 
cleavage and shedding. The data clearly indicate that uPAR and uPAR fragments are present 
notably in vitro, but also in vivo under physiological and pathological conditions. The generation 
of soluble uPAR and soluble uPAR fragments under natural conditions gives rise to several 
questions: First, what are the underlying mechanisms? Second, what is the molecular structure. 
Third, what is the biological activity of these molecules, not only with respect to uPAR binding 
functions, but especially as integrin-modulators and as chemotactic factors. Finally, how about 
the measurement of uPAR or its fragments in the clinic for diagnostic or prognostic purposes.
In this last chapter I discuss the possible biological relevance of the data presented in this 
thesis. I will furthermore give my suggestions for possible experiments that may answer the 
questions raised by the obtained results.
Mechanism of uPAR shedding
The shedding of uPAR from the cell surface occurs in many different normal and 
transformed cell lines (Chavakis et al., 1998; Lau and Kim, 1994; Ploug et al., 1991; Chapter 5). 
No cells have so far been described which express uPAR but do not shed it to the medium. It thus 
appears that the process of uPAR shedding is an ubiquitous process, which occurs in all cells.
It is possible that uPAR shedding simply reflects uPAR which "escapes" GPI-anchoring. 
This may in particular occur under conditions of high uPAR expression where the GPI-anchoring 
machinery of the cell could be saturated. Two lines off evidence suggest that the absence of GPI- 
anchoring is not the major reason for suPAR production. First, the drug Brefeldin A which blocks 
the intracellular translocation of secretory proteins between the endoplasmic reticulum and the 
golgi apparatus (Misumi et al., 1986) does not affect the cellular release of suPAR (Wilhelm et 
al., 1999). Second, the D2D3 fragment, which is generated on the surface of U937 cells, is also 
shed (Chapter 5).
Bacterial phospholipase C (PIPL-C) is capable of releasing uPAR from the cell surface, 
but a similar enzymatic activity has not been described in humans. Purified preparations of the 
related mammalian enzymes phospholipase D and phospholipase A2 (PfPL-D and PLA-2) fail to 
catalyse the process (Ploug et al., 1991). Serum contains high levels of PIPL-D but the enzyme 
requires the presence of detergent in order to hydrolyse GPI-anchors (Low and Huang, 1991). 
Recently it has been suggested that a cellular form of PIPL-D may be the enzyme which catalyses 
the release of uPAR (Wilhelm et al., 1999). Cellular PIPL-D co-localises with caveolin 
suggesting that uPAR shedding could preferentially occur when both uPAR and PIPL-D are 
associated with caveolin. This would in fact connect the phenomenon of uPAR shedding to the
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process of cell adhesion and migration. The fact that 1,10-phenanthroline inhibits uPAR shedding 
(Wilhelm et al., 1999) also suggests that MMPs may be involved in the process. Although highly 
speculative, one could imagine a scenario in which MMPs activate serum or cellular PIPL-D 
which then hydrolyses the GPI-anchor of uPAR.
Mechanism of uPAR cleavage
Cleavage of uPAR occurs in many different cell types and tumour tissues (Holst-Hansen 
et al., 1999; H0yer-Hansen et al., 1992; Ragno et al., 1998; Solberg et al., 1994; Chapter 6).
uPA is able to cleave suPAR in solution but the reaction is slow and requires high 
concentrations of uPA (Hdyer-Hansen et al., 1992). The reaction does not depend on binding of 
uPA to suPAR, as the cleavage is equally well performed by low molecular weight uPA which 
lack the uPAR binding domain. uPA catalysed uPAR cleavage is more than 10 fold accelerated 
on the surface of cells (H0yer-Hansen et al., 1997b). The cell-surface acceleration requires the 
binding of uPA to uPAR as the interaction antagonist ATF inhibits the reaction almost 
completely. These data clearly demonstrate that uPA is able to cleave uPAR, but that it does not 
preferentially cleave the receptor to which it may be bound. Taken together a model emerges in 
which the cell surface acceleration of uPAR cleavage is caused by the concentration of uPA on 
the cell surface, and that uPAR bound uPA cleaves flanking uPAR molecules (H0yer-Hansen et 
al., 1997b). One experiment aimed at validating this mechanism could be the "labelling" of cell 
surface uPAR by incubation with sub-saturating concentrations of 125I-labelled ATF, followed by 
immobilisation using a chemical cross-linker. A subsequent release of Dl/ATF complexes upon 
incubation with saturating concentration of uPA would provide evidence for lateral cleavage, as 
the binding of uPA and ATF to uPAR is mutually exclusive.
From several points of view, uPA is a likely candidate for the enzyme cleaving uPAR. 
However, it is not likely to be the only mechanism, because cleavage occurs in cell systems 
where uPA is unlikely to be involved. Cleavage of uPAR occurs in murine 32D cells transfected 
with human uPAR. The absence of uPA expression by these cells and the species barrier for 
binding between murine uPA and human uPAR almost completely excludes any role for uPA in 
the cleavage of uPAR in this cell system (Chapter 5). No information about proteases expressed 
by 32D cells is available and the first hint to the identity of the responsible enzyme may come 
from the determination of the uPAR cleavage site.
uPA is also not likely to be responsible for all of the uPAR cleavage observed on 
monocytes and neutrophils (Chapter 5). The blood is a neutralising environment for proteases as 
it contains high levels of general protease inhibitors such as o^-antiplasmin and a 2- 
maeroglobulin. Resting human monocytes have high levels (-50%) of cleaved uPAR on the
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surface in contrast to cultured U937 cells. Monocytes may express low levels of pro-uPA but as 
serum contains PAI-1, the effective concentration of active uPA on the surface of resting 
monocytes is expected to be very low. A similar situation is true for neutrophils. Approximately 
80% of uPAR on neutrophils is cleaved (Chapter 5) and of the remaining 20% only one tenth is 
occupied by uPA or pro-uPA (Plesner et al.» 1994). Neutrophils have intracellular granules that 
can be mobilised to the plasma membrane upon different kinds of stimuli. These granules contain 
different types of pro-inflammatory molecules and a number of proteases including pro-uPA/uPA 
and neutrophil elastase. These granules also contain uPAR (Plesner et al., 1994). uPAR is 
distributed equally between the easily mobilised granules (characterised by their mobilisation by 
fMLP), and in the specific and primary granules which require a stronger stimulation (in 
experimental conditions TNFct or PMA are used). In contrast to the distribution of uPAR, pro- 
uPA/uPA is mostly confined to the specific and primary granules (Plesner et al., 1994). It is thus 
possible that uPAR cleavage in neutrophils may take place before the receptor arrives at the cell 
surface. In fact, it is possible that uPAR is also "shed" prior to release of the granules as 
suggested by the rapid accumulation of suPAR antigen in the conditioned medium from fMLP 
stimulated neutrophils (Chapter 5).
Data not presented in this thesis show that PMA-induced uPAR cleavage in endothelial 
cells (HUVEC) is almost completely inhibited by the broad-range MMP inhibitor batimastat. The 
involvement of MMPs in uPAR cleavage is not easy to explain. All the MMPs tested fail to 
cleave suPAR efficiently in vitro. However, the absence of efficient cleavage in vitro does not 
exclude that the reaction might be favoured on the cell surface (as is true for several processes 
described in this thesis). As the linker region in uPAR does not contain any obvious MMP 
cleavage sites, it is likely that the mechanism is indirect and involves the activation of other 
proteases. Anti-catalytic uPA antibodies and the plasmin inhibitor trasylol should be tested to 
establish whether uPA and plasmin are the enzymes actually responsible for the cleavage. Further 
experiments aimed at identifying the responsible MMP(s) should be initiated by the use of more 
specific inhibitors.
The uPAR chemotactic epitope
The data presented in chapter 4 strongly suggest that the position of the cleavage site in 
the linker region determines whether the chemotactic SRSRY epitope (amino acid 88-92) will be 
located on the D l or D2D3 fragments, or whether it will be destroyed by the cleavage.
Two relevant proteases in uPAR cleavage appear to be uPA and plasmin. These two 
proteases are intimately connected to uPAR as their active forms are generated in a process which 
occurs in the molecular vicinity of uPAR. Trypsin, plasmin and uPA cleave uPAR at the same
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two positions in the linker region: Arg83/Ala84 and Arg89/Ser90. Cleavage at Arg83/Ala84 
results in the localisation of the chemotactic epitope to the generated D2D3 fragment while 
cleavage at Arg89/Ser90, localised in the centre of the chemotactic epitope, is expected to 
generate D l and D2D3 fragments, which are both devoid of chemotactic activity. Cleavage of 
uPAR catalysed by uPA on the surface of U937 cells occurs equally well at both sites, whereas 
there is a weak preference for the Arg83/Ala84 site when the cleavage occurs in solution (H0yer- 
Hansen et al., 1997b). Thus, cleavage of uPÀR by uPA has the potential to generate a 
chemotactically active D2D3 fragment, two fragments devoid of activity, but never an active Dl 
fragment. In fact, no protease cleavage sites have been identified carboxyterminal to the 
chemotactic epitope and the possible existence in vivo of D l fragments carrying the SRSRY 
motif is therefore speculative. However, a recombinant D l fragment carrying the SRSRY motif is 
chemotactically active, demonstrating that the epitope works also in this position (Fazioli et al., 
1997). The cleavage sites for chymotrypsin and human neutrophil elastase (NE) are both located 
aminoterminal to the chemotactic epitope and therefore generate D2D3 fragments expected to be 
chemotactically active. In fact, the aminoterminal border of the chemotactic epitope is defined 
based on the chemotactic activity of a D2D3 fragment generated by chymotrypsin cleavage 
(Fazioli et al., 1997).
So far, only chymotryptic uPAR fragments and various recombinant proteins and peptides 
have been tested for their chemotactic activity (Fazioli et al., 1997; Resnati et al., 1996). To 
confirm the data obtained using these physiologically not relevant molecules, experiments testing 
the chemotactic activity of uPAR fragments generated by uPA, plasmin, and neutrophil elastase 
cleavage of uPAR should be performed. This analysis is however complicated by the fact that 
uPA and plasmin posses two cleavage sites in the linker region. One solution to this problem is 
the production of recombinant suPAR in which one of the cleavage sites has been destroyed by 
site-directed mutagenesis. In particular the destruction of the Arg83/Ala84 cleavage site would be 
informative, as this would force uPA and plasmin cleavage to the Arg89/Ser90 site located in the 
chemotactic epitope. The chemotactic activity of uPA or plasmin generated fragments of this 
mutant suPAR, compared with that of normal suPAR cleaved with the same enzyme, should 
determine the respective contributions of the two cleavage sites to the chemotactic activity.
Further experiments are needed to establish more precisely the structural requirements for 
the uPAR chemotactic epitope. By analogy with the experiments presented in chapter 4 this may 
be performed using synthetic peptides or recombinant uPAR fragments in which the desired 
mutations have been engineered.
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The structure and biological activity of suPAR fragments found in vivo
The evaluation of uPAR fragments by immunoprécipitation and western blotting allow for 
the determination of the domain structure of suPAR fragments, but is not informative with 
respect to the exact cleavage point in the linker region. In chapter 5 and 6 I showed that uPAR 
fragments are indeed produced by endothelial cells, leukocytes and tumours, and that these 
fragments can be found in urine. Determination of the molecular structure and biological activity 
of these fragments is of high priority, as this may yield information with respect to enzymes 
responsible for the cleavage and the possible biological function of these fragments. The most 
interesting sources of these fragments for further characterisation are conditioned medium from 
freshly isolated leukocytes and urine.
The determination of the chemotactic activity is an attractive starting point as the 
fragments are expected to be active at sub-nanomolar concentrations (Fazioli et al., 1997; Resnati 
et al., 1996). Experimentally, the different uPAR fragments could be affinity purified using 
domain specific monoclonal antibodies such as R2 and R3, and the captured material could be 
analysed by chemotaxis experiments using responsive cells such as THP-1 or smooth muscle 
cells. Confirmation of the chemotactic activity of these fragments would strengthen the 
hypothesis that these fragments play a functional role in vivo.
Determination of the molecular structure of the uPAR fragments also requires purification 
of the fragments. The method of purification would be the same as for the determination of the 
biological activity, but requires larger amounts of starting material. To obtain enough urinary 
D2D3 fragment to perform aminoterminal sequencing, purification from 1-2 litres of urine is 
required. Human urine is easy to obtain in large quantities and the purification should therefore 
be rather straightforward. Purification of the D2D3 fragment from conditioned medium from 
monocytes and neutrophils is complicated by the limited number of cells available, but should 
also be possible with some patience. Urine from xenografted mice carrying the human MDA435 
tumour contains as much as 50-100 ng/ml of the human D l fragment and is therefore a perfect 
source of tumour-derived uPAR fragments. The cleavage point of uPAR cannot be determined by 
aminoterminal sequencing of the D l fragment, and the analysis should in this case be performed 
by mass spectroscopy. In fact, mass spectroscopic techniques are becoming so sensitive that both 
the amino- and carboxyterminal termini may be determine on sub-microgram quantities of 
purified uPAR fragments.
Neither aminoterminal sequencing, nor mass spectroscopy are suitable techniques for the 
qualitative analysis of uPAR fragmentation in large numbers of samples or in situations where 
the amount of sample is limited. The generation of monoclonal antibodies specific for cleaved 
uPAR will therefore be crucial for the analysis o f uPAR cleavage in this type o f samples. These
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antibodies should recognise epitopes within the linker region but fail to recognise the same 
epitopes in intact and ligand-associated uPAR.
Identification of the adapter molecule
The fact that suPAR fragments have chemotactic effects on several different cell types 
strongly suggests the existence of cell surface molecules capable of binding the fragments and 
transmitting a signal over the cell surface (Fazioli et al., 1997; Resnati et al., 1996). In spite of 
extensive experimental work in our laboratory this "adapter" molecule has not yet been 
identified.
The intracellular signalling induced by cleaved suPAR involve the function of G proteins 
as it is inhibited by Pertussis toxin (Degrysê et al., 1999; Fazioli et al., 1997). G-proteins are 
involved in signalling by chemokine receptors from the seven-transmembrane family. Chemokine 
receptors are therefore candidate molecules for the uPAR adapter.
uPAR can directly interact with and modulate the function of integrin receptors (Wei et 
al., 1996; Wei et al., 1999). uPAR can modulate the signalling by P1-integrins in HEK293 cells in 
a process which involve the membrane protein caveolin (Wei et al., 1999). Both uPAR and p,- 
integrins mediated signal transduction involves scr family kinases (Degryse et al., 1999; Resnati 
et al., 1996; Wei et al., 1999). Also integrin receptors and caveolin are therefore good candidates 
for the adapter molecule.
The chemotactic effect of cleaved suPAR is maximal at picomolar levels, suggesting that 
the cellular binding site has a high affinity for the uPAR chemotactic epitope. However, 
biochemical methods such as co-immunoprecipitation, cross-linking and in vitro binding assays, 
have so far failed to consistently identify any of the mentioned molecules as the adapter molecule 
able to bind the chemotactic uPAR epitope.
Identification of the uPAR adapter molecule may be obtained using biological assays in 
which the introduction of candidate adapter proteins (or an expression library!) in an appropriate 
cell system, generates the desired and measurable signal upon incubation with the chemotactic 
epitope. This approach has so far been hampered by the fact that the uPAR chemotactic epitope 
seems to induce signalling in most cells (Degryse et al., 1999; Fazioli et al., 1997).
The biological function of uPAR shedding and cleavage
The biological roles of suPAR and suPAR fragments have not been determined. Cleavage 
and shedding of uPAR irreversibly destroys the well-defined functions of uPAR in plasminogen 
activation and cell adhesion. In this respect, suPAR and suPAR fragments may be considered 
inert metabolites. However, the strong biological activity of suPAR fragments in vitro and the
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occurrence of these fragments in vivo strongly suggest a biological function. suPAR fragments 
are apparently devoid of affinity for uPA and vitronectin and their possible function in vivo is 
thus expected to be related to their chemotactic activity.
Neutrophils are the first cells to arrive at sites of microbial infection and tissue damage. 
By the release of pro-inflammatory molecules» present in intracellular granules, neutrophils are 
thought to promote the concomitant recruitment of monocytes and lymphocytes. Most of uPAR 
in neutrophils is cleaved and fMLP stimulation caused a rapid release of some of this suPAR 
material (Chapter 5). It is thus possible that the release of chemotactically active suPAR 
fragments contributes to the recruitment of inflammatory cells.
A similar situation may be true in cancer. Proteolysis is particularly active at the invasive 
front of tumours and this process may generate chemotactic suPAR fragments. The presence of 
these fragments at the invasive front may promote the directed migration of tumour cells towards 
zones of proteolysis. Release of chemotactic suPAR fragments from tumour cells may recruit and 
activate stromal cells to produce proteases sustaining the process of invasion. Also endothelial 
cells may be recruited promoting the process of tumour vascularisation.
Many different experiments aimed at addressing these possibilities could be performed. 
Subcutaneous implantation of beads, slowly releasing defined suPAR fragments, may provide 
information about the recruitment of inflammatory cells. Migration of cells into an artificial ECM 
containing suPAR fragments may provide information about the effects on tumour invasion, 
stromal cell recruitment and angiogenesis.
Integrin associations with cleaved uPAR
Physical and functional interactions between uPAR and integrin receptors have been 
extensively documented in the literature. uPAR is required for neutrophil migration (Gyetko et 
al., 1994) and is found dynamically associated with Mac-1 and CR4 depending on the activation 
state of the cells (Kindzelskii et al., 1997). Approximately 80% of uPAR in neutrophils is cleaved 
(Chapter 5). Taken together these data raise a number of questions. Does cleaved uPAR associate 
with integrins? If yes, is the association between integrins and cleaved uPAR an inhibitory or 
stimulatory interaction?
Non-catalytic uPAR ligands inhibit the adhesion of neutrophils to vascular endothelium 
(May et al., 1998) suggesting that the ligand-free conformation of uPAR, which is interestingly 
the non-chemotactic conformation, promotes adhesion. In the same system suPAR, but not 
soluble D2D3 which is the chemotactically active configuration of cleaved suPAR, restores the 
adhesion of PIPL-C treated neutrophils to the same endothelium.
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Antibodies specifically recognising cleaved uPAR would much facilitate the experimental 
approach to the analysis of interactions between integrins receptors and cleaved uPAR. Until 
these antibodies will be available the immunoprecipitation/westem blotting system described in 
chapter 5 may provide the desired information. Any co-immunoprecipitation of Mac-1 or CR-4 
with cleaved uPAR would suggest a functional role, inhibitory or activating, of cleaved uPAR in 
neutrophils. A preferential co-immunoprecipitation between cleaved uPAR and Mac-1 in 
migrating (fMLP stimulated) neutrophils would suggest an inhibitory function of cleaved uPAR.
uPAR, cell adhesion and cancer metastasis
High expression of uPAR in tumour tissue is associated with short survival in different 
types of cancer. Two critical points in tumour metastasis are cancer cell dissemination and 
extravasation. Dissemination is the process in which metastatic cancer cells dissociate from the 
primary tumour and enter the vasculature. Extravasation is the process in which circulating 
tumour cells leave the vasculature to form a metastasis.
High levels of intact uPAR may inhibit the capacity of cancer cells to disseminate by 
causing firm cell adhesion to vitronectin in the stromal tissue. However, uPAR mediated effects 
on cancer cell adhesion may also favour cell migration and thus dissemination. Again, this effect 
would be inverted by uPAR cleavage. Addressing these possibilities experimentally is not easy as 
it requires the controlled expression and cleavage of uPAR in suitable experimental tumour 
systems. However, indirect indications of the involvement of uPAR in the process of 
dissemination may come from the analysis of the prognostic value of uPAR cleavage in cancer 
patients.
uPAR expressed by circulating tumour cells may promote adhesion to the vascular 
endothelium and may therefore facilitate the process of extravasation. On the other hand, strong 
uPAR mediated cell adhesion to the vascular endothelium may prevent the spreading of the cells 
in the organism. The effect of uPAR expression on tumour cell extravasation could be addressed 
experimentally. Tumour cells may be selected, or engineered in vitro, to express high levels of 
uPAR and the extravasation of the cells may then be followed after intravenous injection in mice.
Metabolism of suPAR and suPAR fragments
Blood and urine from healthy persons contain measurable levels of suPAR antigen (Sier 
et al., 1999; Sier et al., 1998; Stephens et al., 1997; Chapter 6). While suPAR found in serum is 
all full-length (Holst-Hansen et al., 1999; Chapter 6), urine also contains the suPAR fragments 
Dl and D2D3 (Sier et al., 1999; Chapter 6). The concentrations of suPAR antigen in serum and
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in urine are highly correlated suggesting that urinary suPAR antigen derives from the circulation 
(Sier et al., 1999).
Cells associated with the vasculature produce suPAR and suPAR fragments, suggesting 
that these cells, at least partially, are the source of circulating and urinary suPAR (Chavakis et al., 
1998; Chapter 5). suPAR fragments present in urine may derive from the degradation of full- 
length suPAR in the kidney and urine, or from the cellular release of these fragments in distant 
parts of the organism, followed by clearance to the urine. Experiments with xenografted mice 
demonstrate that a D l fragment released by a distant tumour tissue ends up in the urine without 
causing detectable D l in the circulation (Chapter 6). In contrast, release of full-length suPAR 
from tumour tissue in xenografted mice causes the appearance of full-length suPAR in the 
circulation and D2D3 fragment in urine, demonstrating that suPAR may be degraded to the D2D3 
fragment upon entry into the urinary compartment. However, degradation of full-length suPAR in 
human urine is very limited, suggesting that urinary suPAR fragments predominantly derive from 
the cellular release of these fragments (Chapter 6).
The failure to detect the D l and D2D3 fragments in the circulation is most likely caused 
by a rapid clearance of these proteins, and experiments aimed at confirming the transient 
presence of these fragments in the circulation could be performed. Indirect evidence may be 
obtained by measuring the serum half-life, and urine accumulation, of human recombinant 
suPAR and suPAR fragments injected into mice. A large difference in the half-life between full- 
length suPAR and of the fragments would support the hypothesis. Another approach involves the 
use of specific monoclonal antibodies to prolong the half-life of suPAR fragments in the 
circulation. Antibodies have a rather long half-life in the circulation (in the order of days) and 
may therefore also slow down the clearance of their ligands. Injection of uPAR specific 
antibodies into tumour bearing mice followed by immunoprécipitation and western blot analysis 
on serum samples, obtained after a given time interval after injection, might therefore prove the 
presence of the fragments in the circulation.
Serum and urinary suPAR as prognostic markers
The expression level of uPAR in tumour tissue is a prognostic marker in several different 
tumour types, including squamous cell lung cancer, breast cancer and colon cancer (Ganesh et al., 
1996; Gr0ndahl-Hànsen et al., 1995; Pedersen et al., 1994). Patients suffering from ovarian, colon 
and breast cancer furthermore have elevated levels of suPAR antigen in serum and urine, and 
high concentrations may be associated with a bad prognosis (Sier et al., 1999; Sier et al., 1998; 
Stephens et al., 1999; Stephens et al., 1997; Chapter 6).
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The correlation between elevated levels of circulating suPAR and cancer strongly 
suggests that the tumour tissue is the source of the excess suPAR present in the circulation. 
Evidence supporting this notion comes from nude mice xenografted with human tumours where 
the presence of the tumour causes appearance of human suPAR antigen in the blood and urine 
(Holst-Hansen et al., 1999; Chapter 6). The level of human suPAR in plasma from xenografted 
mice is strongly correlated with the tumour size and is therefore (at least in mice) a measure of 
tumour mass (Holst-Hansen et al., 1999). The fact that a large tumour size is associated with poor 
survival may thus partially explain the prognostic value of serum suPAR. Cleavage of uPAR has 
been suggested to occur preferentially at sites of high uPA activity and in particular at sites of 
tumour invasion (H0yer-Hansen et al., 1997b; Solberg et al., 1994). uPAR cleavage may 
therefore be an indicator of tumour invasivehess. Tumour invasiveness is intrinsically connected 
to metastasis, which is the major cause of death in cancer patients, and specific markers for 
tumour invasiveness are thus expected to be highly prognostic.
Even though the potential prognostic value of uPAR cleavage in cancer has been 
recognised for more than five years, no data have been presented to confirm or reject tliis 
hypothesis. Two lines of data presented in this thesis suggest that an evaluation of uPAR 
cleavage is both possible and feasible.
The first step in the analysis of uPAR cleavage is the development of a reasonably simple 
assay with the potential to provide a quantitative evaluation of uPAR cleavage in spite of the 
highly heterogeneous glycosylation of uPAR. In Chapter 5 I have presented an assay by which 
this type of analysis is possible. The assay is based on the immunoprécipitation of total uPAR 
antigen from the biological sample followed by enzymatic deglycosylation and sensitive western 
blotting analysis. Application of this assay on collections of tumour extracts from several 
different cancer types could reveal the value of uPAR cleavage as a prognostic marker in cancer.
The pattern of suPAR fragments in urine from nude mice carrying xenografted human 
tumours reflects uPAR cleavage on the tumour cells (Chapter 6) and a similar situation is likely 
to be true in humans. The identification of tumour-derived uPAR fragments in human urine is 
currently impossible, as the tumour-derived suPAR fragments cannot be distinguished from the 
suPAR fragments already present in normal urine. The pattern of suPAR fragments in urine from 
healthy individuals is rather regular and the altered pattern of suPAR fragments observed in urine 
from cancer patients (Chapter 6) may thus be a consequence of the presence of tumour-derived 
suPAR fragments. If uPAR cleavage in tumour-tissue is a strong prognostic marker, and if we are 
able to "read" the tumour-component of the urinary suPAR fragments, the analysis of urinary 
suPAR fragments could provide a completely novel approach to the prognosis of cancer patients.
Essentially all diseases that involve inflammatory responses or tissue damage, are 
expected to be associated with local upregulation of uPAR expression. HTV infection upregulates
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uPAR expression in monocytes and lymphocytes (Nykjaer et al., 1994; Speth et.al., 1998) and 
chronic progressive multiple sclerosis is associated with upregulation of uPAR expression in 
monocytes and vascular endothelial cells (Dore-Duffy et al., 1992; Graham et al., 1998; 
Washington et al., 1994). Data not presented in this thesis indeed demonstrate that the level of 
serum and urinary suPAR is elevated in HIV infected individuals, and that high levels are 
associated with a bad prognosis.
Taken together the available data suggest that many malignant conditions may be 
associated with elevated levels of serum and urinary suPAR. This fact obviously reduces a 
possible diagnostic value of suPAR, but, does not necessarily affect the value of suPAR in 
prognosis. The real strength of suPAR measurements in disease is most likely in the monitoring 
of patients in therapy. Changes in suPAR levels during therapy may for example reflect the 
efficacy of chemotherapy in cancer patients, or the efficacy of anti retroviral therapy in HIV 
patients.
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Figure 1.1: Primary structure of uPAR
The primary aminoacid sequence of human uPAR is shown in single letter code. Disulphide bonding is 
indicated as thick lines connecting cysteine residues. The disulphide pattern of domain 2 and 3 has not 
actually been determined and is based on the known pattern in domain 1. Diamonds indicates potential 
glycosylation sites. Large arrows indicate the position of introns in the uPAR gene. Small arrows 
indicate protease cleavage sites in the linker region connecting domain 1 and 2. Chym., chymotrypsin; 
Hnel., human neutrophil elastase; Chym., chymotrypsin. Plasmin and uPA can also cleave uPAR at the 
same sites as trypsin (Hpyer-Hansen et al., 1992)
The figure is reproduced from (Ploug and Ellis, 1994).
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Figure 3.1: Adhesive properties of 32D and U937 cells.
Non-stimulated (A) or PMA stimulated (B) 32D cells (closed bars) and U937 cells (open bars) were 
allowed to adhere to wells coated with fibronectin, vitronectin or BSA under serum free conditions. 
After 1 hour, the wells were washed and bound cells fixed and stained. The amount (in arbitrary units) 
of bound cells were calculated by measuring the absorbance at 540 nm and subtracting the value 
obtained from wells that received no cells.
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Figure 3.2: EL-3 stimulation of cell binding to fibronectin.
Binding of IL-3 starved 32D cells to vitronectin and fibronectin in the absence (open bars) or presence 
(closed bars) of 100 U/ml recombinant mouse IL-3. Bound cells were quantified as before and the 
value obtained in wells coated with BSA subtracted. The data represent the mean +/- SD of triplicate 
determinations from a representative experiment.
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Figure 3.3: Binding of uPAR transfected 32D cells to vitronectin.
Pools of G418 resistant cells obtained after transfection with an uPAR expression vector (circles) or 
empty expression vector (squares) were allowed to adhere to wells coated with increasing 
uunuentrations o f vitronectin and the bound cells were quantified as before.
Appendix I: Figures
A
2.5
2 -o
in
JQ
o>
% 0.5 -
C14 617 c24 c21 C22.7 c8 c2 c22 d  c18 c6 c13 c19
32 D/- 32D/uPAR 32D/D2D3
B 250
200
|  “
o
£  loo 
5
o
Figure 3.4: Binding of 32D uPAR/D23 clones to vitronectin.
(A) Clones of 32D cells transfected with full-length uPAR (cl4, cl7 , c24, c21, c22.7, c8, c2, c22, and 
c l)  or with a D2D3 (c l8, c6, cl3, and cl9) were allowed to adhere to vitronectin under serum free 
conditions in the presence (filled bars) or absence (open bars) of 5 nM pro-uPA. (B) Surface expression 
of uPAR and D2D3 on cells was evaluated by flowcytometry using the R2 monoclonal antibody that 
recognises an epitope on domain 3 of human uPAR. The mean fluorescence (in arbitrary units) is 
indicated and the clones have been arranged from left to right in order of increasing expression level.
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Figure 3.5: Stimulation of binding by pro-uPA.
uPAR transfected 32D cells clone 21 (circles) and clone 24 (squares) were allowed to adhere to 
vitronectin in the presence of increasing concentrations of pro-uPA. Bound cells were measured as 
before.
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Figure 3.6: Antibodies against uPAR domain 1 inhibit binding.
32D/uPAR clone 1 cells expressing high levels of uPAR were allowed to adhere to vitronectin in the 
presence of monoclonal antibodies against either uPAR domain 3 (mAh R2 and R4), uPAR domain 1 
(mAh R3 and R5), or a negative control antibody (mAb M2). Cellular binding was determined as 
described before.
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Figure 3.7: Requirement for integrin activation.
32D/uPAR clone 1 cells were allowed to adhere to vitronectin or fibronectin in the presence (filled 
bars) or absence (open bars) of IL-3 (100 U/ml) at 37°C or at 4°C as indicated. The cells had been IL-3 
starved for 8 hours prior to the experiment.
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Figure 3.8: uPAR mediated vitronectin binding does not lead to cell spreading
uPAR transfected 32D cells (clone 1) were allowed to adhere to plastic dishes coated with BSA (panel 
A) or vitronectin (panel B) for one hour at 37°C after which the cells were photographed.
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Figure 3.9: Cell binding to anti-uPAR antibodies.
32D cells transfected with uPAR (open bars) or the mutant D2D3 receptor (closed bars) were allowed 
to adhere to wells coated with vitronectin or antibodies against uPAR (5 pg/ml). After washing of the 
plates bound cells were quantified as before.
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Figure 3.10: Binding of soluble uPAR to vitronectin.
ELISA plates were coated with vitronectin (5 pg/ml) and the remaining binding sites blocked with 
BSA. Wells were incubated 0.15, 1.5, 15 or 150 nM of FLAG tagged soluble uPAR (squares) or D2D3 
mutant (circles). The binding was performed in the presence (filled) of absence (open) of 50 nM pro- 
uPA. After washing, the amount of bound protein was quantified by sequential incubations with an 
anti-FLAG antibody, a horseradish peroxidase conjugated secondary antibody and a colorimetric 
peroxidase substrate. The absorbance at 412 nm was measured in an ELISA reader and taken as a 
measure of bound proteins. The data represent the medium value of duplicate determinations (+/- SD) 
from a representative experiment. The curves for the D2D3 protein cannot be seen very well as they are 
superimposed with the curve for soluble uPAR in the absence of pro-uPA.
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Figure 4.1: Scheme depicting the basic structure of suPAR and it's mutated 
derivatives.
uPAR has three domains, an amino terminal (Dl), an intermediate (D2) and a carboxyterminal domain 
(D3), which is connected to the GPI-anchor (Ploug et al., 1991; Ploug and Ellis, 1994). All the uPAR 
constructs express soluble molecules since they employed the basic cDNA modification described 
before (Masucci et al., 1991; Roldan et al., 1990). The symbol for the full size soluble uPAR is D123. 
Truncated molecules are identified by the number of the domains (i.e. D l, D2, D3) and by the number 
of amino acids they express (i.e. D li-92, domain 1, from residue 1 to 92).
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Figure 4.2: Chemotactic response of THP-1 cells to different recombinant suPAR 
fragments.
The position of the sequence SRSRY in the linker region between domain 1 and 2 of uPAR is shown 
on top. Panels A-D refer to the indicated soluble recombinant uPAR mutants. Panels E and F refer to 
the chymotryptic fragments isolated from wild type suPAR 1.274. THP-1 cells migrated towards a 
solution containing different concentrations of the chemoattractants. Random cell migration of 
untreated THP-1 cells is referred to as 100% migration.
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Figure 4.3: Chemotactic response of THP-1 cells to different concentrations of the 
indicated peptides.
THP-1 cells migrated towards a solution containing different concentrations of the chemoattractants. 
Random cell migration of untreated THP-1 cells is referred to as 100% migration.
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Figure 4.4 Effect of PTX on THP-1 cells chemotaxis in response to peptide-1 or 
chymotrypsin-cleaved suPAR.
THP-1 cells were pre-incubated 4 hours with (100 ng/ml) PTX or its inactive mutant (Pizza et al.,
1989), washed and their chemotactic response measured. Medium alone (black bars), 0.1 pM peptide1 
1 (dotted bars), 1 pM peptide-1 (white bars), 10 pM chymotrypsin-cleaved suPAR (striped bars). 
Random cell migration of untreated THP-1 cells is referred to as 100% migration.
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Figure 4.5 Outline of the protease-sensitive uPAR linker located between domain 1 
(Dl) and 2 (D2)
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Figure 5.1: uPAR antigen in U937 cell lysates and in conditioned medium.
U937 cells were plated in the absence (open bars) or presence of PMA (black bars). After 24, 48 and 72 
hours, cells and conditioned medium was harvested. uPAR antigen in cell lysates (panel A) and in the 
conditioned medium (panel B) was measured by ELISA.
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Figure 5.2: Full length and cleaved forms of uPAR on U937 cells.
U937 cell lysates (20 pg total protein) and conditioned medium (0.25 ml) obtained as described in the 
legend to figure 5.1 were immunoprecipitated with a mixture of monoclonal antibodies R2 and R3. The 
absorbed material was analysed by western blotting using a polyclonal anti-uPAR antibody. The 
position of molecular weight markers, full-length uPAR, cleaved uPAR (D2D3) and the released 
domain 1 (D l) is indicated. The right-most panel is a long exposure of the lane containing conditioned 
medium from U937 treated with PMA for 72 hours.
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Figure 5.3: Molecular structure of uPAR fragments in conditioned medium from 
U937 cells.
(A) Conditioned medium obtained from a 72 hour PMA stimulation of U937 cells was either 
immunoprecipitated with antibodies recognising uPAR domain 3 (mAb R2 and R4), or uPAR domain 1 
(mAb R3), or an anti-uPA antibody (mAb c6), or an irrelevant antibody (mAb M2). After washing, the 
precipitates were denatured, reduced and treated for two hours without (left panel) of with PNGase-F 
(right panel).
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Figure 5.4: uPAR shedding from monocytes and neutrophils.
Human monocytes and neutrophils were isolated from 'huffy coats' as described in the materials & 
methods section. Cell were seeded (106/ml) in leukocyte culture medium in the absence (Ct.) or 
presence of PMA (PMA, only monocytes). After 48 hours of incubation cells were harvested by 
centrifugation and the conditioned medium collected. Cell lysates (Lys) and conditioned medium (CM) 
was analysed by immunoprécipitation and western blotting as described in the legend to figure 5.2.
(B) Cell lysates and conditioned medium from monocytes and neutrophils were immunoprecipitated 
with a mixture of monoclonal antibodies R2 and R3 and the absorbed material reduced and treated for 
two hours with PNGase-F. The deglycosylated material was analysed by western blotting using a 
polyclonal antibody against uPAR.
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Figure 5.5: uPAR shedding from fMLP stimulated neutrophils.
Freshly isolated neutrophils were incubated in serum free medium (20x1 OVml) for 30 minutes at 37°C 
in the absence (no) or presence of 5 nM fMLP (fMLP). The cells were pelleted and the amount of 
uPAR antigen in the conditioned medium measured by ELISA. The indicated values are the mean 
obtained from neutrophils isolated from two independent buffy coats +/- standard
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Figure 5.6: uPAR cleavage and shedding in HUVEC cells.
Human umbilical vascular endothelial cells (HUVEC, passage 5) were allowed to grow to confluence. 
The medium was replaced with fresh medium without (Ct.) or with PMA (PMA). After 24, 48 and 72 
hours the conditioned medium was collected and cells lysates were prepared after 72 hours. Lysates 
and conditioned medium were analysed by immunoprécipitation and western blotting as described in 
the legend to figure 5.2. Panels labelled with a "#" are short exposures.
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Figure 5.7: PMA stimulation and "Wounding” of HUVEC promotes uPAR 
shedding.
Confluent monolayers of HUVEC cells were "wounded" by "scratching" using the side of a rubber 
policeman. The total wounded area was small (> 1%) and the wounding was repeated once after 24 
hours. As a positive control separate plates received medium containing PMA. After 48 hours of 
incubation the conditioned medium was harvested and the concentration of uPAR antigen measured by 
ELISA. The indicated values are the mean of duplicate plates +/- SD. The experiment was performed 
only once.
Control PMA Wound
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Figure 5.8: uPA independent cleavage of uPAR in 32D cells.
Cell lysates (Lys) and conditioned medium (CM) from 32D cells transfected with wild-type uPAR 
(uPAR) and a mutant lacking domain 1 (D2D3) were immunoprecipitated with a mixture of 
monoclonal antibodies R2 and R3. The absorbed material was analysed by western blotting using a 
polyclonal anti-uPAR antibody. The position of full-length uPAR and cleaved uPAR (D2D3) are 
indicated.
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Figure 6.1:
Urinary suPAR levels normalised for creatinine in ovarian cancer patients (n=25) and age matched 
healthy women (n=20). The difference is significant (P = 0.004) according to Mann-W hitney's U-test. 
Patients with FIGO stage IIIc carcinomas are indicated as full circles. The remainder of the patients had 
FIGO stage I/II carcinomas. The horizontal bar indicates the median value of controls plus two times 
the standard deviation.
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Figure 6.2:
(A) Diagram illustrating the domain structure of uPAR and the proteolytic fragments thereof. The 
receptor is composed of three domains (D l, D2, and D3) and is linked to the cell-surface by a GPI- 
anchor attached to D3. Proteolytic cleavage in the region between D l and D2 results in release of the 
D l fragment, leaving behind on the cell surfaces the D2D3 fragment. Soluble forms, lacking the GPI- 
anchor, exist for both uPAR and D2D3. Monoclonal antibodies specific for D l (mAb R3) and D3 
(mAb R2) are used in this study to identify the different uPAR fragments. (B) Immunoblot 
demonstrating the presence of suPAR and suPAR fragments in urine. Concentrated sample 
(corresponding to 1 ml urine) from an ovarian cancer patient was immunoprecipitated with monoclonal 
antibodies recognising uPAR (mAb R2 and R3) or an irrelevant control antibody (mAb Ct). The 
absorbed material was analysed by immunoblotting using a polyclonal antibody directed against human 
uPAR.
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Figure 6.3:
Difference in suPAR fragmentation pattern in urine from ovarian cancer patients. Panel A: urine from 
seven healthy individuals; panel B: urine from seven ovarian cancer patients; panel C: Serum from the 
same seven patients. Urine, normalised for creatinine content, and serum samples (0.1 ml) were 
immunoprecipitated with a combination of mAb R2 and R3 and the absorbed material was analysed by 
immunoblotting with a polyclonal antibody directed against human uPAR.
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Figure 6.4:
Human suPAR levels in urine from mice xenografted with the ovarian carcinoma HOC8 and the breast 
carcinoma MDA435 in comparison with non-tumour bearing control mice.
Pooled urine from five (HOC8) or two (MDA435) xenografted mice was collected in metabolic cages 
and analysed by ELISA as described in the materials and methods section.
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Figure 6.5:
Human uPAR fragmentation in mice carrying the xenografted human tumours HOC8 or MDA435. 
Tumour extracts (20 pg total protein), serum (0.02 ml) and urine (0.05 ml) were subjected to 
immunoprécipitation with a mixture of mAb R2 and R3. The absorbed material was analysed by 
immunoblotting with a polyclonal antibody directed against human uPAR.
- 160-
Appendix I: Figures
CHAPTER 7: FINAL DISCUSSION
- 161 -
Appendix I: Figures
Trypsin
Plasmin
Trypsin
Plasmin
i iDomain 
1
Domain 
2
Domain 
3
Chemotactic  ep itope
Figure 7.1: The uPAR chemotactic epitope
Schematic diagram showing the primary sequence of linker region between uPAR domain 1 and 2. 
Aminoacids are indicated by single letter code and the aminoacid number. Arrows indicate cleavage 
sites for trypsin, plasmin, uPA, neutrophil elastase (NE) and chymotrypsin. The minimal chemotactic 
epitope is underlined.
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